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Hematopoiesis, literally to make blood, is a biological process in which new blood 
cells are formed. Under normal circumstances hematopoiesis mainly takes place 
in the bone marrow. Blood cells are produced by proliferation and differentiation 
of a small subset of pluripotent hematopoietic stem cells (HSCs) that have the 
ability to replenish themselves by self-renewal.1 The progeny of HSCs progresses 
through various intermediate maturational stages that generate multi-potential 
progenitors and progenitors devoted to one lineage differentiation (Figure 1).2 
Mature blood cells include: erythrocytes, thrombocytes or platelets, myeloid cells, 
and lymphocytes. Because mature blood cells have a restricted lifespan, HSCs are 
required throughout life to replace multipotent progenitors and the precursors 
committed to individual hematopoietic lineages.
Figure 1. The hematopoietic system where the multipotent HSCs are on the left, and 
terminally differentiated cells on the right. Abbreviations: CLP common lymphoid progenitor; 
CMP common myeloid progenitor; BFU-E burst forming unit-erythroid; CFC colony forming 
cells; CFU colony forming unit. (figure adapted from www.awaremed.com)
Cytopenias
A shortage in (mature) functional cells can occur due to many reasons. Causes can 
be summarized as: low production (e.g. due to iron deficiency, vitamin B12 and 
folic acid deficiency, bone marrow failures syndromes), increased use (e.g. due to 
hemolysis, infections, auto-immune diseases), increased apoptosis (e.g. caused by 
medication, splenomegaly, myelodysplastic syndromes), or a combination. Anemia 
is a shortage of erythrocytes, leukopenia a shortage of leukocytes (neutrophils, 
monocytes or lymphocytes) and thrombopenia a shortage of thrombocytes or 
megakaryocytes. Clinical presentations are similar with the type of cytopenia 
and duration of the disease. A diagnosis should be established based on careful 
evaluation of the patient history, clinical characteristics and a complete physical 
examination, followed by analysis of biochemical indicators in the blood that might 
point to deficiencies or underlying (chronic) illnesses. Once non-clonal causes 
are considered less likely, the diagnosis myelodysplastic syndromes should be 
considered.
Myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are a group of clonal bone marrow disorders, 
characterized by persistent cytopenia(s) and an increased risk of leukemic 
transformation. The incidence rate of MDS in the Netherlands is about 5.4 cases 
per 100,000 persons per year in the general population. The incidence rises with 
older age, with the highest incidence rate at the age of ≥80 years: 84.4 per 100,000 
persons a year.3
Essential criterion for the diagnosis of MDS is constant cytopenia(s) for more than 
3 months; and all other conditions that may cause that cytopenie should have 
been excluded.4,5 Landmarks in the diagnosis of MDS are presence of dysplasia in 
>10% of cells within one or more cell lineages and/or the presence of >15% ring 
sideroblasts and/or presence of cytogenetic abnormalities typical for MDS and/
or presence of a mutation in the splicing factor SF3B1 in combination with >5% 
ring sideroblasts.6–8 The cytomorphology, immunohistochemistry and cytogenetic 
results are used to classify patients in different disease subtypes, as described by 
the WHO-classification. The WHO-classification is revised every few years. Most 
of the studies described in this thesis were performed in the “era” of WHO-2008 
(Table 1).9 Most recent WHO-classification (2016), removed the terms ‘refractory 
anemia’ and ‘refractory cytopenia’, and replaced them by MDS,  with ‘unilinear’ 
dysplasia or ‘multilinear’ dysplasia to provide a more comprehensive description. 
MDS-RAEB (reactive anemia with excess blasts) is replaces by MDS-EB (Figure 2).
Although the WHO 2008 criteria seem quite straightforward, the diagnosis of MDS 
can still be challenging. Evaluation of dysplasia by cytomorphology is difficult and 
is not always restricted to a clonal disorder. It might also occur in non-neoplastic 
disorders, such as vitamin B12, folic acid deficiency or iron deficiency. In addition, 
inter-observer reproducibility of quantification of dysplasia is poor and experts 
typically report more frequent and more severe dysplasia than non-experts for 
the same patient cases.10
The diagnosis MDS-unclassifiable (MDS-U) consists of 3 subtypes and is not
10 11
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Table 1. WHO Classification 2008 for MDS adapted from Vardiman et al.5
Classification Blood findings Bone marrow findings
Refractory cytopenias 
with unilineage dysplasia 
(RCUD):
• Refractory anemia (RA)







Unilineage dysplasia in ≥10% of 
the cells in one lineage
<5% blasts
<15% of erythroid precursors 
are ring sideroblasts




Dysplasia in ≥10% of the cells in 
erythoid lineage
<5% blasts
≥15% of erythroid precursors 
are ring sideroblasts






<1 x 109/L monocytes




<1 x 109/L monocytes





<1 x 109/L monocytes
Uni- or multilineage dysplasia
5-9% blasts
Auer rods





<1 x 109/L monocytes







Dysplasia in <10% in cells in 
one or more lineages when 
accompanied by a cytogenetic 
abnormality considered as 
presumptive evidence for a 
diagnosis of MDS
<5% blasts
MDS associated with 
isolated del(5q)
Anemia
Usually normal to 
elevated platelets
<1% blasts





Deletion(5q) as sole cytogenetic 
abnormality
Figure 2. 2001, 2008 and 2016 revisions of the WHO classification for MDS. Abbreviations: 
RA(RS): refractory anemia (with ring sideroblasts), RCUD: refractory cytopenia with unilineage 
dysplasia, RT: refractory thrombocytopenia, RN: refractory neutropenia, RCMD(RS): 
refractory cytopenia with multilineage dysplasia (with ring sideroblasts), del(5): isolated 
deletion of chromosome 5q, SLD: single lineage dysplasia, MLD: multilineage dysplasia, EB: 
excess blasts.
necessarily characterized by dysplasia, but by presence of cytogenetic 
abnormalities or >1% blasts in the peripheral blood without an increase of blasts 
in the bone marrow. Diagnostic pitfalls by the current diagnostic tools are: 1). 50-
70% of the MDS patients do not have any cytogenetic abnormalities, therefore, 
MDS patients without abnormal karyotype might be unrecognized;11 2). Various 
cytogenetic abnormalities (e.g. a trisomy of chromosome 8) may also be observed 
in other myeloid neoplasms (e.g. in acute myeloid leukemia or myeloid proliferative 
diseases);5 and 3). blast cells in the blood can occur in other hematological 
malignancies, e.g. in case of marrow fibrosis or population of the bone marrow by 
other malignant cells. Therefore, additional diagnostic tools are needed to exclude 
other causes before diagnosing MDS. Molecular biology can be used to suggest 
other myeloid neoplasms by analyzing presence of frequent genomic aberrations 
such as FLT3, AML1-ETO, CBF-beta/MYH11, MLL, EVI-1 overexpression, NPM1 
mutation, BCR-ABL and Jak2.
Cytopenia of uncertain significance and dysplasia of uncertain significance
Unfortunately, the cause of the cytopenia is not always revealed by this standard 
diagnostic approach. Patients with an unexplained cytopenia, without a clonal 
disease, are now categorized as a idiopathic cytopenia of undetermined significance 
(ICUS).12,13 Patients with or without cytopenias but with e.g. a clonal mutation are 
called clonal disease as clonal hematopoiesis of indeterminate potential (CHIP).14 
Patients with clear dysplasia by cytomorphological evaluation, but no cytopenia or 
other abnormalities in laboratory work-up are classified as idiopathic dysplasia of 
12 13
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undetermined significance (IDUS).15 Of note, the latter two categories are mostly 
discovered by coincidence, i.e. during a routine screening.16
Introduction to flow cytometry
Overall, more diagnostic tools are needed to distinguish MDS from non-clonal 
causes of cytopenia and ICUS. Furthermore, with the increased availability of 
disease-modifying therapies there is a growing need for standardized tools that 
may predict therapy response.17 In the recently published European LeukemiaNet 
guidelines for diagnosis and treatment of MDS, flow cytometry (FC) is added 
as a recommended tool for diagnostic and prognostic purposes, if performed 
according to standard European LeukemiaNet guidelines.18
Flow cytometry as diagnostic tool in patients with an unexplained cytopenia
By the use of FC physical and histochemical characteristics of hematopoietic 
cells can be evaluated. MDS-specific FC evaluates the myeloid progenitors, B 
cell progenitors, maturing myelo- and monocytic, and erythroid cell subsets in 
bone marrow aspirates. In 2009, the ELN working party on Flow Cytometry in 
MDS published guidelines concerning recommended methods for cell sampling, 
handling and processing.19 In 2012, a paper was published by the same working 
party that described a minimum consensus panel of antibody combinations 
to study the myelo-/monocytic and erythroid cell subsets.20 Knowledge of age-
matched normal maturation patterns and expression levels of lineage identifying 
markers is mandatory to be able to evaluate MDS bone marrow analysis by 
FC.21 There is no single specific FC marker for MDS, but the presence of multiple 
abnormalities predicts the presence of a clonal disorder. Multiple MDS-FC 
scoring systems describe evaluation of different markers and different scoring 
strategies.22–28 An example of a MDS-FC scoring system that applies most of the 
recommended markers is displayed in Table 3.
Most MDS-FC scoring systems focus on two cell compartments: 1). quantifying 
aberrancies in the myelo-/monocytic cell lineage, analyzing lineage specific marker 
expression and presence of lineage infidelity marker; 2). analysis of percentage 
of myeloid progenitor cells and their differentiation-related antigen expression 
levels and the presence of asynchronous markers and lineage infidelity markers. 
Scoring systems show a wide range of parameters counted; from few-parametric 
strategies to complex MDS-FC scoring systems, with a sensitivity and specificity 
ranging from 69 to 98% and 78 to 93%, respectively.22–25,27,28,30 The most commonly 
used diagnostic strategy is the “diagnostic score” according to Ogata et al.22 This 
is a simple MDS-FC scoring system based on four parameters: 1). percentage of 
CD34-positive myeloid progenitors in all nucleated cells; 2). percentage of B cell 
progenitors within CD34-positive compartment; 3). CD45 expression level of CD34 
positive myeloid progenitors (related to CD45 expression level on lymphocytes); 4). 
sideward light scatter peak channel value of granulocytic cells (related to sideward 
light scatter peak channel value of lymphocytes).  Each abnormality scores 
1 point in which scoring ≥2 points is associated with MDS. The sensitivity and 
specificity of this score are 69% and 89%, respectively. Most of the MDS-FC scoring 
systems are developed and validated in MDS patient cohorts, comparing groups 
of MDS patients with patients with non-clonal cytopenia(s) and normal controls. 
By this approach, FC is able to identify different categories within separate WHO 
subcategories in MDS.31,32 This is demonstrated by the detection of multilineage 
dysplasia in patients where standard cytomorphology only observed unilineage 
dysplasia.
Until recently, the evaluation of the erythroid cell lineage by FC was challenging due 
to lack of validation of markers. Nowadays, CD45, CD71, CD235a, CD36, CD117 
and CD105 are applied to study the erythroid cell lineage.25,33,34 An erythroid score 
(RED score) that evaluates specific erythroid FC markers and hemoglobin level, in 
addition to the diagnostic score (described above), revealed that the sensitivity of 
this score is increased to 88%, whereby the specificity remained around 90%.35 FC 
analysis of megakaryocytes faces technical challenges due to their scarcity. Efforts 
are undertaken to overcome these issues by analyzing thrombocytes.26 Validation 
studies are ongoing within the ELN working party on Flow Cytometry in MDS.
To summarize, FC has a high sensitivity and specificity in the detection of myelo-/
monocytic and erythroid dysplasia. FC should be interpreted not as a sole 
diagnostic tool in MDS, but can underline the diagnosis in indifferent cases. FC 
results need to be included in an integrated diagnostic report, together with 
cytomorphological, cytogenetic and/or molecular findings as dysplastic changes 
by FC can also be observed in other disorders than MDS.36 According to the WHO 
classification, MDS can only be diagnosed when all other causes for the cytopenia/
dysplasia are excluded.9
Prognostic value of flow cytometry
The International Prognostic Scoring System (IPSS) and the WHO adjusted 
Prognostic Scoring System (WPSS) and their revised versions are the most applied 
prognostic scoring systems in MDS. These scoring systems use WHO classification, 
cytogenetic risk categories, transfusion dependency, bone marrow blast counts, 
and peripheral blood counts such as hemoglobin level, thrombocyte count 
and absolute neutrophil count (Table 4).6,7,37,38 Originally MDS-FC models were 
designed as a prognostic tool that was able to identify different risk categories
14 15
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Table 3 Example of a MDS-FC scoring system, applying most of the recommended markers. 
Adapted from Wells et al,23 scores adjusted as by Cutler et al.29
Points Myeloid progenitors Granulocytes* Monocytes*
0 No abnormalities No abnormalities No abnormalities
1 <5% myeloid progenitors 
with one of the following: 
Lymphoid markers present 
(CD2, CD5, CD7, CD19, 
CD25, CD56)
AND/OR
Two of the following 
abnormalities:


























One of the following:
Abnormal CD45/SSC
Decreased/increased 












2 5-10% myeloid progenitors 2-3 abnormalities as described above
Presence of CD34 on mature myelo-/monocytic 
cells
Presence of lymphoid markers (such as CD56)
3 11-20% myeloid 
progenitors
4 or more abnormalities or one or more 
abnormalities plus presence of CD34 or 
lymphoid marker present
4 21-30% myeloid 
progenitors
2 or more abnormalities in granulocytic AND 2 
or more in monocytic compartment. 
1 Extra <5% abnormal progenitors 
without additional 
granulocyte or monocyte 
abnormalities
Myeloid/Lymphoid ratio < 1
*The sum of the granulocyte score and monocyte score has a maximum of 4 points, 
excluding the described extra point. $Decreased CD33 in all cell subsets is seen as a 
polymorphism, and in that case not scored as abnormal.
within IPSS and IPSS-R risk categories. 39–41 The MDS-FC scores within validated 
risk categories are heterogeneous. This means, within specific IPSS and IPSS-R risk 
categories, that FC is able to identify different risk categories based on quantity of 
FC aberrancies. The presence of multiple abnormalities by FC revealed a poorer 
prognostic risk within (low risk) MDS based on the IPSS(-R).42 Moreover, the 
presence of aberrant myeloid progenitors by FC in patients with <5% blasts by 
cytomorphology negatively impacts prognosis.43 Finally, in patients with unilineage 
dysplasia (RCUD) based on cytomorphology FC may identify multilineage dysplasia 
which is associated with worse prognosis.44
Table 4A The Revised International Prognostic Scoring System (IPSS-R) for MDS
Variable 0 0.5 1 1.5 2 3 4
Cytogenetics Very 
good
- Good - intermediate Poor Very
poor
BM blasts, % ≤2% - >2% - <5% - >5% - <10% >10% -
Hemoglobin ≥10 - 8 - <10 <8 - - -
Platelets ≥100 50 - 
<100
<50 - - - -
ANC ≥0.8 <0.8 - - - - -
*ANC: absolute neutrophil count
Table 4B IPSS-R risk categories with corresponding overall survival and risk on leukemic 
transformation.
Risk category Score Median OS (years) AML 25% (years)
Very low ≤1.5 8.8 NR
Low >1.5-3 5.3 10.8
Intermediate >3-4.5 3.0 3.2
High >4.5-6 1.6 1.4
Very high >6 0.8 0.73
Treatment modalities in myelodysplastic syndromes
About 80% of the MDS patients will present with an anemia, of which 40% will be 
treated with supportive care. This means erythropoietin (ESAs) and granulocyte-
colony stimulating factor (G-CSF) with or without red blood cell transfusions.45,46 
Other treatment modalities are immune-suppressive strategies such as 
ciclosporine in hypoplastic MDS or lenalidomide in MDS patients with an deletion 
16 17
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of chromosome 5q. Patients with high risk disease will be treated with conventional 
high dose chemotherapy with or without an allogeneic stem cell transplantation, 
or high risk patients are treated with  hypomethylating agents (in some cases 
followed by an allogeneic stem cell transplantation).
Prediction of response to treatment
With the increased availability of disease-modifying therapies in MDS there is 
a growing need for tools that can predict treatment response and can guide 
treatment decisions.17 One of the first FC studies addressing this topic evaluated 
the presence of aberrant myeloid progenitor cells in predicting response to 
erythropoiesis stimulating agents. It was illustrated that presence of aberrant 
myeloid progenitors by FC acted as a significant biomarker for treatment failure.47 
Patients with abnormal progenitor cells by FC showed no response or only short 
response duration to erythropoietin (EPO) with or without granulocyte-colony 
stimulating factor. Moreover, in high risk MDS patients receiving hypomethylating 
therapy (azacitidine), FC proved to have additional value in the prediction of 
treatment response and FC results correlated with survival.48 Patients with 
treatment response after 3 cycles revealed a significant decrease in number of FC 
abnormalities in comparison to patients without therapy response. The presence 
of aberrant myeloid progenitors at start of therapy, irrespective of progenitor cell 
percentages, was significantly correlated with lack of response. In addition, a low 
number of aberrancies at the start of therapy was correlated with a significantly 
increased overall survival. Studies evaluating the role of FC in predicting treatment 
response, e.g. upon immune-modulating agents, are ongoing.
One of the studies that evaluate the use of immune-modulating agents is the 
HOVON 89 trial. This study is a Phase II randomized multicenter study to assess the 
efficacy of lenalidomide with or without EPO and granulocyte-colony stimulating 
factor in patients with low and intermediate-1 risk myelodysplastic syndrome 
(according to the IPSS). The trial is registered at www.trialregister.nl as NTR1825; 
EudraCT nr.: 2008-002195-10. Patients entered in this study protocol, were either 
refractory to EPO; loss of response on EPO or were not likely to respond on EPO 
based on the Nordic predictive response model.
Three add-on studies are attached to this study to verify the efficacy of 
multiple diagnostic tools in MDS: 1). validation of flow cytometric parameters in 
myelodysplastic syndromes. 2). identification of genetic aberrations in MDS using 
high resolution single nucleotide polymorphism (SNP) arrays.49 3). Implementation 
of next generation sequencing in diagnostic and prognostic strategies in MDS. 
Part of the subjects discussed in this thesis are related to these add-on studies.
Aim of the thesis – part 1
The aim of this thesis is to investigate the efficacy of multiple diagnostic tools in 
the diagnosis of MDS differentiating clonal from non-clonal causes of cytopenias, 
focusing on the value of multiparameter FC. This includes the development and 
validation of erythroid lineage evaluation by FC and addition of selected markers to 
currently applied MDS-FC algorithms. In addition, investigations were performed 
to correlate of FC with state-of-the-art molecular techniques performed within the 
context of a prospective clinical trial within HOVON, (HOVON89).
Chapters 2 and 3 focus on currently used MDS-FC approaches. Chapter 2 aims 
to investigate the predictive value of current applied MDS-FC scoring systems 
in detection of MDS, particularly, the role of FC, when other diagnostic tools 
are inconclusive. Chapter 3 focusses on the FC markers that demonstrate the 
granulocytic cell differentiation, which forms the cornerstone of currently applied 
diagnostic strategies for myelodysplastic syndromes (MDS).
Chapters 4 and 5 investigate the role of FC in evaluating the erythroid lineage. 
Chapter 4 describes an international multicenter study that aims to identify MDS-
specific erythroid aberrancies. In Chapter 5 the MDS-specific erythroid aberrancies 
are/were validated and added to current applied MDS-FC models.
Chapter 6 demonstrates the application of FC and emerging molecular technology 
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Chapter 2
Multiparameter flow cytometry 
is instrumental to distinguish 
myelodysplastic syndromes from 
non-neoplastic cytopenias
E.M.P. Cremers, T.M. Westers, C. Alhan, C. Cali, 
M.J. Wondergem, P.J. Poddighe, G.J. Ossenkoppele, 
A.A. van de Loosdrecht. 




Mandatory for the diagnosis of myelodysplastic syndromes (MDS) is presence of 
dysplasia in >10% of cells within one or more cell lineages or presence of >15% 
ring sideroblasts or presence of MDS associated cytogenetic (CG) abnormalities. 
Discrimination between neo-plastic and non-neoplastic causes of cytopenias can 
be challenging when dysplastic features by cytomorphology (CM) are minimal and 
CG abnormalities are absent or non-discriminating from other myeloid neoplastic 
disorders. This study evaluated a standard diagnostic approach in 379 patients 
with unexplained cytopenias and highlights the additional value of flow cytometry 
(FC) in patients with indeterminate CM and CG. CM reached no diagnosis in 44% of 
the patients. Here, CG was able to identify two additional patients with MDS; other 
CG results did not reveal abnormalities or were non-specific. Based on FC results 
patients without a diagnosis by CM and CG were categorized ‘no MDS-related 
features’ (65%), ‘limited number of MDS-related changes’ (24%), and ‘consistent 
with MDS’ (11%). Patients were followed over time in attempt to establish or 
confirm a diagnosis (median follow-up: 391 days; range 20-1764). The specificity 
(true negative) of MDS-FC analysis, calculated after follow up was 95%. FC can aid 
as a valuable tool to exclude MDS when CM and additional CG are not conclusive 
in patients with cytopenia.
Introduction
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of 
hematopoietic stem cell disorders, characterized by ineffective hematopoiesis 
resulting in cytopenias and a variable risk on transformation to acute myeloid 
leukemia.1 For the diagnosis of MDS, cytomorphological (CM) assessment of 
peripheral blood and bone marrow (BM) in combination with cytogenetic (CG) analysis 
are mandatory.2–4 The WHO classification is based on CM and CG findings in blood 
and BM evaluating cytopenias, dysplasia, presence of ring sideroblasts, enumeration 
of blasts, Auer Rods and cytogenetic findings.3,4 The minimal CM criterion for MDS is 
the presence of dysplasia in >10% of the cells in at least one cell lineage, i.e. erythroid, 
myeloid or megakaryocytic cell lineage. This is challenging, since dysplasia can also 
occur in myeloid neoplasms other than MDS, or in reactive conditions. Therefore, 
other possible causes of dysplasia such as deficiencies, or viral infections should 
be excluded before the diagnosis of MDS can be established.5,6 A supplementary 
hallmark in the diagnosis is presence of MDS associated CG abnormalities, present 
in approximately 40-50% of the patients.7,8 CG abnormalities described as typical 
MDS are commonly seen in other myeloid neoplasms.9,10 For example, a trisomy of 
chromosome 8 does not lead to the diagnosis of MDS, as this mutation is also seen 
in myeloid proliferative disorders. Therefore, cytogenetic results should always be 
interpreted in the context of CM results. In cases of minimal abnormalities by CM 
and absence of (MDS associated) CG abnormalities there is a need for additional 
diagnostic tools. Flow cytometry (FC) has proven additional value in the identification 
of myelodysplasia in large study cohorts of suspected MDS patients.11,12 The aim of 
the present study is to evaluate the use of FC as diagnostic tool when CM and CG 
are not informative in a cohort of patients with unexplained cytopenias.
Patients and methods
Patients
Bone marrow samples of 379 adult patients with cytopenias, defined according 
to WHO-criteria, sent to our department from January 2009-January 2014 were 
evaluated. Median age: 66 years (range 20-94), 245 male and 134 female (Table 1). In 
accordance with diagnostic guidelines, CM assessment by at least one experienced 
hematologist-cytologist was performed.11,13 The hematologist-cytologist determined 
the necessity of CG, and molecular biology (MB). FC was performed standardly 
(supplementary files). Patients were followed over time until a diagnosis was 
established or verified. The study was approved by the local ethical committee and 
in accordance with the declaration of Helsinki.
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Table 1 Demographics and clinical characteristics.





379 101 54 57 167





















































Aplastic anemia/pure red cell aplasia






























































Normal bone marrow (N=18; 5%)
<10% Dysplasia
>1 diagnosis possible 




























Gender (m/f) 245/134 72/29 43/11 34/23 96/71













































FCSS* 4 or more
iFS* no MDS-related features
iFS* limited number of changes
























































*Evaluation of dysmyelo-/dysmonopoiesis by flow cytometry, the text provides an 
explanation per score. Abbreviations: FCSS: flow cytometric scoring system; iFS: integrated 
flow cytometric score.
Flow Cytometry
Data generated by FC were used to calculate validated MDS-FC scores, the diagnostic 
score and the (modified) flow cytometric scoring system (FCSS), respectively.14–16 Both 
scores were integrated into one FC result, as previously described by our group.17
Diagnostic score. This four-parameter diagnostic score comprises the percentage 
of CD34+ myeloid progenitors in nucleated cells; percentage of B cell progenitors 
within CD34+-compartment; CD45 expression level of CD34+ myeloid progenitors; 
SSC peak channel value of granulocytes. Each abnormality (compared to reference 
ranges) scores one point; ≥2 points allocates ‘MDS’.14
Flow cytometric scoring system. The FCSS evaluates differences from normal regarding 
percentages, expression levels, maturation patterns and aberrant expression levels 
of lineage specific and lineage infidelity markers of immature myeloid progenitor 
cells and maturing granulocytes and monocytes. Patients were categorized: ‘no to 
mild dysplasia’ (0-1 points), ‘moderate dysplasia’ (2-3 points), and ‘severe dysplasia’ 
(≥4 points). Cutler et al. modified this score by adding an extra point in case of <5% 
abnormal progenitors without additional granulocyte or monocyte abnormalities.15,16
Integrated flow cytometric score. The iFS combines the diagnostic score and the 
modified FCSS into one FC result (Table 2). The diagnostic score separates patients 
into two categories: ‘<2 points’ versus ‘≥2 points’. Second, is the evaluation of the 
myeloid progenitor cells (SSC low-intermediate/CD34+ and/or CD117+) separating 
patients into two categories: normal or aberrant myeloid progenitors. Third, is the 
evaluation of neutrophils and monocytes according to parameters described in ELN 
guidelines, separating patients into: normal or aberrant myelopoiesis.18 According 
to this strategy patients were classified as ‘no MDS-related features’, ‘limited number 
of MDS-related changes’, or ‘consistent with MDS’.
 
Table 2 The integrated flow cytometric score.
Diagnostic flow score <2 <2 <2 <2 ≥2 ≥2 ≥2 ≥2 
Aberrant myeloid 
progenitors 
- - + + - - + +
Aberrant neutrophils 
(SSC or two or more other 
aberrancies)
Aberrant monocytes 
(CD56 or two or more other 
aberrancies
- + - + - + - +
Conclusion** A A/B* A/B* C A/B* B/C* B/C* C
The integrated flow cytometric score (iFS) is based on the diagnostic score and the flow 
cytometric scoring system (FCSS).[14–16]  This model is adapted from Van de Loosdrecht et 
al.17 Abbrevations FC: flow cytometry; SSC: sideward light scatter; *Choice for “A or B” and “B 
or C” depends on the kind and number of aberrancies that are encountered; ** A: ‘results 
show no MDS-related features’, B: ‘limited number of MDS-related changes’, and C: ‘results 




Diagnostic tools were evaluated at two time-points; first after the integration of all 
results after initial assessment, and second after addition of follow-up data. To be 
able to evaluate the additional value of FC in the diagnostic strategy in patients with 
cytopenias, patients without a diagnosis at the second time-point were excluded 
from the analysis. If patients could were diagnosed with a myeloid neoplasm other 
than MDS, patients were excluded from further analysis.19
Results
Results of cytomorphology and immunohistochemistry at initial assessment
CM categorized 27% patients as ‘MDS’, 14% patients as ‘other myeloid disease’, 15% 
patients as ‘non-myeloid disease’, and 44% patients as ‘non-clonal’. The ‘non-clonal’ 
category consisted of 60% patients with ‘<10% dysplasia in one or more cell lineages’, 
10% patients with ‘>1 diagnosis possible’ (i.e. dysplasia but also iron incorporation 
disorder or deficiency), and 19% patients with ‘dry tap/not enough cells’, and 11% 
patients with apparently ‘normal bone marrow’ (Table 1).
Additive value of karyotyping and fluorescence in situ hybridization
CG analysis was performed in 80% patients. In addition, iFISH was performed in 4% 
patients. Thirty-one out of 10% patients were labeled: ‘typical MDS’, 15% were labeled 
‘not typical MDS’ and 75% were labeled ‘normal’. CG results within the different 
categories based on CM are displayed in Table 1.
Within the ‘non-clonal’ category based on CM, CG analysis was performed in 75% 
patients. Note, for BM aspirates considered normal by CM, CG analysis was not 
performed. Analysis was ‘typical MDS’ 2% patients: two patients with a monosomy 
7, and one patient with a complex karyotype. The latter and one of the two patients 
with a monosomy 7 were classified as MDS unclassifiable. The second monosomy 
7 patient had a history of chronic myeloid leukemia (CML). However, BCR-ABL was 
negative at time of analysis; this patient was not classified as MDS.20 Cytogenetic 
analysis was ‘not typical MDS’ in 12% patients. Isolated deletion of chromosome Y 
was the most frequent abnormality (n=9); none of these results added to diagnosis 
or exclusion of a specific disease. CG analysis was ‘normal’ in 86% patients, and 
thereby not contributory. So, within the no diagnosis CM subgroup, CG was able to 
identify two additional MDS cases.
Additive value of molecular biology
Molecular analysis was indicated in 29% patients. In 73% patients no abnormalities 
were reported. Twenty patients had a JAK2 mutation. BCR-ABL was positive in one 
patient who was therefore diagnosed as CML. In two patients MB analysis failed due 
to poor sample quality (Table 1). Within the ‘non-clonal’ category based on CM, MB 
was performed in 11% patients. In all of these patients MB revealed no abnormalities.
Flow cytometric results per cytomorphological category
Multiparameter FC analysis focusing on myeloid dysplasia was performed 
successfully in 365/379 (96%) patients and failed in 4% cases due to poor sample 
quality. According to the iFS 43% patients FC showed ‘no MDS-related features’, 23% 
were labeled ‘limited number of MDS-related changes’, and 34% ‘consistent with 
MDS’. Table 1 illustrates the results of the three applied MDS-FC scoring systems 
within the different CM categories. The iFS is discussed in more detail below.
Flow cytometric results within ‘non-clonal’ category based on CM. Here, 65% were labeled 
as ‘no MDS-related features’, 24% as ‘limited number of MDS-related changes’, and 
11% as ‘consistent with MDS’, based on the iFS. FC cannot be used as an additional 
diagnostic tool without knowledge about the predictive value of MDS-FC in patients 
with a clear diagnosis. Therefore, we first compared FC results in cases where CM 
could establish a diagnosis.
Flow cytometric results within the ‘MDS’ category based on CM. Within the ‘MDS’ 
category based on CM, 15% of patients were labeled as ‘no MDS-related features’, 
25% as ‘limited number of MDS-related changes’, and 60% as ‘consistent with MDS’ 
(iFS). FC detected dysmyelo-/dysmonopoiesis in 86% MDS patients identified by CM 
(Table 1). Fifteen percent of patients with MDS by CM were not identified by FC. 
These concerned four patients with isolated dyserythropoiesis; six patients with 
dysmegakaryopoiesis and dyserythropoiesis; one patient with dysmegakaryopoiesis, 
dyserythropoiesis, and <10% granulocytic dysplasia; three patients with trilineage 
dysplasia; and one patient with isolated dysgranulopoiesis. These 15 patients had 
normal myeloid progenitor cell counts.
Flow cytometric results within ‘other myeloid disease’ category  based on CM. Myeloid 
neoplasms may show dysmyelo-/dysmonopoiesis by CM. Therefore, it is expected 
that current MDS-FC scoring systems might label these entities as MDS. Hence, 79% 
patients within the ‘other myeloid disease’ category by CM were labeled ‘consistent 
with MDS’ by FC; 12% were labeled ‘limited number of MDS-related changes’; and 
10% were labeled ‘no MDS related features’ (Figure 1).
Flow cytometric results within ‘non-myeloid disease’ group based on CM. Within 
this category 65% were labeled as results show ‘no MDS-related features’ (true 
negative), 29% were labeled ‘limited number of MDS-related changes’, and 6% were 
labeled ‘consistent with MDS’ (false positive). The three false positive patients were 
two patients with reactive BM, and one patient with infiltration of a solid tumor. 




Figure 1 The flow chart of the study.
The 379 patients entered in de study, subdivided in categories by cytomorphology (CM). 
The next steps show the addition of cytogenetic (CG) analysis and molecular biology (MB), to 
the diagnosis by CM. CG alters the diagnosis of three patients into two MDS patients (MDS 
unclassifiable) and one patient with a myeloid disease (AML).  MB alters the diagnosis of 
one MDS patient into myeloproliferative disease. Initial diagnosis based on CM, CG and MB 
are subdivided by flow cytometric (FC) results ; A ‘FC results show no MDS-related features’; 
B ‘limited number of MDS-related changes’; and C ‘FC results are consistent with MDS’.
The bottom of the graph shows the diagnosis after a median follow-up of 377 days (20-
1764; N=234). Diagnosis in bold are used to calculate sensitivity, specificity, negative and 
positive predictive value per diagnostic tool. *Flow Cytometry was not be performed, due 
to poor sample quality.
Summary of the results after initial diagnostic work-up
After initial work-up a diagnosis could be established in 215/379 (57%) cytopenic 
patients. CM was able to diagnose 101 MDS patients, 54 patients with ‘other 
myeloid disease’, and 57 patients with ‘non-myeloid disease’. CG analysis identified 
two more MDS patients where CM was inconclusive. MB altered the diagnosis of 
one MDS patient into MPD. After this initial work up: CM, CG and MB revealed no 
cause for the cytopenia in 43% patients (Figure 1). FC was able to categorize 98% 
patients, yet the additional value of this tool in the diagnostic work-up can only be 
established after follow-up.
Confirmation of the results from initial diagnostic work-up during follow-up
Follow-up data were collected to confirm results, in case of lacking explanation 
for the cytopenia patients were followed until a diagnosis could be established. 
Follow-up data were present in 282/379 patients with a median follow-up time 
of 377 days (range 6-1764 days). Within the ‘non-clonal’ category by CM follow-up 
was available in 77% patients, median follow-up time of 366 days (range 6-1716). 
Patients without follow-up were excluded from further analysis. Note, in 7 patients 
the initial diagnosis of MDS was altered during follow-up, and 7 other patients 
were diagnosed with MDS within approximately 1 year. After follow-up, 5 patients 
within the ‘non-clonal’ category were diagnosed with ‘MDS’, three were diagnosed 
with an ‘other myeloid disease’, 114 were diagnosed with a ‘non-myeloid disease’, 
and for 39 there was still no diagnosis (Figure 1).
Specificity and sensitivity of cytomorphology and flow cytometry
As previously described CM is the gold standard in the diagnosis of MDS. Specificity 
and sensitivity calculated after follow-up were 96% (95% CI: 86.1-99.4), and 94% 
(95% CI: 87.4-97.8), respectively.
To calculate results for FC at initial work-up, FC results ‘consistent with MDS’ was 
scored as MDS; ‘limited number of MDS-related changes’ and ‘no MDS-related 
features’ were scored as no MDS.
Calculation of specificity for FC revealed similar results as for CM: 95% (95% CI: 
90.1-97.5). Sensitivity was 61% (95% CI: 51.2-70.9). This lower sensitivity is most 
likely to be explained by false negative results in MDS patients with only dysery-/
dysmegakaryopoiese, not evaluated by current MDS-FC scoring systems.
The role of flow cytometry at initial assessment in patients with cytopenias of 
indeterminate origin
In 95% ‘non-clonal’ patients with non-myeloid disease after follow-up, MDS was 
considered unlikely according to FC results at initial work up. The 6 MDS-FC 
positive patients were diagnosed as reactive BM, iron deficiency, and medication 
induced cytopenia. FC predicted MDS in 2/5 cases that developed MDS during 
follow-up. The three MDS patients not-predicted by FC had dysmegakaryopoiesis 
with or without dyserythropoiesis by CM. As described earlier, analysis of these 
lineages is not incorporated in current MDS-FC scoring systems.
Besides, in 7/102 patients within the ‘MDS’ category by CM at initial assessment 
this diagnosis was withdrawn during follow-up. In five of these patients FC already 
predicted MDS to be less likely. From the other two patients with MDS-like FC, 




Myelodysplastic syndromes (MDS) should be considered in every patient with an 
unexplained cytopenia. The gold standard in the diagnosis of MDS is presence 
of specific cytomorphological (CM) features and/or presence of MDS associated 
cytogenetic (CG) abnormalities.4,7 However, the classification of patients with 
persistent cytopenias can be challenging when dysplastic features by CM 
are minimal, and CG is normal or non-specific. As FC is now recommended as 
diagnostic tool in the diagnostic work-up in MDS it raised the question whether FC 
was contributory when CM and CG are indeterminate.11
In the cohort of 379 patients described here, CM and CG revealed a diagnosis in 
57% patients. In the other cases CM in combination with CG found no cause for the 
cytopenias; this declined to 10% after follow up. In the initially CM-indeterminate 
patients FC identified 89% of cases as non-MDS. After follow-up, 97% of patients 
within the latter category did not develop MDS. This illustrates a low probability of 
development of MDS in patients with normal or minimal changes by FC at initial 
assessment, in cases where CM was indeterminate and CG analysis was normal. 
This forfends patients from receiving several bone marrow biopsies, which is not 
only less invasive for the patient but also saves time and money.
The specificity and sensitivity for FC calculated after follow-up were 95% and 
61%, respectively. The found specificity was comparable to the specificity of CM 
assessment and also comparable to the results of other FC study groups (mean 
specificity of 94%).14,18,21–23 Within the studied patient cohort, FC remained highly 
specific in excluding MDS. The sensitivity of FC in this study was lower than 
reported by others (average 75%). 14,18,21–23 In general, FC results should always be 
interpreted in the context of other diagnostic results. The FC-false negative MDS 
patients showed mostly dysmegakaryopoiesis with or without dyserythropoiesis, 
not evaluated by current MDS-FC. Other study groups showed that addition of 
erythroid markers to the FC analysis increased the sensitivity to identify MDS.21,24,25 
A prospective validation study is to evaluate the incorporation of FC erythroid 
assessments is ongoing.
No diagnosis could be established for the cytopenia in 43% of the investigated 
patients at initial work-up. According to the WHO 2008 criteria, presence of 
typical CG abnormalities is diagnostic for MDS. Cytogenetic abnormalities were 
expected to be present in 40-50% of the MDS cases. Loss of chromosome Y as 
single abnormality was most commonly seen. However, interpretation of a loss of 
chromosome Y, here considered not typical MDS, is challenging as it might also be 
age-related.10 In the current study none of the patients with loss of Y developed 
MDS during follow-up.26
One could question if ‘MDS’ patients by CM when based on minimal criteria, 
without abnormalities by CG, and FC are indeed myeloid clonal diseases or better 
categorized as idiopathic cytopenia or dysplasia of uncertain significance.27,28 
However, longer follow-up is necessary. Additional molecular analysis, i.e. whole 
exome sequencing or targeted sequencing of described mutations associated 
with MDS might contribute in near future.29
In conclusion, in this patient cohort of 379 patients with cytopenias, FC showed to 
be highly instrumental to exclude MDS at the initial diagnostic work-up in cases 
where CM was indeterminate.
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Analysis of blast count and dysplasia was performed after May-Grünwald-
Giemsa staining, in a 500-cell differential of nucleated cells in BM smears and 
in 200-cell differential peripheral blood smears. An iron staining was used for 
the evaluation of (ring) sideroblasts. In 176/379 (46%) patients BM biopsies were 
available for immunohistochemistry. Immunohistochemistry results were added 
to the CM results, in which CM results were decisive. In cases of a dry tap, poor 
quality of the aspirate, localization of lymphoma, or solid tumor in the biopsy, 
immunohistochemistry results contributed to CM results. Patients were classified 
according to WHO 2008 criteria.
CM was used as gold standard to categorize patients ‘MDS’, ‘other myeloid disease’, 
‘non-myeloid disease’, or ‘no diagnosis’ (Table 1). The latter category included 
patients with ‘<10% dysplasia’, ‘>1 diagnosis possible’, or ‘dry tap/not enough cells 
evaluable’. Patients with cytopenias but apparently normal BM by CM were also 
labeled as ‘no diagnosis’.
Karyotyping and fluorescence in situ hybridization
After CM assessment, CG analysis was considered mandatory in 305/379 patients 
(80%). A minimum of 20 metaphases was evaluated and described according to the 
International System for Human Cytogenetic Nomenclature recommendations.1 
Interphase fluorescence in situ hybridization (iFISH) was performed according 
to standard procedures when no metaphases were present in the cell cultures 
(11/305) or in some cases to confirm abnormalities found by conventional 
karyotyping (6/305). MDS-iFISH comprised deletion of chromosome Y, monosomy 
5 and 7, trisomy 8 and specific cytogenetic alterations such as del(5q), del(7q), 
del(17p) and del(20q).
CG results were used to categorize patients as: abnormal i.e. ‘typical MDS’ or ‘not 
typical MDS’, or ‘normal’, according to the WHO criteria.2,3 With the exception of 
deletion of chromosome Y as single abnormality which was labeled ‘not typical 
MDS’ as it can be age-related.(4) Patients without ‘MDS’ by CM who had ‘typical 
MDS’ CG results, were diagnosed as MDS according to diagnostic guidelines.5
Molecular biology
Molecular biology was performed to rule out other myeloid neoplasms, i.e. 
a myeloproliferative disease (n = 111; Table 1). Molecular assessment was 
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performed using a panel comprised of the most frequent genomic aberrations 
associated with myeloid neoplasms such as AML1-ETO, CBF-beta/MYH11, MLL, 
EVI-1 overexpression, NPM1 mutation, BCR-ABL and Jak2.
Flow Cytometry
Flow cytometry was performed within 24 hours according to ELN guidelines for 
FC in MDS.(6,7) After ammonium chloride-based erythrocyte lysis and sequentially 
washing of the samples in phosphate-buffered saline/human serum albumin 0.1%, 
cells were pre-incubated with human serum immunoglobulins 5 mg/mL for 10 
minutes. aThe applied antibody panel outlined in Table S1, illustrates that CD45 or 
CD45/CD34 was used as back-bone marker in a 4-color analysis (2009-2012) and 
CD34, CD117, HLA-DR and CD45 were used as back-bone markers in the 8-color 
analysis (2012-2014).(6–8) Antibodies CD2 (FITC), CD5 (FITC), CD10 (PE), CD13 
(FITC) CD16 (FITC), CD25 (PE), CD64 (PE), and CD117 (APC), were purchased  from 
DakoCytomation, Glostrup, Denmark. CD7 (PE and APC), CD10 (APC-H7), CD11b 
(PE and APC), CD14 (APC and APC-H7), CD15 (FITC), CD19 (PE and APC-H7), CD33 
(PE and APC), CD34 (FITC, PerCP-Cy5.5, and APC), CD45 (PerCP), CD56 (PE), CD117 
(PE), and anti-HLA-DR (APC and V450) from BD Biosciences San Jose, CA, USA. 
CD36  (FITC) from Sanquin, Amsterdam, The Netherlands. CD45 (KO), CD117 (PC7), 
and CD123 (PE) were from Beckman Coulter, Miami, FL, USA. IREM2/CD300e (APC) 
was purchased from Immunostep Diagnostics, Salamanca, Spain.
At least 100,000 white blood cell events (CD45 positive cells) were acquired, 
including a minimum of 250 CD34 positive cells using a FACSCaliburTM  (with red 
and blue solid-state lasers from BD Biosciences; 2009-2012) or FACSCanto TM  II 
(with red, blue and violet solid-state lasers from BD Biosciences; 2012-2014). 
Aberrancies with regard to cell percentages (i.e. CD34 myeloid progenitors, B 
cell progenitors, etc.), sideward light scatter (SSC), expression levels of lineage 
specific markers and lineage infidelity markers on (im)mature myelomonocytic 
cells, were evaluated using Cell QuestPro (BD Biosciences) or Infinicyt software 
(Cytognos) for 4- and 8-color FC, respectively. Gating strategies were performed as 
previously described by the Dutch Working Party on FC in MDS and the European 
LeukemiaNet Working Party on FC in MDS.6,9
Analytical strategy
The data were analyzed using descriptive and explorative methods. Diagnostic 
categories were reported using absolute and relative frequencies (Table 1). The 
data was analyzed using SPSS, Version 20.0, LA.
Table S1A Four color panel of monoclonal antibodies used for immunophenotypic analysis 
of myeloid dysplasia.
FITC PE PerCP APC
1 CD45
2 CD16 CD13 CD45 CD11b
3 CD34 CD11b CD45 HLA-DR
4 CD36 CD33 CD45 CD14
5 CD36 CD64 CD45 CD14
6 CD15 CD10 CD45 CD34
7 CD34 CD117 CD45 CD13 /CD33
8 CD45 CD34
9 CD5 CD19 CD45 CD34
10 CD2 CD56 CD45 CD34
11 CD13 CD7 CD45 CD34
12 CD13 CD25 CD45 CD34




PC7 APC APC-H7 V450 KO
1 CD34 CD117 HLA-DR CD45
2 CD16 CD13 CD34 CD117 CD11b CD10 HLA-DR CD45
3 CD2 CD64 CD34 CD117 IREM2 CD14 HLA-DR CD45
4 CD36 * CD34 CD117 CD33 * HLA-DR CD45
5 CD5 CD56 CD34 CD117 CD7 CD19 HLA-DR CD45
6 CD15 CD25 CD34 CD117 * * HLA-DR CD45
7 CD7 * CD34 CD117 CD13 * HLA-DR CD45
CD45 or CD45 in combination with CD34 was used as back-bone marker in the 4 color 
analysis (A) and CD34, CD117, HLA-DR, CD45 were used as backbone markers in the 8 
color analysis (B). Abbreviations FITC: fluorescein isothiocyanate; PE: phycoerythrin; PerCP: 
Peridinin chlorophyll; PerCP Cy5.5: Peridinin chlorophyll cyanine 5.5; PC7: phycoerythrin-
cyanine 7; APC: allophycocyanin; APC-H7: allophycocyanin-Hilite7; V450: 405-nm violet; KO: 
Krome Orange.
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Due to the wide availability of flow cytometric (FC) markers that demonstrate 
the granulocytic cell differentiation, this compartment became the cornerstone 
of currently applied flow cytometric diagnostic strategies for myelodysplastic 
syndromes (MDS). In this study, we evaluated the diagnostic utility of granulocytic 
FC markers in a cohort of 239 samples. Bone marrow samples of 123 MDS patients, 
72 pathological controls and 24 healthy controls were retrospectively analyzed. 
Identified FC markers were analyzed in a separate MDS cohort of 70 patients.
The evaluation of all markers in the currently applied MDS-FC neutrophil analysis 
showed that percentage of the most immature neutrophil population (based on 
phenotype), premature expression of CD11b, delayed and decreased expression 
of CD16, and ≥10% of CD56-positive neutrophils were highly suggestive for MDS. 
Decreased sideward light scatter is frequently observed in MDS, but is at the same 
frequency affected in pathological controls. The total (decreased) percentage of 
granulocytes, might underline the diagnosis of MDS but need to be interpreted 
with caution as they face technical challenges due to hemodilution.
In conclusion, this study identified highly MDS specific neutrophil FC parameters 
that can contribute to more specific, more sensitive and most importantly more 
concise MDS-FC panels.
Introduction
Flow cytometry (FC) is a supplementary diagnostic instrument in myelodysplastic 
syndromes (MDS).1 With FC the myeloid, monocytic and erythroid cell compartments 
can be evaluated.2,3 Due to the wide availability of validated markers that demonstrate 
the granulocytic  differentiation, this compartment became the cornerstone of 
applied MDS-FC diagnostic strategies.4–6 Nowadays, more extensive multicolor FC 
and more advanced software tools have led to a gain in knowledge of normal and 
dysplastic granulopoiesis.
There is a wide range from few-parametric to complex MDS-FC scoring systems, 
with a sensitivity and specificity ranging from 69 to 98% and 78 to 93%, respectively.7 
Although many papers are published that describe the granulocytic maturation, 
there is no study that describes the validity of these markers in particular. In theory, 
a combination of a few highly specific markers will lead to highly specific identification 
of MDS. An increased number of markers will increase sensitivity, but will probably 
result in a less specific model. In this study, we analyzed applied granulocytic FC-
parameters in order to identify those markers that are most informative. This data 
may enable development of more concise MDS-FC panels which are less time 
consuming and less expensive.
Patients and Methods
We retrospectively analyzed 219 bone marrow samples from 123 untreated MDS 
patients, 72 non-clonal pathological controls and 24 healthy controls (age-matched 
volunteers), collected between October 2012 and January 2016. Diagnoses are 
listed in Table 1. The bone marrow samples from the healthy controls served as 
a references group.  FC-parameters that were significantly different between all 
groups and especially those markers that were significantly different between the 
MDS cases and pathological controls were validated in a different cohort of 70 MDS 
patients (Table 1).
Samples were processed according to guidelines recommended by the European 
LeukemiaNet Working Group on FC in MDS (IMDS-flow); data was obtained by 
8-colors FC (FACSCanto II; BD Biosciences, San Jose, CA) and analyzed with Infinicyt 
software (Cytognos, Salamanca, Spain).7,8 After assigning myeloid progenitors and 
monocytes (based on SSC/CD45/CD34/HLA-DR), granulocytes were selected by 
means of SSC/CD45. After elimination of eosinophils and apoptosis the studied 
neutrophil FC-parameters were: sideward light scatter (SSC; median and mode 
within different granulocytic subpopulations), median fluorescence intensity (MFI) 
and/or percentage of CD10, CD11b, CD13, CD15, CD16, CD33, CD45, CD64, HLA-DR, 
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expression of lineage infidelity markers CD2, CD5, CD7, CD14, CD56 and CD71.2,9 
Seven maturation stages, from most immature to most mature (G1-G7) were 
determined (population definitions are provided in the supplemental files: Figures 
S1-S2).
Statistical analyses were performed using PASW Statistics version 20.0 (SPSS, 
Chicago, IL). Reference p-value for significance was <0.05. Differences between 
patient groups were identified by the Kruskall Wallis test. The Mann-Whitney U 
test was applied as post-hoc test to analyze inter-group correlations.
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Abbreviations: RA: refractory anemia; RARS: refractory anemie with ring sideroblasts; 
RCMD: refractory cytopenia with multilineage dysplasia; RCMD-RS: refractory cytopenia 
with multilineage dysplasia with ring sideroblasts; Isolated del(5q): an isolated deletion of 
chromosome 5q; RAEB-1: refractory anemia with excess blasts type 1; RAEB-2: refractory 




Peripheral blood neutropenia is often observed in MDS. Therefore, a decreased 
percentage of neutrophils in the bone marrow may be considered as sign of 
possible MDS. As described determination of absolute cell counts is challenging by 
FC.10 The relative proportion of lymphocytes to myeloid cells can be used to detect 
abnormal low portions of myeloid cells. Our data revealed that the neutrophil-
lymphoid ratio was significantly decreased in MDS as compared to both control 
groups (Table 2). The neutrophil to lymphocytes ratio was not significantly different 
between patients with <5% or >5% myeloid progenitors (P=0.247). Patients with 
<5% myeloid progenitors had a median ratio of 5.2; range 0.3-25.8. Patients with 
>5% myeloid progenitors a median ratio of 3.0; range 0.3-44.5.
Side scatter
Hypogranulation of neutrophils is a cytomorphological characteristic often seen 
in MDS.11 The SSC is the FC equivalent of granulation. Within our cohort the SSC 
(ratio to lymphocyte SSC) proved to be specific for MDS as there was a significant 
decrease in SSC between MDS and both control groups.
Table 2 Comparison of potential granulocytic aberrancies in MDS, pathological controls 
and healthy controls
Parameter Cell subset MDS/HC MDS/PC HC/PC Total
SSC mode Total population <0.001 0.043 0.001 <0.001
CD10 negative 
population ns ns ns ns
CD10 positive 
population <0.001 0.005 0.027 <0.001
SSC median Total population <0.001 0.030 <0.001 <0.001
CD10 negative 
population 0.001 ns 0.004 0.002
CD10 positive 
population <0.001 0.048 <0.001 <0.001
CD10 
Percentage CD10 
positive ns ns ns ns
MFI ns <0.001 ns <0.001
CD15 MFI <0.001 ns <0.001 <0.001
CD45 MFI ns ns ns ns
CD64* Percentage ns ns ns ns
HLA-DR MFI ns ns ns ns
Presence of lymphoid 




Parameter Cell subset MDS/HC MDS/PC HC/PC Total
CD7 ns ns ns ns
CD56 <0.001 0.001 0.004 <0.001
Population size§ Percentage <0.001 <0.001 ns <0.001
Neutrophils/
lymphocytes <0.001 <0.001 ns <0.001
Neutrophils/
monocytes 0.023 0.043 ns 0.021
Percentage in G1 <0.001 <0.001 ns <0.001
Percentage in G2 ns ns ns ns
Percentage in G3 <0.001 <0.001 ns <0.001
Percentage in G4 ns 0.010 ns 0.021
Percentage in G5 <0.001 0.001 ns <0.001
Percentage in G6 ns ns ns ns
Percentage in G7 ns 0.816 ns ns
CD11b MFI in G4 0.025 0.003 ns 0.003
MFI in G5 ns 0.002 0.003 0.002
MFI in G6 ns 0.002 0.027 0.004
MFI in G7 ns 0.031 ns ns
CD13 MFI in G1 0.020 ns 0.008 0.032
MFI in G2 0.030 ns ns 0.050
MFI in G3 ns <0.001 0.003 <0.001
MFI in G4 ns <0.001 0.014 <0.001
MFI in G5 ns 0.007 0.002 0.003
MFI in G6 0.014 ns 0.004 0.018
MFI in G7 ns ns ns ns
CD16 MFI in G5 0.010 <0.001 ns <0.001
MFI in G6 <0.001 <0.001 Ns <0.001
MFI in G7 <0.001 0.005 0.036 <0.001
Eosinophils Percentage ns ns ns ns
Apoptosis Percentage <0.001 ns <0.001 <0.001
An overview of the statistical results per flow cytometry parameter. *Calculated based 
on limited number of cases, as CD64 was only evaluated in small subset. §Percentage of 
neutrophils (as ratio to lymphocytes) within the white blood cell fraction, and percentages of 
cells gated within the granulocytic cell subset after exclusion of eosinophils and apoptosis. 
Abbreviations: SSC is sideward light scatter; MFI is median fluorescence intensity; G1-G7 are 
subsets that categorize seven different maturation stages within the granulocyte fraction 
defined by expression of CD117/ HLA-DR/CD13/CD11b/CD16 (Figures S1 and S3).
The SSC was also decreased in pathological controls but still significantly different 
from MDS (Figure 1). The applied analysis software provides the median and the 
mode (peak channel value) of the SSC; when calculated for the total neutrophil 
population there was no difference between the mode or median. The SSC of 
the CD10-negative neutrophil compartment can be used to bypass the effect of 
hemodilution on FC results.12 However, we showed that both the mode as the 
mean SSC value of the CD10-negative cell population did not differ significantly 
between MDS and pathological controls. The SSC mode and median values of 
the CD10-positive neutrophil compartment were significantly different between 
MDS and both control groups. These results are in line with the cytomorphological 
observation of hypogranulation of mature neutrophils in peripheral blood smears. 
Furthermore, as CD10 can be aberrantly lost on neutrophils in MDS patients this 
advocates against this strategy of neutrophil selection based on CD10.
Figure 1 Scatter plots of most discriminatory FC-parameters in MDS analysis.
The parameters that were highly significant different between groups (healthy, PC, MDS) 
are plotted. The lines represent the median value per patient group. SSC mode and median 
are decreased in MDS, CD10 MFI is decreased in MDS, CD15 MFI is decreased in MDS, total 
population size (ratio lymphocytes/granulocytes) is decreased in MDS, population size in 
G1 is increased in MDS (% within granulocytes), CD11b is increased in G4 in MDS, and CD16 
is decreased in G6 in MDS. Note, that SSC, CD15-MFI and total population size are not MDS-




With use of differential expression of CD117, HLA-DR, CD11b, CD13 and CD16 we 
defined seven neutrophil maturation subsets (Supplementary files). An increased 
percentage of the most immature cells (G1: CD117-positive/HLA-DR-positive/
CD11b-negative/CD13-positive/CD16-negative) revealed to be highly specific 
for MDS (p<0.001 for MDS versus both control groups). Furthermore, this G1 
subset was significantly increased in MDS patients with >5% myeloid progenitors 
compared to MDS patients with <5% (p<0.001). Sizes of other immature neutrophil 
subsets were also significantly enlarged (G3) or decreased (G5) in MDS compared 
to the control groups.
We next evaluated CD11b-MFI, CD13-MFI, and CD16-MFI within the different 
maturational subsets. CD11b is normally present from G4 onwards, and CD16 
is normally present from G5 onwards. In MDS patients, there was a significant 
increased CD11b-MFI in G4 (Figure 1G; N=24/123 MDS patients; p=0.003). 
CD16-MFI was significantly decreased in G5 and G6 (Figure 1H-I; N=17/123 MDS 
patients; p<0.001 and p<0.001). Early increase in expression of CD11b (G4) and 
delayed or low expression of CD16 (G5-G6) appeared to be highly specific for 
MDS. This delayed expression of CD16 resulted in the characteristic convex CD13/
CD16 pattern (Figure S3).
CD10 is expressed on the most mature neutrophil subsets (from G6 onward). 
We found a significantly different expression of CD10 between the 3 groups. 
Remarkably, this was based on an increased CD10-MFI in pathological controls. 
Mainly caused by two outliers in the pathological control group. There was no 
difference with respect to CD10 expression between MDS and normal controls 
(G7; Figure 1C). Notably, CD10 is also lost on apoptotic cells. Apoptosis of 
hematopoietic cells within the bone marrow is a well-known phenomenon in MDS. 
Neutrophil apoptosis can easily be identified in the CD16/CD11b plot by selecting 
the CD16 diminished-to-positive, CD11b diminished cell population (Figure 2) (12). 
We found an increased percentage of apoptosis in MDS cases, however, there was 
not a significant difference between MDS and pathological controls.
CD15 is strongly expressed on mature granulocytes, with lower expression on the 
more immature cells. A decreased CD15-MFI is thought to be MDS-associated, 
in line with the left-shift commonly seen in MDS. In this analysis, a decreased 
CD15-MFI significantly distinguished MDS from healthy controls, but not from 
pathological controls.
Usually HLA-DR is not expressed on the more mature neutrophils in normal 
hematopoiesis. However, HLA-DR is described to be aberrantly expressed on 
neutrophils in MDS.10 In this study the HLA-DR expression was not significantly 
different in MDS patients comparted to the control groups.
Lineage infidelity markers
CD14 may be expressed on neutrophils in MDS.6 However, in our current cohort 
aberrant CD14 expression was not observed. Likewise, no expression of CD2, CD5, 
and CD7 was observed. In contrast, CD56 expression was detected on neutrophils 
in MDS and pathological controls, whereas it was absent on neutrophils in healthy 
controls (<1%). Thirty-seven percent of the MDS patients, 10% of the pathological 
control cases and none of the healthy controls had >1% CD56 positive neutrophils 
When applying a cut-off of ≥10%, 17% of the MDS patients and none of the control 
patients would be considered CD56-positive. In case of CD56-positive neutrophils 
≥10%), monocytes also expressed CD56.
Other markers
There was no significant difference in percentage of CD64, percentage of CD71, or 
CD45-MFI between MDS and the control group.
Due to polymorphism of CD33, CD33 was analyzed in a group comparison 
(expression of CD33 on myeloid progenitors, neutrophils and monocytes). 
Regardless of this, CD33 expression was increased in 10 cases (8 MDS patients and 
1 pathological control), decreased in 5 cases (3 MDS patients and 2 pathological 
controls) and normal in 158. This did not lead to a significant difference between 
the evaluated patient groups.
Identified parameters in an additional patient cohort
As described in the methods section, the aim of this study was to identify those 
parameters which are most significantly different between MDS, pathological 
controls and normal BM), especially focusing on markers that are significantly 
different between the MDS and pathological controls. To test the parameters 
identified in the study cohort, a test cohort of 70 MDS patients was assembled 
(Table 1). Within this validation cohort we tested, the percentage of cells within 
G1, CD11b expression in G3, CD16 expression in G4-G5, and the presence of 
≥10% of CD56-positive neutrophils. Here, we found that 49 out of the 70 (70%) 
patients showed ≥1 of these aberrancies (results in Table S1). The 26 patients 
without any aberrancy were: 1 RA patient, 2 RARS, 9 RCMD patients (of which 4 
had dysgranulopoiesis by cytomorphology), 6 RCMD-RS patients (of which 2 had 
dysgranulopoiesis by cytomorphology), 1 RAEB-1 patients, 2 RAEB-2 patients (both 
dysgranulopoiesis by cytomorphology), and 1 hypoplastic MDS patient.
In the test cohort, 41 of the 70 patients showed dysgranylopoiesis by 
cytomorphology, and 49 patients of the 70 patients had neutrophil aberrancies 
according to the described FC parameters. Although both techniques describe 





The granulocytic cell differentiation forms the corner stone of currently applied 
diagnostic strategies for myelodysplastic syndromes (MDS). The aim of this study 
was to provide a rational for reducing the number of parameters in current MDS-
FC panels, to implement the wider use of FC in MDS diagnosis. In daily clinical care, 
patients with possible MDS will present based on the presence of cytopenias. 
Therefore, to optimize the use of MDS-FC parameter selection focus should be on 
distinction between MDS and pathological controls, and not on the distinction of 
patients from normal, healthy bone marrow per se. The data show that an increase 
in the percentage of the most immature neutrophil population (assigned as G1), 
the early expression of CD11b (G1), decreased expression of CD16 on maturing 
neutrophils (G5-G6; convex CD13/CD16 pattern), and the expression of CD56 (10% 
cut-off) were highly indicative for MDS. Within our cohort the sideward light scatter 
(SSC; as a ratio to lymphocyte SSC) proved to be frequently decreased in MDS. 
This confirms data from Ogata and colleagues who described SSC as a cardinal 
diagnostic parameter.14 The SSC might be of additional relevance but needs to be 
interpreted with caution, as it distincts MDS from healthy controls but not from 
pathological controls. In our data SSC is as frequently decreased in pathological 
controls. Therefore, in this analysis the SSC is not included in validation cohort.
Total percentage of neutrophils and the CD10-MFI are also markers that might 
be of additional relevance, but one needs to keep in mind that these are easily 
influenced by sample quality as they are influenced by hemodilution.
Abnormal maturation patterns reflected by abnormal CD11b/CD13, CD13/CD16 and 
CD11b/CD16 patterns are also described in pathological controls.15 However, early 
increased expression of CD11b and decreased expression of CD16 appeared to be 
highly indicative for MDS. Note, that CD16 detects a glycosylphosphatidylinositol-
linked antigen and loss can also be characteristic for a paroxysmal nocturnal 
hemoglobinuria (PNH) clone, co-occurring with MDS (seen in very low frequencies) 
and aplastic anemia. However, the difference between PNH and MDS is easily 
made by total absence of CD16 versus decreased expression on only the most 
mature cell subsets.
Another pitfall in the selection of G1-G7 subgroups by pattern recognition is the 
asynchronous left shift described in MDS. Furthermore, aberrant expression 
of subpopulation defining markers can influence the population selection, 
i.e. prolonged expression of CD117 that is therefore still present in G3. Here, 
expression of CD45 and SSC might help to correctly identify the different 
subpopulation. For G1 this forms less of a problem, as this population can easily 
be identified by CD34negative/CD117positive and the previous described markers 
(Supplementary files).
Increased apoptosis of BM cells is one of the main features in low grade MDS bone 
marrow. Since, apoptosis is influenced by sample quality and processing time, 
it may not be a reliable diagnostic parameter.4 Our data showed that increased 
apoptosis was not MDS-restricted. However, it remains important to identify 
apoptosis as apoptosis can result in altered marker expression, i.e. decreased 
CD10, CD11b and CD16. Marker aberrancies that might therefore be falsely 
interpreted as typical MDS.
Finally, a considerable percentage of CD56-positive neutrophils (≥10%) were only 
detected on neutrophils of MDS patients. These results were in line with Bardet 
et al.16 However, they pointed out that neutrophil-CD56 expression was not a 
sensitive marker as only 3% of the MDS cases showed CD56-positive neutrophils 
(cut-off >30%). In our analyses, none of the pathological controls had ≥10% CD56-
positive neutrophils. Therefore, we propose that CD56-positive neutrophils are 
highly suggestive for MDS, and a threshold of ≥10% is feasible to score CD56 as 
an aberrant marker.
Our data on flow cytometric analysis of dysplastic granulopoieis underscore the 
contribution of FC in the distinction of patients with cytopenia based on MDS or 
other causes of cytopenia. Therefore, FC is currently part of the recommendations 
for the diagnostic work-up in MDS. However, the use of FC in MDS needs further 
refinements and is subject of extensive research to further improve MDS 
diagnosis.2 Analysis of granulopoiesis is an important part of current MDS-FC 
strategies. We identified herein that only part of the recommended markers is 
highly indicative for MDS. This is the first step to optimize more concise MDS-FC 
panels that are more specific, less time-consuming and easier to apply in routine 
daily laboratory medicine.
Sources of support: none declared.
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Figure S1 The evaluated neutrophil maturation stages.
The graph illustrates the median CD-marker expression levels of 20 normal 
controls for each maturation stage, from most immature (G1) to most immature 
(G7). The expression levels are in logarithmic scale. Additionally, HLA-DR and 
CD117 expression were used.
G1: CD117 positive/HLA-DR positive/CD11b negative/CD13 bright/CD16 negative
G2: CD117 positive/HLA-DR negative/CD11b negative/CD13 positive/CD16 negative
G3: CD117 negative/HLA-DR negative/CD11b negative/CD13 negative/CD16 negative
G4: CD117 negative/HLA-DR negative/CD11b positive/CD13 negative/CD16 negative
G5: CD117 negative/HLA-DR negative/CD11b positive/CD13 negative/CD16 positive
G6: CD117 negative/HLA-DR negative/CD11b positive/CD13 positive/CD16 positive
G7: CD117 negative/HLA-DR negative/CD11b positive/CD13 bright/CD16 bright
Figure S2 Example MDS neutrophil maturation stages.
This graph illustrates the expression levels of CD11b, CD13 and CD16 of the same 
MDS patient as provides in Figure S3. CD11b is normally expressed within the 
different subsets. CD13 is increased expressed in G1-G3 and stays expressed, 
even in the normally CD13 negative population (G4). CD16 is decreased expressed 
in G5-G6.
Table S1 Results of the test cohort.
WHO2001 %G1 CD11bG3 CD16G4-5 CD56 Total
RA 1 0 0 0 1
RA 0 0 1 0 1
RA 0 0 0 0 0
RARS 0 0 0 0 0
RARS 0 0 0 0 0
RCMD 1 0 0 1 2
RCMD 1 0 1 0 2
RCMD 1 1 0 0 2
RCMD 0 0 1 0 1
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD 1 0 1 1 4
RCMD 1 0 1 0 3
RCMD 0 0 1 0 2
RCMD 1 0 1 0 2
RCMD 0 1 1 0 2
56 57
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RAEB-2 1 0 1 0 2
RAEB-2 1 0 0 1 2
RAEB-2 1 0 0 0 1
RAEB-2 0 0 1 0 1
RAEB-2 0 0 1 0 1
RAEB-2 1 0 1 1 3
RAEB-2 1 0 1 0 3
RAEB-2 0 0 1 0 3
RAEB-2 0 0 1 0 1
RAEB-2 0 0 0 0 0
RAEB-2 1 1 1 0 3
Del(5q) 1 0 0 0 1
Hypoplastic MDS 0 0 0 0 0
Hypoplastic MDS 1 0 0 0 1
Table S1 (continue)
WHO2001 %G1 CD11bG3 CD16G4-5 CD56 Total
RCMD 1 0 1 0 2
RCMD 1 0 0 0 2
RCMD 0 0 0 0 1
RCMD 0 1 0 1
RCMD 0 0 0 0 0
RCMD 0 0 0 0 0
RCMD-RS 1 0 1 1 3
RCMD-RS 0 0 1 1 2
RCMD-RS 1 0 1 0 2
RCMD-RS 1 0 0 0 1
RCMD-RS 1 0 0 0 1
RCMD-RS 0 1 0 0 1
RCMD-RS 0 0 1 0 1
RCMD-RS 0 1 0 0 1
RCMD-RS 0 0 0 0 0
RCMD-RS 0 0 0 0 0
RCMD-RS 0 0 0 0 0
RCMD-RS 0 0 0 0 0
RCMD-RS 0 0 0 0 0
RCMD-RS 0 0 0 0 0
RCMD-RS 1 0 1 0 2
RCMD-RS 0 0 0 0 1
RCMD-RS 1 1 0 0 1
RCMD-RS 0 0 0 0 1
RCMD-RS 0 1 1 0 1
RAEB-1 1 0 1 0 2
RAEB-1 1 0 1 0 2
RAEB-1 1 0 0 0 1
RAEB-1 0 0 0 0 0
RAEB-1 1 0 1 1 3
RAEB-1 1 0 1 0 3
RAEB-1 1 0 1 0 3
RAEB-1 1 0 0 0 1
RAEB-1 1 0 0 0 1
RAEB-2 1 0 1 0 2
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Current recommendations for diagnosing myelodysplastic syndromes (MDS) 
endorse flow cytometry (FC) as an informative tool. Most FC protocols focus on 
analyzing progenitor cells and the maturing myelomonocytic lineage. However, 
one of the most frequently observed symptoms in MDS is anemia, which may be 
associated with dyserythropoiesis. Therefore, analysis of changes in FC features 
of nucleated erythroid cells may complement current FC tools. The multicenter 
study within the IMDSFlow Working Group reported herein focused on defining FC 
parameters that enable discrimination of dyserythropoiesis associated with MDS 
from non-clonal cytopenias. Data from a learning cohort were compared between 
MDS and controls, the results were validated in a separate cohort. The learning 
cohort comprised 253 MDS cases, 290 pathological and 142 normal controls; 
the validation cohort 150 MDS cases, 153 pathological and 49 normal controls. 
Analysis of expression of CD36 and CD71 in combination with the percentage 
of CD117+ erythroid progenitors provided the best discrimination between MDS 
and non-clonal cytopenia (specificity and sensitivity: 90% and 33% in the learning 
cohort and 92% and 24% in the validation cohort, respectively). This marker 
combination may improve the evaluation of cytopenic cases with suspected MDS, 
particularly when combined with FC assessment of the myelomonocytic lineage.
Introduction
Discriminating between cytopenia due to myelodysplastic syndromes (MDS) and 
cytopenia due to other (non-clonal) causes can be challenging, especially when 
dysplasia as assessed by cytomorphology does not fulfill the diagnostic criteria of 
MDS according to WHO criteria, and when other MDS-specific features are absent 
(e.g. ring sideroblasts (RS) or cytogenetic aberrations). Current recommendations 
for the diagnosis of MDS endorse flow cytometry (FC) as a valuable additional 
diagnostic tool. In this respect, it has been recommended to follow the guidelines 
set down by the International/European LeukemiaNet Working Group for FC in 
MDS (IMDSFlow).1-3
Despite the fact that FC for MDS correlates with cytomorphology, the sensitivity 
of current validated FC scores for diagnosing MDS requires improvement.4-7 
So far, most of the designed FC scores have comprised the analysis of the (im)
mature myelomonocytic lineage with a median sensitivity of 75% for identifying 
MDS (median specificity, 94%; summarized in 3). Since anemia is a frequently 
observed symptom in MDS, often accompanied by erythroid dysplasia, analysis of 
immunophenotypic changes of nucleated erythroid cells (NEC) may complement 
current FC analysis.8, 9 Thus far, this has not been studied in great detail. Integration 
of results from analysis of the erythroid lineage to the primarily myelomonocytic 
and progenitor cell-based FC scores may improve sensitivity of FC analysis in 
MDS.7, 10-12
Incorporating erythroid markers in FC protocols requires knowledge of normal 
erythroid differentiation, and of potential aberrancies and pitfalls. The characteristic 
morphological stages of normal erythroid differentiation are reflected by their light 
scatter properties and by their differential expression of CD45, CD117, CD105, CD71, 
CD36 and/or CD235a (Figure 1).13-15 Some of the FC aberrancies that have been 
reported to reflect MDS-related dyserythropoiesis are: a) an increased number of 
NEC within total nucleated cells; b) an altered proportion of consecutive erythroid 
differentiation stages, such as an increased number of immature erythroid cells 
(CD117+ and/or CD105+) or, by contrast, a decrease in erythroid progenitors; c) 
an abnormal pattern of CD71 versus CD235a; d) a reduced expression of CD71 
and/or CD36; and e) an overexpression of CD105. Most of these aberrancies are 
present in 70–80% of MDS cases.7, 10-12, 14, 16-20 However, a number of features may 
be shared across the spectrum of non-clonal cytopenias.21-23
The multicenter study reported herein focused on defining those erythroid FC 
parameters that enable discrimination of dyserythropoiesis associated with MDS 
from non-clonal cytopenias. Hereto, data from a learning cohort were compared 





MDS patients and controls
Nineteen centers (members of the IMDSFlow group) collected FC data on the 
erythroid lineage in mainly low grade MDS cases (<5% blasts) and controls. Data 
were acquired from bone marrow samples taken from 1037 patients and healthy 
controls after informed consent in accordance with the Declaration of Helsinki; 
where required, local ethics committee approval was obtained. The learning cohort 
comprised 685 cases (18 centers, data collected between October 2012 and 
September 2013) and the validation cohort 352 cases (9 centers, data collected 
between December 2013 and April 2014). In total 403 MDS cases, 443 pathological 
controls, and 191 normal controls were analyzed (Tables 1 and 2). Information 
regarding age, gender, cytomorphology and cytogenetics were requested. One 
center with limited access to cytomorphology results only included MDS patients 
with typical features of MDS as the presence of more than 15% RS and MDS-
Figure 1 Flow cytometric profiles of normal erythroid differentiation.
Early erythroid precursors are defined as CD45dim/SSCint/CD34+/CD117+/CD105+, 
proerythroblasts as CD45dim/-/SSCint/CD117+/CD105+/CD71+/CD36+/CD235a+, basophilic 
erythroblasts as CD45dim/-/SSCint/CD105+/CD36++
/CD71+/CD235a+, polychromatic erythroblasts as CD45-/SSClow/FSCint/CD36+/CD71+/
CD235a+ and orthochromatic erythroblasts CD45-/ SSClow/FSClow/CD36+/-/CD71+/CD235a+. 
Indicated colors reflecting erythroid subsets are not present in the CD71 vs. CD235a plot. 
Pink colored cells represent the total erythroid lineage in this plot. Mature erythrocytes 
(CD45-/CD36-/CD71-/CD235a++)  can be seen in  improperly lysed cell preparations (Fig 1F). 
Reticulocytes are not covered in these graphs, but they may appear as CD71dim-to-negative 
in non-lysed cell preparations. Myeloid progenitors are CD34+/CD117+/HLA-DR+/CD105- 
(Figure 1C and D.) and have slightly higher CD45 expression than erythroid precursors; 
moreover, erythroid cells do not express HLA-DR in contrast to myeloid progenitors 
(adapted from references (13-15))
Table 1 Characteristics of MDS patients and controls in the learning and validation cohort
Learning cohort Validation cohort
Normal
n 142 49












age 61 (43-85)a 79 (39-88)a
male:female 1:1 2.5:1
Comparison of age
normal vs. pathological controls p = 0.007 p = 0.193
pathological controls vs. MDS p < 0.001 p = 0.013
Comparison of gender n.s. n.s.
Note: adata  is expressed as the median and range; abbreviations: MDS: myelodysplastic 
syndromes; n: number; n.s.: not significant, RAEB: refractory anemia with excess of blasts.
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associated cytogenetic anomalies. In 354/403 MDS cases subclassification 
according to the WHO-2008 (ref. 24) was provided. MDS-RAEB (refractory anemia 
with excess of blasts; 29/403 MDS) was considered a separate subset, because it 
is less challenging to separate these MDS cases from pathological controls than 
low grade MDS. The median contribution per center to the total study cohort was 
47 cases (range 6–100) and the median number of erythroid FC markers analyzed 
per case was 7 (range 1–9 of 10 proposed markers).
Sample preparation and antibody combinations
Flow cytometric analysis in MDS requires the removal of mature, enucleated 
erythrocytes through the use of lysis protocols. The vast majority of centers 
used ammonium chloride-based solutions, either home-made or commercial 
(e.g. PharmLyse; BD Biosciences, San Jose, CA); two centers used FACSLyse (BD 
Biosciences) and one other VersaLyse (Beckman Coulter, Miami, FL). FACSLyse 
contains a fixative, whereas VersaLyse is recommended for use with a fixative 
when the sample contains anticoagulants other than EDTA. The lysis time and 
temperature varied among centers (5-25 minutes and 4-37°C, respectively), 
but most lysed for 10 minutes (n=10) at room temperature (n=16). Two centers 
reported the use of an additional fixative in their staining protocols, both 
in combination with an ammonium chloride-based lysing solution. Detailed 
information can be found in Supplementary information. Most centers used 
the IMDSFlow-recommended lyse-stain-wash procedure; five centers performed 
stain-lyse-wash. Antibody combinations were similar between centers, but clones 
and fluorochromes differed. Most centers used a backbone of CD45 and CD34 
and/or CD117 and added antibodies such as CD235a, CD71, CD36 and CD105. 
Examples of antibody combinations and panels were described previously.2, 25, 
26 Nuclear dyes were not routinely included in the panels; one center applied 
the live/dead stain 7-AAD. The flow cytometers used included: FACSCalibur 
(BD Biosciences; n=3); FACS CANTO-II (BD Biosciences; n=10); a combination of 
FACSCalibur and FACS CANTO-II (both BD Biosciences; n=2); and Navios (Beckman 
Coulter; n=4).  Panels comprised 4-, 5-, 6-, 8- and/or 10-color FC; WinList 7.0 (Verity 
Software House, Topsham, ME), Kaluza (Beckman Coulter), CellQuestPro, FACS-
DIVA (both BD Biosciences), and/or Infinicyt (Cytognos, Salamanca, Spain) software 
packages were used for data analysis.
Table 2 Subcategories of MDS and pathological controls in the learning and validation cohort
Learning cohort Validation cohort
MDS subcategories
RCUD 23 (9.1%) 14  (10%)
RARS 16 (6.3%) 12 (9.3%)
RARS-t 2 (0.8%) 1  (0.7%)
RCMD 155 (61.2%) 75  (50%)
del(5q) 14 (5.5%) 5 (3.3%)
MDS-U 3 (1.2%) 3 (2.0%)
RAEB-1 5 (2.0%) 12  (8.0%)
RAEB-2 3 (1.2%) 9 (6.0%)
other 2 (1.3%)*
not specified 32 (13%) 17 (11%)**
Subcategories of pathological controls
iron deficiency anemia 22 (7.6%) 13 (8.5%)
iron incorporation disturbances or anemia 
in chronic disease
42 (14.5%) 8 (5.2%)
vitamin B12/folic acid deficiencies 11  (3.8%) 11 (7.2%)
anemia in auto-immune diseases 13 (4.5%) 7 (4.6%)
anemia due to renal failure 6 (2.1%) 5 (3.3%)
anemia other 9 (3.1%) 9 (5.9%)
cytopenia associated with marrow 
infiltration
20 (6.9%) 7 (4.6%)
cytopenia induced by chemotherapy or 
medication or post-SCT
27 (9.3%) 8 (5.2%)
ITP or neutropenia or auto immune 
cytopenia NOS
30 (10.3%) 14 (9.2%)
reactive conditions or cytopenia induced 
by infections
32 (11%) 10 (6.5%)
normal bone marrow, peripheral cytopenia 6 (2.1%) 0
other than defined subcategories 29 (10%) 23 (15%)
inconclusive 11 (3.8%) 8 (5.2%)
non clonal cytopenia NOS 25 (8.6%) 19 (12,4%)
ET, PV, primary myelofibrosis 5 (1.7%) 7 (4.6%)
PNH 1 (0.3%) 0
AA 1 (0.3%) 4 (2.6%)
Values in brackets represent the relative distribution within MDS or pathological control 
subgroups; *other concerns one case of hypoplastic MDS and one case of MDS with fibrosis; 
**not specified, but the presence of MDS-associated cytogenetic aberrations indicated; 
abbreviations: AA: aplastic anemia, ET: essential thrombocythemia; MDS: myelodysplastic 
syndromes, MDS-U: MDS-unclassifiable; NOS: not otherwise specified, PNH: paroxysmal
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hemoglobinuria, PV polycythemia vera; RA: refractory anemia,  RAEB: refractory anemia with 
excess of blasts,  RCMD: refractory cytopenia with multilineage dysplasia, RCUD: refractory 
cytopenia with unilineage dysplasia,  del(5q): MDS with isolated del(5q). Comparison of 
the distribution of MDS subsets among the learning and validation cohorts did not differ 
(Chi-Square test; p=0.511 when excluding MDS RAEB cases); the distribution of subsets of 
pathological controls did (p<0.001).
Gating strategy and data collection
The gating strategy was discussed during the IMDSFlow meeting in 2011 and re-
evaluated in 2012. All participants performed FC analysis of the erythroid lineage 
defined as CD45dim-to-negative and SSClow-to-intermediate. Noteworthy, the initially proposed 
gating strategy (erythroid lineage defined by CD45 negativity) was altered to 
include early erythroid precursors that are within the CD45dim cell population.2, 
3, 12 Six or more color panels enabled the inclusion of a myeloid-defining marker 
such as CD13 or CD33 and a more accurate separation of myeloid and erythroid 
progenitors. Moreover, to exclude platelets and platelet aggregates, a combination 
of scatter properties and CD36high/CD71- was suggested. The final gating strategy 
was distributed among all centers (further details in Supplementary information 
on gating strategy).
The following parameters were collected: the percentage of NEC within all 
nucleated cells; the expression pattern of CD71 versus CD235a; the percentage 
of CD71dimCD235a+ cells within the CD71/CD235a pattern; CD71 and CD36 
expression levels; the percentage of CD117+ cells in the erythroid compartment; 
CD105 expression level and the percentage of CD105+ cells in the erythroid 
compartment. Recent knowledge, such as the finding that CD71 and CD36 
expression represented as CV is statistically more significant than when 
represented as mean fluorescence intensity (MFI)27, led to adjustments in the 
initially proposed protocol and hence, reanalysis of the list mode data files by the 
individual centers. Some examples of FC plots of MDS in comparison to normal 
subjects are displayed in Supplementary information on gating strategy.
Statistical analyses
Due to differences in sample processing, instrument settings, clones, and 
fluorochromes between centers, the expression levels of CD71, CD36, and CD105 
varied. Therefore, the median expression levels of CD36, CD71, and CD105 in 
the subset of normal bone marrow samples were calculated for each individual 
center. Expression levels were then normalized against the median value for 
that particular marker for each center separately. Patient and control groups 
were compared using the Kruskal Wallis test for continuous data, and the Chi-
square or the Fisher’s exact test for dichotomous data. Correlations between 
certain markers, and between markers and age, were analyzed using Spearman’s 
rank correlation coefficients. Cut-off values for aberrancies were based on the 
10th and/or 90th percentile of the data of pathological controls in the learning 
cohort. Multivariate logistic regression analyses were performed to determine 
the erythroid markers that discriminate between pathological controls and MDS; 
all variables that displayed a univariate difference of p<0.1 were included in a 
backward selection procedure based on the Likelihood Ratio score. Regression 
coefficients of the variables in the final model were used to define the weight of 
these markers in a descriptive score for dyserythropoiesis. Cut-off level of the 
score indicating MDS-associated erythroid aberrancies was determined based on 
the total weight of these variables and a specificity of at least 90%. The sensitivity 
and specificity of the marker combination were calculated to illustrate predictive 
accuracy. The data were analyzed using SPSS 20.0 (IBM Corp, Armonk, NY), and 
GraphPad 6.0 software (La Jolla, CA). P-values <0.05 were considered significant.
Results
Flow cytometric analysis of the erythroid lineage in normal bone marrow 
samples: comparison of results from participating centers
Discrepancies in erythroid analysis between centers (and samples) can occur 
at several levels: a) sample quality (e.g., hemodilution); b) sample preparation 
(e.g., lysing procedure); c) data acquisition (e.g., acquisition rate and threshold 
of forward light scatter); and d) degree of adherence to the proposed gating 
strategy. Therefore, we first compared the FC results for normal bone marrow 
samples (learning cohort) between centers in terms of each defined marker. 
The percentage of NEC was highly diverse among centers; yet, it seemed to be 
independent of the applied lysing method (Supplementary Figure 1). Similarly, 
the percentage of CD71dim cells differed largely between centers. Furthermore, 
two centers reported higher percentages of CD117+ erythroid progenitors (up 
to 50% within the NEC) than the other centers (<15%). Results for one center 
could be explained by their stringent lysing procedures (i.e. 15 minutes at 37°C) 
which removed more mature (orthochromatic and polychromatic) erythroblasts 
resulting in a relative increase in early progenitors (data not shown). To circumvent 
the issues regarding differences in percentages of erythroid (sub)populations 
between centers, data of percentages of NEC, CD117+ and CD105+ erythroid 
progenitors were also normalized as described for expression levels of the 
antigens (see Material and Methods statistics section); these are further referred 
to as relative percentages, i.e. relative to the median percentage in normal 
bone marrow samples (Supplementary Figure 2). CD71dim cells are rarely seen 
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in normal controls; therefore, results for the percentage CD71dim could not be 
normalized.
Erythroid aberrancies that may discriminate between MDS and pathological 
controls
Next, all FC-erythroid parameters in the learning cohort were compared between 
MDS and controls. The results from the learning cohort are summarized in 
Figure 2 (p-values in Supplementary Table 1). The relative percentage of NEC 
within the total nucleated cell population was significantly higher in MDS than 
in the pathological and normal controls (p<0.001). Similarly, the CD71-CD235a 
differentiation pattern was more frequently considered aberrant in MDS (65%, 
109/167 cases) than in pathological and normal controls (18% (44/254) and 
3.7% (5/134) of cases, respectively (p<0.001)). To objectify the evaluation of this 
pattern, we analyzed its components separately. CD71 expression was analyzed 
in terms of MFI, CV, and the presence of a subpopulation with reduced CD71 
expression (CD71dim). The relative CD71 MFI was significantly reduced in MDS, 
whereas the relative CV for CD71 and the percentage of CD71dim cells were 
significantly higher than those in both control groups (p<0.001); no significant 
differences were observed between the pathological controls and normal bone 
marrow samples. The expression of CD235a largely depends on the success of 
removing mature erythrocytes from a sample. Moreover, membrane fragments 
of lysed erythrocytes may stick to other cells in the analysis sample mimicking 
positivity. Hence, this parameter was considered too unreliable for evaluation 
when considered individually.
The percentage of immature erythroid progenitors can also affect the appearance 
of the differentiation pattern. This was evaluated by calculating the relative 
percentage of CD117+ (and CD105+) erythroid progenitor cells, which revealed a 
broader range of these cells in MDS, although not significantly different from the 
control groups.
Relative expression of CD105 was either increased or decreased in MDS. 
Nonetheless, CD105 expression did not discriminate between MDS and 
pathological controls.
Similar to that for CD71, the relative MFI of CD36 was significantly lower and the 
relative CV for CD36 was significantly higher in MDS than in the control groups. 
Figure 2 Distribution of results for erythroid markers analyzed by flow cytometry among 
MDS patients and controls within the learning cohort. Results of the analysis of indicated 
markers of the erythroid lineage are plotted along the X-axes: relative (rel.) percentages of 
nucleated erythroid cells (NEC), rel. mean fluorescence intensity (MFI) for CD36, CD71 and 
CD105, rel. coefficient of variation (CV) of CD36 and CD71, and rel. percentages of CD117+ 
and CD105+ erythroid progenitors. Relative frequencies (as percentage of the MDS or 
control cohort for a particular marker) are depicted along the Y-axes. Dotted lines represent 
results for normal bone marrow (NBM) samples, dashed lines pathological controls (PC) and 
solid lines MDS cases. P-values of comparison between groups are depicted: **: <0.001, *: 
<0.05, ns: not significant (Kruskal Wallis test). Grey boxes indicate reference ranges for the 
analyzed markers as defined by 10th and 90th percentiles of pathological controls. Note that 
MDS-RAEB cases were excluded from the MDS group in these graphs.
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To summarize, the markers that showed a significantly different distribution in MDS 
as compared to controls were: the relative percentage of NEC and the percentage 
of CD71dim cells (increased in MDS); the relative MFI of CD71 and CD36 (decreased in 
MDS); and the relative CV for CD71 and CD36 (increased in MDS); Figure 2.
Selection of a combination of erythroid FC aberrancies that distinguish MDS from 
pathological controls
To be applicable in FC analysis of a single patient in daily practice, cut-offs for the 
identification of MDS-associated changes of all potential aberrancies were defined 
(10th and 90th percentiles of the pathological controls, Supplementary Table 2) and 
compared between MDS and controls (Table 3). All parameters differed between 
groups at a p-value of <0.1 and thus could have been considered for the multivariate 
logistic regression analysis. However, due to large differences between centers, 
regarding the percentages of NEC and CD71dim cells (likely due to technical variation 
as shown for normal controls), these parameters were not entered in the multivariate 
analysis. Besides, irrespective of the finding that data for CD105 significantly 
discriminated between subgroups (Table 3), this marker was not included. Entering 
CD105 data would have reduced the power of the (multicenter) analysis, since data on 
CD105 were only available in a limited number of centers (5/18) and cases.
Table 3 Aberrancies in FC markers of the erythroid lineage between MDS and controls 
within the learning cohort









rel. %NEC 2.9 10.1 32.1 <0.001 <0.001   0.013
pattern CD71 vs. CD235a 3.7 17.3 64.9 <0.001 <0.001 <0.001
%CD71dim 0.8 10.0 31.5 <0.001 <0.001 <0.001
rel. MFI of CD71 4.0 10.0 27.8 <0.001 <0.001   0.045
rel.CV of CD71 4.5 10.3 45.5 <0.001 <0.001   0.152
rel. MFI of CD36 0.8 10.3 25.8   0.001 <0.001 <0.001
rel. CV of CD36 0.0 10.2 30.1 <0.001 <0.001   0.001
rel. %CD117 progenitors 8.2 19.4 33.8   0.005 <0.001   0.008
rel. %CD105 progenitors 6.7 20.8 48.4   0.001 <0.001   0.092
rel. MFI of CD105 29.8 22.5 58.7 <0.001   0.004   0.395
Note: After applying cut-offs as defined in the set of pathological controls, the results were 
expressed as ‘0’ and ‘1’ for within and beyond reference range(s), respectively (ranges as 
displayed in Supplementary table 2). Percentages of subjects with aberrancy are displayed 
for normal bone marrow (NBM), pathological controls (PC) and MDS cases. Results were 
compared among subgroups using Fisher’s Exact test; p-values are depicted. Abbreviations; 
CV: coefficient of variation; dim: diminished; MFI: mean fluorescence intensity; NEC: 
nucleated erythroid cells; rel.:relative. MDS-RAEB cases were excluded from this analysis.
The multivariate logistic regression analysis identified the CD36 CV as the best 
discriminator between MDS and pathological controls in combination with the CV of 
CD71, the MFI of CD71 and the percentage of CD117+ erythroid cells (Table 4A). These 
four markers were used to define a FC-erythroid dysplasia score in which aberrancies 
were scored in a weighted manner: four points for increase in CD36 CV; three points 
for increase in CD71 CV; two points for decreased CD71 MFI; and two points in case 
of decreased or increased percentage of CD117+ erythroid cells (reference ranges 
are summarized in Table 5). A cut-off of ≥5 points resulted in the identification of 
MDS-associated erythroid aberrancies by FC at a specificity of 90% (95% CI: 84–94%) 
and a sensitivity of 33% (95% CI: 24–42). Results for the selected markers and the 
application of the FC-erythroid dysplasia score in the learning cohort are displayed in 
Table 6 and Figure 3A. In daily practice, a numerical score based on one point per 
aberrancy would be more convenient. This involves the definition of a new cut-off; i.e., 
≥2 aberrant markers; Figure 3C. Note that, the exception to this numerical score is 
that the combination of aberrancies in CD71 MFI and percentage CD117+ alone is not 
sufficient to conclude dyserythropoiesis by FC (only 4 points in the weighted score). 
The latter was seen in one pathological control and three MDS cases.
Table 4 Results of multivariate logistic regression analysis in learning (A), validation (B) and 
combined cohorts (C and D).
parameter exp(B) 95% CI p-value
A   learning cohort CD36 CV 3.7 1.6 – 8.5   0.003
CD71 CV 3.2 1.6 – 6.4   0.001
CD71 MFI 2.2 1.1 – 4.5   0.033
%CD117 1.7 0.92 – 3.2   0.084
B   validation cohort CD36 CV 2.6 0.94 – 7.4   0.067
%CD117 2.6 1.1 – 5.2   0.007
CD36 MFI 2.3 1.3 – 4.9   0.038
C   combined cohorts CD36 CV 2.9 1.5 – 5.6   0.001
CD71 CV 2.9 1.7 – 4.9 <0.001
%CD117 2.0 1.3 – 3.2   0.004
CD36 MFI 1.7 0.99 – 2.8   0.053
D   combined cohorts CD71 MFI 3.6 1.2 – 11   0.025
%CD105 3.6 2.0 – 6.5 <0.001
CD36 CV 3.2 1.1 – 9.7   0.036
CD71 CV 3.1 1.4 – 7.1   0.007
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Note: Panels A-C: markers entered in the analysis were relative CD36 MFI, CD36 CV, CD71 
MFI and CD71 CV, and the relative percentage of CD117+ erythroid cells (%CD117). Panel 
D: markers entered in the analysis were similar as in panel A-C but now including the 
percentage of CD105+ erythroid cells (%CD105). Relative expression of CD105 was excluded 
because of a significant correlation with age.
Panel A; 270/535 cases were available for analysis of which 152 pathological controls and 
118 MDS cases in the learning cohort; p<0.001). Panel B; 199/282 cases were available for 
analysis of which 106 pathological controls and 93 MDS cases; p<0.001). Panel C; 469/817 
cases were available for analysis of which 258 pathological controls and 211 MDS cases; 
p<0.001). Panel D; 242/575 cases were available for analysis of which 125 pathological 
controls and 117 MDS cases; p<0.001).
Table 5 Reference ranges of FC parameters incorporated in the FC-erythroid dysplasia score
Reference
Rangesc
# of PC 
casesa
# of NBM 
casesb
relative CV of CD36 <145% 175 92
relative CV of CD71 <133% 177 86
relative MFI of CD71 >46% 250 126
relative %CD117+ erythroid cells 37–212% 182 122
Reference ranges represent values relative to median values for the analyzed markers in 
the erythroid compartment of normal bone marrow subjects. These values represent 10th 
and/or 90th percentiles as determined in the set of pathological controls (PC) within the 
learning cohort. anumber of PC cases that were available to calculate cut-off values (10th 
and 90th percentiles); bnumber of NBM cases that were available to calculate median values. 
Abbreviations: CV: coefficient of variation; MFI: mean fluorescence intensity.
Correlation between erythroid markers and age
The incidence of MDS increases with age; hence, erythroid markers that are 
significantly correlated with age may be less suitable for discriminating between 
MDS and controls. Since we observed significant differences between the groups 
regarding age (Table 1); correlations between FC results for erythroid markers and 
age were evaluated for normal bone marrow samples. Only CD105 MFI, a variable 
that was not included in the multivariate analysis, demonstrated a moderate-to-
good correlation with age (Spearman’s Rho -0.55, p<0.001, n=47, Supplementary 
Table 4 and Supplementary Figure 3).
Validation of FC aberrancies in the erythroid lineage in MDS and pathological 
controls
The value of the FC erythroid score was tested in an independent cohort. Nine 
centers provided data for this validation cohort; the results are depicted in Figure 
4 and Supplementary Table 1. Similar to results in the learning cohort the relative 
CVs of CD36 and CD71 were significantly increased in MDS as compared to controls; 
CD36 MFI was significantly decreased. Since the distribution of subcategories 
was similar in the MDS learning and validation cohorts, we compared FC results 
between the two MDS cohorts. This revealed that the increase in the CD71 CV 
and the decrease in CD71 MFI were significantly less evident in the MDS validation 
cohort than in the learning cohort (t-test, p<0.001). Results for CD36 CV and the 
percentage of CD117+ erythroid cells did not differ between both MDS cohorts 
(p=0.134 and 0.116, respectively).
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Figure 3 FC-erythroid dysplasia score in the learning and validation cohorts.
The weighted score consists of four parameters, i.e.: increase in CD36 CV (4 points) and CD71 
CV (3 points); decrease in CD71 MFI (2 points); and decrease or increase of CD117+ erythroid 
progenitors (2 points). A maximum score of 11 points can be reached. Data are grouped 
as normal bone marrow (NBM), pathological controls (PC) and MDS (excluding RAEB-1 and 
-2), relative distribution of the results for the score is displayed along the Y-axes. Panel A. 
represents the learning cohort consisting of 79 normal bone marrow samples (NBM), 153 
pathological controls (PC) and 119 MDS cases. The FC-erythroid dysplasia score could only 
be calculated in those cases with data on all four defined parameters (351/670 cases). 
Panel B. represents the results in the validation cohort consisting of 42 NBM samples, 106 
pathological controls and 93 MDS cases (241/320 cases; RAEB excluded). Clonal disorders as 
aplastic anemia and those within the category of essential thrombocythemia, polycythemia 
vera and primary myelofibrosis were excluded from both cohorts (two and nine cases for 
learning and validation cohorts, respectively). A cut-off of ≥5 points resulted in a specificity 
of 90% (95% CI: 84–94%) and a sensitivity of 33% (95% CI: 24–42) in the learning cohort; 
in the validation cohort, specificity was 92% (95% CI: 86–97%) and sensitivity 24% (95% CI: 
15–34%). The numerical score, depicted in panels C and D, consists of four parameters, 
i.e.: increase in CD36 CV and CD71 CV; decrease in CD71 MFI; and decrease or increase of 
CD117+ erythroid progenitors. A maximum score of 4 points can be reached. A cut-off of 
≥2 points resulted in a specificity of 90% (95% CI: 84–94%) and a sensitivity of 35% (95% CI: 
27–45) in the learning cohort; in the validation cohort, specificity and sensitivity were 92% 
(95% CI: 86–97%) and 25% (95% CI: 16–35%), respectively.
Reference ranges as defined in the learning cohort were applied to evaluate the 
data from the validation cohort and next, to calculate the weighted FC-erythroid 
dysplasia score. This revealed a specificity of 92% (95% CI: 86–97%) and a sensitivity 
of 24% (95% CI: 15–34%) for identifying MDS-associated erythroid aberrancies 
(Figure 3B and Supplementary Table 5). In most cases, the numerical score 
could have been applied (cut-off ≥2 aberrancies; Figure 3D); only one MDS had 
decreased CD71 MFI in combination with an altered CD117+ percentage.
To verify the selection of markers that identified FC changes in the erythroid 
lineage associated with MDS, we performed multivariate logistic regression 
analysis in the validation cohort and in the combined cohorts. This confirmed the 
discriminatory power of the CV of CD36 and CD71 and the percentage of CD117+ 
erythroid progenitors, whereas CD71 MFI was replaced by CD36 MFI (Table 4B–C). 
CD105 data were too scarce to be taken into account in the separate cohorts; 
yet, entering all available markers present in the combined cohorts, multivariate 
logistic regression analysis identified the combination of CD36 CV, CD71 CV, CD71 
MFI and the percentage of erythroid progenitors defined as CD105+ instead of 
CD117+ (Table 4D).
Figure 4 Distribution of erythroid markers analyzed by flow cytometry among 
MDS patients and controls within the validation cohort. Results of the analysis 
of selected markers of the erythroid lineage in the validation cohort are plotted 
along the X-axes: relative coefficient of variation of CD36 and CD71, and relative 
percentages of CD117+ erythroid progenitors. Normalization was performed 
against results for the normal bone marrow (NBM) samples of the validation 
cohort per each individual center. Relative frequencies are depicted along the 
Y-axes. Dotted lines represent results for NBM samples, dashed lines pathological 
controls (PC) and solid lines MDS cases. Grey boxes indicate 10th and/or 90th 
percentiles of pathological controls defined in the learning cohort that were 
applied for evaluating aberrancies. Note that MDS-RAEB cases were excluded 
from the MDS group.
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Table 6 Results of FC aberrancies in the erythroid lineage and the FC-erythroid dysplasia 


























































































normal 0 5 4 8 3 2/79
pathological control 10 10 10 19 10 15/153
MDSb 30 46 28 34 33 39/119
MDS subcategories
RCUD 25 31 26 41 33 5/15
RARS(-t) 60 64 33 31 57 8/14
RCMD 28 44 25 32 30 24/79
del(5q) 10 30 38 63 13 1/8
RAEB-1/2 40 25
MDS NOS 80 40
Pathological control subcategories
iron deficiency anemia 11 0 0 11 6 1/18
iron incorporation disturbances or
anemia in chronic disease
7 10 3 23 10 3/29
vitamin B12/folic acid deficiencies 0 17 0 25 0 0/6
anemia in auto-immune diseases 0 0 20 0 0 0/5
anemia due to renal failure 25 0 0 60
anemia otherc 0 22 11 0 0 0/5
cytopenia associated with marrow 
infiltration
0 20 16 40
cytopenia induced by 
chemotherapy or medication or 
post-SCT
10 0 24 9 0 0/7
ITP or neutropenia or
auto immune cytopenia NOS
17 9 12 9 14 3/21
reactive conditions or
cytopenia induced by infections
19 39 24 19 28 5/18
normal bone marrow
 (peripheral cytopenia NOS)
0 20 33 67 20 1/5
other than defined subcategories 
NOS
5 0 4 16 0 0/20
inconclusive 0 0 0 18 0 0/11
Displayed numbers correspond to the percentage of cases per subgroup that were beyond 
the reference ranges (Table 5). The CV for CD71 and CD36 were tested against the 90th 
percentile; the expression level (MFI) of CD71 was against the 10th percentile; and the 
percentage of CD117 erythroid progenitor cells was tested against both the 10th and 90th 
percentiles. Only data of subsets with five or more cases are depicted. Diagonally marked 
cells represent data not available or reliable (i.e., missing or only small data sets (<5 cases)) 
Note: anumber of cases with a FC-erythroid dysplasia score of ≥2  per total number of cases 
in which all parameters were available that comprise the score; bMDS subcategory RAEB 
is excluded from these results; c the subcategory ”anemia other” comprises among others 
cases of normocytic anemia, anemia unexplained; NOS: not otherwise specified.
Discussion
Analysis of erythroid dysplasia is rarely included in current FC protocols for MDS, 
since the significance of FC data from the erythroid lineage is, to a large extent, still 
under debate.3 Here, we report the results of a multicenter study within the IMDSFlow 
group, which focused on defining erythroid parameters that enable discrimination 
of dyserythropoiesis associated with MDS from non-clonal cytopenia. The results 
revealed that aberrancies in the erythroid markers CD71 and CD36 (expressed as the 
CV), together with the MFI of CD71 and an abnormal percentage of CD117+ erythroid 
progenitor cells within the distinct stages of erythroid differentiation provided the 
best discrimination between MDS and non-clonal cytopenia. A weighted score was 
based on these four parameters; this resulted in a specificity of 90% (95% CI: 84–94%) 
and a sensitivity of 33% (95% CI: 24–42) in the learning cohort; in the validation cohort, 
specificity was 92% (95% CI: 86–97%) and sensitivity 24% (95% CI: 15–34%). Specificity 
of the defined markers for identification of MDS-associated erythroid changes by FC 
is considered to be more important than its general diagnostic value for MDS. Hence, 
increasing the cut-off from ≥5 to ≥6 points would optimize the specificity (96% in both 
cohorts); however, at the cost of a decrease in sensitivity (24% and 14%, in the learning 
and validation cohort, respectively). The lower sensitivity compared to the learning 
cohort could be explained by a less evidently increased CD71 CV and decreased CD71 
MFI in the MDS validation cohort. Hence, fewer MDS cases scored CD71 CV and/or 
CD71 MFI as aberrant (Supplementary Table 3).
A numerical score based on one point per aberrancy and a cut-off of ≥2 aberrant 
markers led to similar results. Yet, it must be taken into account that the sole combination 
of CD71 MFI and percentage CD117+ erythroid progenitors is not sufficient to indicate 
MDS-associated changes in the erythroid lineage by FC. Ultimately, the analysis of 
the erythroid and myelomonocytic lineages and hematogones should be combined. 
Future validation should reveal the power of the herein defined erythroid markers. 
In addition, it is relevant to elucidate the value of the combination of myeloid and 
erythroid FC markers in indeterminate cases according to cytomorphology.
The multicentric data presented herein confirmed results from a recent study that 
reported a significant increase in the CV of CD71 and CD36 expression highly suggestive 
78 79
chapter 4
for MDS.27 Yet, discrimination between MDS and controls based on CV values was less 
clear for the present dataset. It was stated that the difference in CD71 CV between 
MDS and controls was less pronounced after erythrocyte lysis; however, this was not 
the case for CD36 CV.27 All data in the present study were obtained after erythrocyte 
lysis, which might explain the observed differences. It may seem paradoxical to use 
erythrocyte lysing solutions when the focus is on analysis of the erythroid lineage. 
Lyse-stain-wash is the recommended protocol for processing samples for FC in MDS.2 
Despite IMDSFlow recommendations, methodological variation between centers 
may have attributed to differences in results as demonstrated in normal controls. 
Harmonization or even standardization of methods may narrow differences and 
improve validity of conclusions from multicenter studies as has been demonstrated 
with respect to lymphocyte screening within the Euroflow consortium.28 Hence, 
grouping of data per technical procedure could have been informative from a practical 
perspective; yet, the power of the analyses within and between numerous subgroups 
of centers would have would have been strongly limited by sample sizes. Notably, in 
daily practice, FC results in subjects suspected for MDS should always be compared 
with a center’s own cohort of control samples.
Despite technical considerations, our data confirm the robustness of the evaluation 
of an increase in the CD71 and CD36 CV on erythroid cells.27 Another solid marker 
in the multivariate analyses in the herein presented cohorts was the evaluation of 
the percentage of erythroid progenitors defined as CD117+. A potential marker for 
future inclusion in erythroid data analysis by FC is CD105. In the multivariate logistic 
regression analysis of the combined cohorts, the evaluation of the percentage of 
CD117+ erythroid progenitors was replaced by the percentage CD105+ erythroid 
progenitors, though, these results were based on data from only 6/19 participating 
centers. Application of CD105 may overcome the potential error of selection of CD117+ 
erythroid progenitors without the aid of other markers such as a myeloid marker. 
Moreover, it has been demonstrated (in normal and pathological controls) that CD105 
is lost before carbonic anhydrase is expressed, which suggests that the majority of 
CD105+ cells are not subject to ammonium chloride-based lysing protocols.15
Next to that, CD105 overexpression was confirmed in some cases of MDS in our 
dataset.16, 18 However, we also observed a decreased expression in MDS; notably 
CD105 expression was negatively correlated with age in normal controls. Future 
studies in larger data sets may elucidate if CD105 is truly valuable in analysis of 
erythroid dysplasia in MDS.
Cytomorphology reports dysplastic features in erythropoiesis in non-MDS cases, 
such as reactive conditions.21-23 Moreover, patients with cytopenia due to marrow 
infiltration may demonstrate FC aberrancies associated with MDS. MDS may even 
coincide with the other malignancy in these patients.29, 30 A subset of patients with 
reactive marrows or marrow infiltration in our dataset indeed showed multiple 
erythroid aberrancies (5/23 and 2/9, respectively; Supplementary Table 5). 
Follow-up analysis after several months may demonstrate MDS in these cases.31 
This stresses that FC analysis in suspected MDS, though proven very specific, 
should always be part of an integrated diagnostic approach rather than a solitary 
diagnostic tool.32
New insights may improve the impact of FC in the diagnosis of MDS. A recent 
report showed that increased expression of CD44 on all maturational stages of 
erythroid cells was associated with MDS, irrespective of presence or absence of 
morphologic dyserythropoiesis.33  In addition, decreased expression of the major 
coxsackie adenovirus receptor (CAR) was demonstrated in dysplastic CD105+ 
erythroid progenitors.34, 35
To summarize, we identified significant aberrancies with respect to the FC markers 
recommended by IMDSFlow for analysis of the erythroid lineage in MDS. The 
best indicators of dysplastic changes associated with MDS were an increased 
CV of CD36 and CD71, a decreased MFI of CD71 in combination with decreased 
or increased percentages of erythroid progenitors (CD117+). The defined FC-
erythroid dysplasia score demonstrated high specificity. Future studies should 
assess the contribution of the selected erythroid markers to the evaluation of the 
myeloid progenitors, the maturing myelomonocytic lineage and hematogones in 
current FC protocols in MDS. This will be implemented in an upcoming multicenter 
data collection exercise within IMDSFlow.
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Relative %NEC <0.001 <0.001 0.503
Pattern CD71/CD235a <0.001 <0.001 <0.001
%CD71dim <0.001 <0.001 0.296
Relative MFI of CD71 <0.001 <0.001 0.619
Relative CV of CD71 <0.001 <0.001 0.485
Relative MFI of CD36 0.001 <0.001 0.139
Relative CV of CD36 <0.001 <0.001 0.020
Relative %CD117 progenitors 0.711 0.787 0.536
Relative %CD105 progenitors 0.399 0.179 0.355
Relative MFI of CD105 0.136 0.002 0.008
Validation cohort
Relative %NEC 0.368 0.022 0.106
Pattern CD71/CD235a <0.001 <0.001 0.284
%CD71dim 0.092 <0.001 <0.001
Relative MFI of CD71 0.180 0.284 0.198
Relative CV of CD71 0.002 <0.001 0.639
Relative MFI of CD36 0.145 0.014 0.101
Relative CV of CD36 <0.001 <0.001 0.254
Relative %CD117 progenitors 0.910 0.148 0.010
Relative %CD105 progenitors 0.162 0.217 0.805
Relative MFI of CD105 0.304 0.168 0.715
Note: Collected data were normalized against the median value determined in the set 
of normal bone marrow samples, except for aberrant pattern of CD71 vs. CD235a and 
%CD71dim. P-values represent the results of the comparison performed by the Kruskal 
Wallis test, except for aberrant pattern of CD71 vs. CD235a which was analyzed by the 
Fisher’s exact test. Abbreviations: dim: diminished; CV: coefficient of variation; MDS: 
myelodysplastic syndromes; NBM: normal bone marrow samples; NEC: nucleated erythroid 
cells; PC: pathological controls. MDS-RAEB cases were excluded from this analysis.
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Table S2 Cut-offs used for evaluation of results from the FC analysis of erythroid markers 





# of PC 
casesa
# of NBM 
cases
Relative %NEC - 268% 238 139
%CD71dim - 17% 250 129
Relative MFI of CD71 45% - 250 126
Relative CV of CD71 - 133% 165 88
Relative MFI of CD36 53% - 203 124
Relative CV of CD36 - 145% 177 92
Relative %CD117 
progenitors
37% 222% 180 122
Relative %CD105 
progenitors
50% 184% 52 59
Relative MFI of CD105 52% 113% 70 47
Note: cut-off values represent the 10th and 90th percentiles of results for erythroid 
markers among pathological controls in the learning cohort. The number of pathological 
control (PC) cases that were available to calculate cut-off values are displayed (a). Most 
values (except for %CD71dim) are expressed as ratio to the median value determined in 
the set of normal bone marrow samples. The utmost right column displays the number of 
normal bone marrow (NBM) cases that were available to calculate these median values. 
Abbreviations: CV: coefficient of variation; dim: diminished; MFI: mean fluorescence 
intensity; NEC: nucleated erythroid cells.
Example on how to translate these reference ranges for application in a single center:
If sufficient data are available on a set of pathological controls, 10th and 90th 
percentiles can be determined. Otherwise, collect data on an appropriate amount 
of normal bone marrow samples (min. 10) and determine median values for the 
parameters in the erythroid score. For instance, the median CV value of CD71 in 
the normal bone marrow samples is 67 and the median percentage of CD117+ 
erythroid progenitors in the erythroid compartment is 8%. Then the reference 
values are: CD71 CV: 133/100*67=89; a CD71CV>89 should be considered 
increased. Similarly for %CD117+: lower cut-off 37/100*8=3.0 and highest cut-off 
222/100*8=17.8; i.e. a CD117+ percentage (erythroid compartment) below 3.0% 
or above 17.8% should be considered aberrant. Otherwise, in case a sufficient 
amount of data is present regarding a large variation of pathological controls, 10th 
and 90th percentiles calculated from a center’s own cohort may be applied when 
comparable to the herein described reference values.




Relative %NEC 2.9 10.1 23.1
Pattern CD71/CD235a 3.7 17.3 64.9
%CD71dim 0.8 10.0 31.5
Relative MFI of CD71 4.0 10.0 27.8
Relative CV of CD71 4.5 10.3 45.5
Relative MFI of CD36 0.8 10.3 25.8






































Relative %NEC 2.1 18.7 23.0
Pattern CD71/CD235a 4.8 16.7 54.5
%CD71dim 4.8 20.6 19.8
Relative MFI of CD71 2.3 8.9 10.6
Relative CV of CD71 2.1 16.7 27.3
Relative MFI of CD36 6.5 14.6 27.4





































Numbers represent percentages of cases that scored abnormal when compared with 
the defined cut-offs for a particular marker (Supplementary Table 2.). Abbreviations: dim: 
diminished; CV: coefficient of variation; MDS: myelodysplastic syndromes; NBM: normal 
bone marrow samples; NEC: nucleated erythroid cells; PC: pathological controls. MDS-RAEB 
cases were excluded from this analysis.
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Table S4 Correlation of age and FC markers of the erythroid lineage in normal bone marrow 
samples within the learning cohort
Spearman’s Rho p-value
Relative %NEC 0.12 0.179
Pattern CD71/CD235a 0.08 0.366
%CD71dim 0.13 0.153
Relative MFI of CD71 -0.20 0.032
Relative CV of CD71 0.17 0.148
Relative MFI of CD36 0.21 0.026
Relative CV of CD36 -0.01 0.925
Relative %CD117 progenitors -0.05 0.640
Relative %CD105 progenitors 0.30 0.136
Relative MFI of CD105 -0.55 <0.001
Abbreviations: CV: coefficient of variation; MFI: mean fluoresce intensity; NEC: nucleated 
erythroid cells
Table S5 Results of the FC erythroid dysplasia score among MDS cases and controls 
stratified per cohort.
Note: Data represent percentage of subjects with an FC erythroid score of ≥2 and the 
actual amount of ‘positive’ cases per available cases. Only data of subsets with five or more 
cases are depicted; diagonally marked cells represent data not available or reliable (i.e., 
missing or only small data sets (<5 cases)). aMDS subcategory RAEB is excluded from these 
results; bthe subset “anemia other” contains among others cases of normocytic anemia, 
anemia unexplained, etc.; NOS: not otherwise specified.
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Figure S1 Results for erythroid markers in normal bone marrow samples analyzed by FC 
within different centers (learning cohort). Data are presented as boxplots with median and 
range. Depicted erythroid markers are percentage of nucleated erythroid cells (NEC), relative 
(rel.) expression of CD71, rel. CV of CD71 expression, rel. expression of CD36, rel. CV of CD36 
expression, subset of CD71dimCD235a+ cells in CD71-CD235a pattern, rel. expression 
of CD105, percentage of CD117+ cells in the erythroid compartment and percentage of 
CD105+ cells in the erythroid compartment. The different centers were anonymized (A to S) 
in order of data entry in the cohort. Open boxes reflect application of ammonium chloride 
as lysing procedure (PharmLyse, BD Biosciences or home-made; yellow boxes: Versalyse 
(BeckmanCoulter); green boxes FACSLyse (BD Biosciences); blue-edged boxes indicate lysis 
at 4ºC, red-edged boxes at 37ºC and black boxes at room temperature. Centers M and R 
use longest duration of incubation with lysing solution 20 and 25 minutes, respectively. No 
data for normal bone marrow samples were are available for centers H and O; center S only 
entered data in the validation cohort. Asterisks indicate the procedures in these centers; 
red: ammonium chloride at 37ºC; black: ammonium chloride at room temperature; green: 
FACS lyse at room temperature. Abbreviations: LSW: lyse-stain-wash; SLW: stain-lyse-wash. 
Centers F and J applied LSW in a tube containing CD235a and SLW in other tubes.
Figure S2 Results for erythroid markers in normal bone marrow samples analyzed by FC 
within different centers (learning cohort). Data are presented as boxplots with median and 
range. Depicted erythroid markers are percentage of nucleated erythroid cells (NEC) and the 
percentage of CD117+ cells in the erythroid compartment before and after normalization 
(upper and lower panel, respectively). The different centers were anonymized (A to S) in 
order of data entry in the cohort. Open boxes reflect application of ammonium chloride 
as lysing procedure (PharmLyse, BD Biosciences or home-made; yellow boxes: Versalyse 
(BeckmanCoulter); green boxes FACSLyse (BD Biosciences); blue-edged boxes indicate lysis 
at 4ºC, red-edged boxes at 37ºC and black boxes at room temperature. Centers M and R 
use longest duration of incubation with lysing solution 20 and 25 minutes, respectively. No 
data for normal bone marrow samples were are available for centers H and O; center S only 
entered data in the validation cohort. Asterisks indicate the procedures in these centers; 
red: ammonium chloride at 37ºC; black: ammonium chloride at room temperature; green: 
FACS lyse at room temperature. Abbreviations: LSW: lyse-stain-wash; SLW: stain-lyse-wash. 
Centers F and J applied LSW in a tube containing CD235a and SLW in other tubes
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Figure S3 Correlation of age and FC markers of the erythroid lineage in normal bone 
marrow samples within the learning cohort and the combination of learning and validation 
cohorts. Scatterplots are displayed for markers that showed a significant relation with age 
in the learning cohort (panel A): relative MFI of CD36, CD71 and CD105. The results of the 
same markers in the combined learning and validation cohorts are displayed in Panel B. 
Spearman’s Rho and p-values are indicated in the plots as no: Spearman’s Rho -0.2–0.2; 
poor: Spearman’s Rho -0.2– -0.5; moderate-to good: Spearman’s Rho -0.5– -0.7; and n.s.: 
p>0.05; *: p<0.05; **: p<0.001, respectively.
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Implementation of erythroid 
lineage analysis by flow 
cytometry in diagnostic models for 
myelodysplastic syndromes 
A study on behalf of the HOVON89 study group
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Flow cytometric analysis is a recommended tool in the diagnosis of myelodysplastic 
syndromes. Current flow cytometric approaches evaluate the (im)mature myelo-/
monocytic lineage with a median sensitivity and specificity of ~71% and ~93%. 
We hypothesized that addition of erythroid lineage analysis could increase the 
sensitivity of flow cytometry. Hereto, we validated the analysis of erythroid lineage 
parameters recommended by the International/European LeukemiaNet Working 
Group for Flow Cytometry in Myelodysplastic Syndromes and incorporated this 
evaluation in currently applied flow cytometric models. One hundred and sixty-
seven bone marrow aspirates were analyzed, 106 patients with myelodysplastic 
syndromes and 61 cytopenic controls. There was a strong correlation between 
presence of erythroid aberrancies assessed by flow cytometry and the diagnosis 
myelodysplastic syndromes, validating the previously described erythroid 
evaluation. Furthermore, addition of erythroid aberrancies to two different flow 
cytometric models led to an increased sensitivity to detect myelodysplastic 
syndromes: from 74% to 86% for the addition to the diagnostic score designed 
by Ogata and colleagues, and from 69% to 80% for the addition to the integrated 
flow cytometric score for myelodysplastic syndromes, designed by our group. In 
both models the specificity was unaffected. The high sensitivity and specificity 
of flow cytometry in the detection of myelodysplastic syndromes illustrates the 
important value of flow cytometry in a standardized diagnostic approach. The trial 
is registered at www.trialregister.nl as NTR1825; EudraCT nr.:2008-002195-10
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic 
disorders characterized by cytopenia(s) and risk of leukemic transformation.1 Multi-
parameter flow cytometric (FC) analysis is a recommended tool to support the 
diagnosis of MDS, which is based on dysplastic features by cytomorphology and typical 
cytogenetic abnormalities.2 The International/European LeukemiaNet Working Group 
for Flow Cytometry in MDS (IMDS-flow) provided recommendations on how to process 
and analyze bone marrow aspirates of patients with unexplained cytopenias suspected 
of MDS.3,4 Analytic methods have been developed and validated for characterization 
and quantification of dysplasia and enable accurate diagnosis of MDS.5–12 The most 
straightforward is a four-parametric diagnostic score that integrates: percentage of 
CD34-positive myeloid progenitors, percentage of B cell progenitors within the CD34-
positive compartment, CD45 expression level of CD34-positive myeloid progenitors 
(related to CD45 expression level on lymphocytes), and sideward light scatter peak 
channel value (SSC) of granulocytic cells (related to SSC of lymphocytes). This diagnostic 
score has a sensitivity and specificity of 69% and 92%, respectively in low-intermediate 
risk MDS.13,14 More elaborate scores can reach specificities up to 100%; this however is 
accompanied by lower sensitivities.15 In accordance with recommendations issued by 
the IMDS-flow, our group designed and validated an integrated MDS-FC score (iFS).16 
The iFS comprises the diagnostic score and evaluation of frequently described aberrant 
expression levels of lineage defining markers and presence of lineage infidelity markers 
on (im)mature myelo-/monocytic cells. Sensitivity and specificity of the iFS within a large 
cohort of patients with persistent cytopenias of unknown origin, were 63% and 98%, 
respectively.17 The lower sensitivity in this and other reports can be explained by the 
fact that most MDS-FC approaches only evaluate the myeloid cell compartment. Since 
dyserythropoiesis is the most prevalent feature by cytomorphology in MDS, addition of 
in depth evaluation of the erythroid compartment is expected to improve sensitivity.18 
MDS patients with erythroid dysplasia but without dysmyelopoiesis, may then be 
identified by FC.
For evaluation of the erythroid compartment different antibody combinations of CD45, 
CD235a, CD71, CD36, CD105, and intracellular markers such as cytosolic H-ferritin, 
cytosolic L-ferritin and mitochondrial ferritin have been described.19–22 The IMDS-flow 
group recently proposed guidelines for erythroid evaluation advising the evaluation 
of CD36 coefficient of variation (CV), CD71 CV and mean fluorescence intensity (MFI), 
and percentage of progenitors (CD117 positive within CD45 negative-diminished cell 
fraction) within the erythroid compartment. Sensitivity and specificity of this marker 
combination for the detection of MDS-associated erythroid aberrancies were 35% and 
90%, respectively. The current study aimed to validate these erythroid parameters in 
an independent cohort of patients diagnosed with MDS treated within a prospective 
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clinical study and in a reference group of patients with proven non-clonal cytopenias. 
Furthermore, the additive value of erythroid evaluation to currently applied MDS-FC 
diagnostic approaches was explored.
Table 1 Erythroid markers that comprise the IMDS-Flow erythroid FC score and the 












Control group 14/61 23 3/61 5 2/61 3 35/61 57 7/61 11
Alcohol abuse 0/2 0 1/2 50 0/2 0 0/2 0 0/2 0
Aplastic anemia 2/3 67 0/3 0 0/3 0 0/3 0 0/3 0
Auto-immune 
cytopenia 3/10 30 0/10 0 1/10 10 8/10 80 3/10 30
Chronic disease 0/3 0 0/3 0 0/3 0 3/3 100 0/3 0
Eosinophilia* 0/1 0 0/1 0 0/1 0 1/1 100 0/1 0
Iron deficiency 6/26 23 1/26 4 1/26 4 15/26 58 4/26 15
Iron incorporation 
disorder 2/10 20 0/10 0 0/10 0 4/10 40 0/10 0
Medication caused 
cytopenia 0/3 0 0/3 0 0/3 0 3/3 100 0/3 0
Vitamin B12 



































































































*Normal bone marrow by cytomorphological assessment. The CD36 CV is the most 
specific parameter (2/61 control patients; 3%), and CD71 CV is the most sensitive 
parameter (70/106 MDS patients; 66%). In summary: 11% of the controls and 64% of the 
MDS patients show MDS-associated erythroid aberrancies, as defined by ≥2 points.
Methods
Patients
A well-defined MDS group and cytopenic control group were assembled between 
May 2009 and July 2014 (Table 1). The MDS group consisted of patients enrolled in 
the HOVON89 study (trial registered at www.trialregister.nl as NTR1825; EudraCT nr.: 
2008-002195-10). Bone marrow aspirates for FC analysis were taken prior to inclusion, 
MDS was diagnosed in accordance with the minimum diagnostic criteria established by 
the WHO 2001 criteria.23 The definition of non-clonal cytopenias was based on clinical 
characteristics, cytomorphology, cytogenetic and biochemical indicators. The median 
age of the MDS group was 71 (range 38-85) median age of the control group was 
65 (range 23-91). The research program was approved by the local ethics committee, 
and all patient-related research strictly abided by the Declaration of Helsinki.
Sample Preparation, Antibody Combinations, and Cell Acquisition
Sample processing was performed according to ELN guidelines for FC within 24 hours.15
A 4-color analysis was performed from 2009-2012, and an 8-color analysis from 2012-
2014. The staining panels are outlined in the supplementary file (Table S1). At least 
100,000 CD45-positive events were acquired, using a FACSCaliburTM or FACSCantoIITM 
(BD Biosciences, San Jose, CA, USA). Cells were analyzed using Cell QuestPro (BD 
Biosciences) or Infinicyt software (Cytognos, Salamanca, Spain), respectively. Gating 
was performed as previously described.15,24
MDS-FC scores
For evaluation of the erythroid compartment, guidelines as described by the IMDS-flow 
were applied. Erythroid evaluation included analysis of CD71 (CV and MFI), CD36 (CV) and 
CD117 (percentage within the CD45-negative-diminished cell fraction). Cut-off values 
were assessed as described in the tandem-paper (see also the mathematical examples 
in the supplementary files of the paper). Examples are provided in the supplementary 
file (Figure S1). Following the simplified recommendations: an increased CV of CD71, 
a decreased MFI of CD71, an increased CV of CD36, and a decreased or increased 
percentage of CD117 were each assigned one point. A score of ≥2 points was defined 
as MDS-associated erythroid aberrancies. The four parameter diagnostic score was 
calculated according to guidelines as previously described, using the defined cut-offs.13 
The iFS was established as described previously.25 The diagnostic score, the iFS and the 
erythroid score are described in Table 2A.
Models for incorporation of erythroid analysis
Tables 2B-2C describe the two models designed to add erythroid FC analysis to 
validated MDS-FC approaches. Patients with MDS-associated erythroid aberrancies 
received one extra point in comparison with the original diagnostic score, a total of ≥2 
points was labeled as MDS. The second model added erythroid evaluation to the iFS. 





Results from MDS-FC were compared between the MDS and control group. Absolute 
numbers and relative percentages described the data. To test the concordance 
between presence of MDS-associated erythroid aberrancies and patient group a 
chi-square test was performed. To compare the results of different techniques the 
McNemar test was used. P-values <0.05 were statistically significant. Specificity and 
sensitivity and 95%-confidence intervals were calculated for each MDS-FC model 
using a two-by-two model. Inter-observer analysis of MDS-FC aberrancies and the 
diagnostic score was tested by an independent MDS-expert center, the Department of 
Immunology of the Erasmus University Medical Center, Rotterdam, The Netherlands. 
Analyses were performed using PASW Statistics version 20.0 (SPSS, Chicago, IL).
Results
Evaluation of erythroid markers
In accordance with the IMDS-flow recommendations we analyzed CD36 (CV), CD71 (CV 
and MFI), and CD117 (percentage within the CD45 negative-diminished cell fraction). 
Table 1 lists the analyzed erythroid markers per group. An increased CV of CD71 was 
the most sensitive marker for MDS as it was positive in 66% of MDS patients, followed 
by an increased/decreased percentage of CD117 (64%). An increased CV of CD36 was 
the most specific marker as only 3% of controls were positive for this marker. Within 
the MDS group 64% patients showed multiple erythroid aberrancies (≥2 points), 
compared to 11% of patients within the control group. The presence of multiple 
erythroid aberrancies was significantly correlated with the diagnosis of MDS (p<0.001).
Correlation between patient group and cytomorphology
As we found a significant correlation between patient group (MDS or control) and the 
presence of erythroid aberrancies, the next step was to evaluate the relation between 
erythroid evaluation by cytomorphology and FC in more detail. As controls might 
have minimal dyserythropoiesis by cytomorphology, FC might also detect erythroid 
aberrancies in controls.26,27 Information about erythroid features by cytomorphology 
was available in 92% patients in the MDS group and in 98% patients within the control 
group. Table 3 provides an overview of the results. Although the positive test results 
(dyserythropoiesis by cytomorphology and erythroid aberrancies by FC) seem equally 
distributed between the MDS and the controls,  FC identified more dysplastic cases 
than cytomorphology (MDS-FC-positive cases within the cytopenic controls based on 
morphology). Therefore the McNemar test which focuses on the differences between 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3 Comparison of dyserythropoiesis as assessed by cytomorphology and flow cytometry.
































































































Note: *Less than 10% erythroid dysplasia and therefore not enough for diagnosis MDS 
or >10% and classified MDS according to WHO criteria; **For one aplastic anemia patient 
there were not enough erythroid cells for proper evaluation; ***Cytomorphological details 
absent in 9 patients.
Addition of erythroid markers to current MDS-FC scoring systems - Diagnostic 
score
The original diagnostic score was indicative for MDS in 78/106 MDS patients, and 
negative for MDS in 53/61 of the control patients (Figure 1). Hence, sensitivity and 
specificity of this diagnostic score were 74% (95% CI: 64%-82%) and 87% (95% CI: 
76%-94%), respectively. By erythroid evaluation 64% of MDS patients and 11% of 
controls revealed erythroid aberrancies by FC (Table 1). Erythroid results were 
added to the diagnostic score as illustrated in Table 2B. This led to an upgrade in 
MDS-FC category in 13 MDS patients and 2 controls. Consequently, the sensitivity 
and specificity for the diagnostic score including erythroid evaluation were, 86% 
(95% CI: 78%-92%) and 84% (95% CI: 72%-92%), respectively.
Addition of erythroid markers to current MDS-FC scoring systems - integrated 
MDS-FC score
With the addition of the erythroid analysis two extra RARS patients, five RCMD 
patients, four RCMD-RS patients, and one del(5q) patients were now recognized as 
MDS. The addition of the erythroid analysis did not alter the results for the RAEB-1, 
MDS-U and CMML patients (Figure 2 and Table S2). Results of the original iFS were 
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C ‘compatible with MDS’ in 73/106, B ‘minor MDS related aberrancies’ in 21/106, 
and A ‘not compatible with MDS’ in 12/106 MDS patients. Interestingly, each MDS 
patient not recognized by the original iFS showed only dyserythropoiesis with or 
without dysmegakaryopoiesis by cytomorphological assessment. In the control 
group results were A in 40/61 patients, B in 20/61 patients, and C in only 1/61 
patients. The calculated sensitivity and specificity of the iFS were 69% (95% CI: 59% 
to 78%) and 98% (95% CI: 91%-100%), respectively.
In the MDS group 33 patients were not assigned as MDS by the original iFS (Figure 
1; category A and B). After addition of the erythroid evaluation 12 MDS patients 
changed from B to C now allocated MDS, and 5 patients in category A were 
changed to B (limited changes but still no MDS). In total, 21 patients were not 
allocated as MDS; 7 in category A, 14 in category B.
In the control group one patient was incorrectly identified as MDS (category C). 
After addition of the erythroid evaluation two extra patients in category B were 
upgraded to C and thus allocated MDS (Figure 1). Overall, the sensitivity of the 
iFS increased to 80% (95% CI: 71%-87%) and the specificity showed only a minor 
decline to 95% (95% CI: 86%-99%).
Figure 1 MDS-FC results in the MDS and control group
The diagnostic score and the integrated MDS-FC score in patients within the MDS group 
and control group. The arrows demonstrate the patients changing groups after addition 
of the erythroid evaluation as recommended by the IMDS-flow group. *Flow cytometric 
results showed minimal dysplastic features, not enough for MDS.
Figure 2 WHO-classifications within different MDS-FC groups
Distribution of WHO-classifications within the original iFS categories, and iFS categories after 
the addition of the erythroid evaluation. With the addition of the erythroid compartment, 
patients shift into a higher MDS-FC category. Category A ‘no MDS-related features’, B ‘limited 
number of changes associated with MDS’, or C ‘features  consistent with MDS’. Absolute 
patient numbers are provides in the Supplementary files (Table S2)
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In summary, the sensitivity for both the diagnostic score and the iFS increased 
significantly after addition of erythroid evaluation. For the diagnostic score, 
sensitivity increased from 74% to 86%, and the iFS sensitivity increased from 69% 
to 80%. For both strategies specificity was only marginally affected: 87% to 84% for 
the diagnostic score and 98% to 95% for the iFS. Figure 2 illustrates distribution 
of WHO classifications within the original iFS and after addition of the erythroid 
evaluation.
Robustness of the MDS-FC results
Interpretation of FC data in MDS is considered to require a high level of expertise. 
To check solidity of our MDS-FC based conclusions, 25% of the MDS cases were 
analyzed blindly by an independent MDS-FC expert center (VHJvdV and JtM). The 
scores were calculated in the same data files. Results for the diagnostic score 
revealed a concordance of 100% and 89% for the 4-color and 8-color analysis, 
respectively. Analysis of the iFS revealed a concordance of 89% and 86%, for the 
4-color analysis for the 8-color analysis, respectively. Addition of the erythroid 
evaluation did not influence the concordance of the MDS-FC models.
Discussion
The evaluation of dyserythropoiesis by a flow cytometric (FC) approach is 
not included in most of today’s MDS-FC models. The International/European 
LeukemiaNet Working Group for Flow Cytometry in MDS (IMDS-flow) proposed a 
method for evaluation of the erythroid compartment by FC. In the current study 
we validated the erythroid evaluation and investigated the value of the introduced 
erythroid evaluation in two previously validated MDS-FC approaches. We analyzed 
167 bone marrow aspirates, 106 patients with MDS and 61 cytopenic controls 
for which the IMDS-Flow erythroid score, diagnostic score, and integrated FC 
score (iFS) were calculated.13,16 Originally, the erythroid score was designed as 
a weighted score. It can also be applied as a numerical score (one point per 
parameters) in which ≥2 points identifies MDS-associated erythroid aberrancies. 
Note, the exception made in the tandem-manuscript: if the 2 points are based on 
the combination of decreased MFI of CD71 and abnormal percentage of CD117, 
an additional aberrancy is warranted. The latter was not seen in this cohort. 
Results from the erythroid evaluation confirmed the results of the IMDS-flow 
report as we showed a strong significant correlation between MDS-associated 
erythroid aberrancies assessed by FC and MDS. Investigation of the correlations 
between  cytomorphological results and FC results suggested that FC detected 
less erythroid aberrancies when compared to cytomorphology results. Here, 
it needs to be considered that both techniques investigate different aspects. 
FC mainly evaluates cell surface characteristics, where cytomorphology also 
evaluates features within the cell such as nuclear bridging. It is unknown whether 
these dysplastic features result in altered antigen expression. The FC method is 
however rather specific as for example, it did not report MDS-associated erythroid 
aberrancies where cytomorphology described dyserythropoiesis in patients with a 
vitamin B12 deficiency. This indicates that both techniques provide supplementary 
information, and complement rather than contradict one another.
The goal of the study was to increase the sensitivity of current applied MDS-
FC models. Indeed, the addition of the erythroid lineage analysis to the current 
applied diagnostic score demonstrated an increased sensitivity (from 74% to 86%) 
without a major loss in specificity (87% to 84%). These results support the findings 
of Mathis et al, who tested the addition of erythroid evaluation by FC in non-lysed 
samples (RED score) to the diagnostic score.22 The combination was analyzed in 
a cohort of 101 patients (83 MDS patients and only 18 controls) resulting in a 
sensitivity and specificity of 88% and 89%, respectively. The RED score and the 
erythroid score described by the IMDS-flow both comprise evaluation of CD36 
CV and CD71 CV. Differences were however i) a non-lysed method in the RED 
score, ii) the addition of the hemoglobin level in the RED score, iii) the added 
value of percentage of CD117 and iii) added value of expression level of CD71. 
As illustrated by Mathis and colleagues hemoglobin showed a strong negative 
correlation with the other markers in the RED-score. Note, hemoglobin might be 
subject to confounders, e.g. transfusion requirements, and as a non-FC parameter 
less suitable in a MDS-FC model.
The second diagnostic MDS-FC model evaluated in the current study was the 
iFS. A more extensive model, comprising the diagnostic score and evaluation of 
frequently described aberrancies on (im)mature myelo-/monocytic cells. Addition 
of erythroid markers to this score led to an increased sensitivity (from 69 to 80%), 
without substantially affecting the specificity (from 98 to 95%). The combination of 
the iFS with the IMDS-flow erythroid score showed the highest specificity; higher 
than the other described scores.
Most described MDS-FC scores were designed and validated in large patient 
cohorts. However, interpretation of results within individual patients can be 
challenging. To our knowledge the iFS is the only MDS-FC algorithm that has 
proven its power in individual patients, demonstrated by its high specificity in 
patients with cytopenias of unknown origin followed over time.17 After addition 
of the erythroid lineage evaluation, its specificity remained high and therefore it 
might be expected that the new model is applicable in individual patient analysis. 
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To not overcall patients with cytopenia of unknown origin as MDS, one would prefer 
to apply the most specific model, however in an era where cost-effectiveness is 
becoming increasingly important a limited panel might be preferred. To improve 
the four-parameter diagnostic score, Bardet and colleagues advised the addition 
of CD7 (on myeloid progenitors) and CD56 (on monocytes) to the diagnostic 
score.28 Specificity of this adjusted score was 87%, however the sensitivity was 
low (66%). Here, the addition of selected erythroid markers might improve the 
sensitivity of FC.
It is suggested to add analysis of mutation in genes involving splicing factors, 
epigenetic regulators, signal transduction or the cohesion complex, to diagnostic 
evaluation.29,30 However, none of the mutations are disease specific, and some 
mutations appeared to be present in a low frequency in the elderly population.31 
Therefore, more research regarding their role in the diagnostic setting in MDS 
is warranted. Until then, FC has proven to be a valuable diagnostic tool, able to 
fill in the gaps where cytomorphology and cytogenetic results are less certain 
of a diagnosis. It showed to be highly specific in the diagnosis of MDS, thereby 
able to exclude patients from unnecessary follow-up. MDS-FC is described to be 
less sensitive in MDS recognition. Our study however, showed that addition of 
erythroid evaluation to current applied MDS-FC models increased the sensitivity 
of FC in the detection of MDS. Thereby we postulate that MDS-FC is ready for 
general clinical application.
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Table S1A The applied 4-color (panel A) and 8-color (panel B) markers.


























































































































































Per antibody CD number, (clone), and manufacturer are depicted. DAKO: DakoCytomation, 
Glostrup, Denmark; BD: BD Biosciences, San Jose, CA, USA. BL: BioLegend, San Diego, Ca, 
USA. Sanquin, Amsterdam, The Netherlands. BC: Beckman Coulter, Miami, FL, USA. IS: 
Immunostep, Salamanca, Spain.
Table 2S Upgraded patients per WHO-Classification after addition of the erythroid 
evaluation. 
WHO-classification Upgrade A > B
‘No MDS’







RA 1 0 2 (4)
RARS 2 2 16 (20)
RCMD 1 5 17 (23)
RCMD-RS 1 4 23 (27)
RAEB-1 0 0 13 (14)
Del(5q) 0 1 9 (12)
MDS-U 0 0 1 (2)
CMML 0 0 4 (4) 
This table provides the absolute patient counts belonging to Figure 2.
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Figure S1 Example of a normal bone marrow (A) and a MDS patient (B)
Figure A provides an example of a healthy control. Figure B provides an example of a 
MDS patient (RCMD-RS) which has an increased percentage of erythroid progenitors (EP). 
Furthermore, CD71 expression is longer retained during maturation. This is reflected in 
the increased CV of CD71 and CD36. Finally, the MDS patient shows a decreased MFI of 
CD71. This patient scores 4 out of 4 points, revealing clear MDS specific dyserythropoiesis 
as assessed by FC. The dotted lines plotted in figure B are the normal reference subtracted 
from figure A.
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Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic 
bone marrow disorders, characterized by cytopenias, dysplasia and increased risk 
of leukemic transformation. The diagnosis is established based on conventional 
diagnostic criteria such as the presence of (>10%) dysplasia in one or more cell 
lineages, the presence of >15% ring sideroblasts (or >5% in case of a SF3B1 
mutation) as assessed by cytology, or the presence of MDS-associated cytogenetic 
abnormalities.1–3 Based on these parameters the WHO classification assigns 
patients to separate diagnostic categories. Although this strategy is straightforward, 
patients within the same category can still be very heterogeneous with respect to 
symptoms, prognosis and response to therapy. In an attempt to identify more 
homogeneous patients categories, diagnostic guidelines for MDS established by 
the European LeukemiaNet (ELN) recommend the addition of flow cytometry (FC), 
and suggest additional molecular techniques to support the diagnosis of MDS.4 5
With the use of FC, myeloid and B cell progenitors, erythroid and maturing myeloid 
cell subsets can be evaluated. This allows detection of multilineage aberrancies 
within patients with unilinear dysplasia by cytomorphology, and detection 
of aberrant myeloid progenitor cells in patients with low blast percentages 
as assessed by cytomorphology.6–8 It was shown, that multiple aberrancies 
correspond with higher risk IPSS-R categories and with a worse outcome within 
the lower IPSS-R groups.9,10 Additionally, presence of aberrant myeloid progenitor 
cells corresponds with poor treatment response in low and high risk MDS, with 
growth factors and azacitidine, respectively.11,12
The role of next generation sequencing (NGS) in the diagnostic strategy in MDS 
is very promising. Large scale genomic screening studies found mutations that 
describe a divers mutational landscape in MDS.13 Mutations are found in genes 
coding for splicing factors, epigenetic regulators, transcription factors, cohesin 
complex components, and signal transduction molecules.14,15 Studies regarding 
correlations between specific mutations and phenotypical characteristics in 
myeloid disease, i.e. MDS/AML, are currently ongoing. For example, bi-allelic 
mutated CEBPA correlates with expression of CD7 on myeloid progenitors in 
AML.16,17
The combined use of FC and targeted NGS might help to improve the diagnosis 
of cytopenic patients suspect for MDS, may add prognostic information, and 
ultimately assist in choosing the most appropriate therapy. Therefore, this study 
displayed the results of conventional and emerging diagnostic techniques within 
Abstract
The diagnosis of myelodysplastic syndromes (MDS) is established on conventional 
cytomorphology, standard karyotyping and recently the presence of a SF3B1 
mutation in relation to ring sideroblasts. Still, MDS remains a very heterogeneous 
disease with respect to disease characteristics, prognosis and treatment response. 
To support knowledge of this heterogeneous disease this study combined 
conventional and emerging diagnostic tools such as high resolution SNP-array, 
flow cytometry (FC) and targeted next-generation sequencing (NGS) in a well-
defined low/intermediate-1 risk MDS cohort of 141 patients. This analysis aimed 
to identify correlations between the results of these different techniques.
SNP-array detected 55 (41%) abnormal cases, FC detected 105 (81%) aberrant 
cases, and NGS detected mutations in ≥1 gene in 99 (74%) cases. In 88% of 
the patients MDS-associated abnormalities were detected when combining the 
results of FC and NGS. Within the distinct WHO categories, results were very 
heterogeneous with respect to FC aberrancies and mutations identified by NGS. 
SF3B1, TET2, DNMT3A and ASXL1 were the most commonly affected genes. 
There was a minor but significant positive correlation between the number 
of FC aberrancies and the number of mutations detected by NGS. Mutations 
in transcription factors and epigenetic regulators correlated with an aberrant 
progenitors, granulocytes and monocytes. This study demonstrates that MDS-FC 
and NGS identify a divers landscape within the well-established WHO categories. 
Addition of these techniques in the standard work-up in MDS might improve 
diagnostic and prognostic models, and might assist prediction of treatment 
response in the future.
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the well-established WHO classifications, in a well-defined low-intermediate-1 risk 
MDS population within a prospective clinical trial. Moreover, this analysis aimed to 
identify correlations between the results of these techniques, to support knowledge 
aid future research on pathophysiological mechanisms to identify homogenous 
patient categories in this heterogeneous disease. More homogenous patients in 
respect to prognoses and treatment response that aid clinical decision making.
The study was conducted within the HOVON89 trial: a prospective randomized 
phase II study, that investigates the efficacy of lenalidomide without (study arm 
A) or with (study arm B) the addition of growth factors. This trial is registered at 
www.trialregister.nl as NTR1825; EudraCT nr.: 2008-002195-10. The samples in 
the current study were taken before treatment with lenalidomide. The results of 
this study will be discussed separately. Therefore, no correlations with treatment 
response to design a predictive model for response is discussed within the current 
report.
Methods
Study design HOVON 89
The HOVON 89 study is a prospective open label multicenter phase II study that 
evaluates the effect of lenalidomide (Revlimid) with or without growth factors. Adult 
low/intermediate-1 risk MDS patients (according to the IPSS18) were randomized 
between lenalidomide alone (arm A) or lenalidomide with a standardized regimen 
of growth factors (arm B). In addition, add-on studies comprised analysis by SNP-
array, FC and NGS. The research was conducted according to the Declaration of 
Helsinki; the research program was approved by the local ethics committees and 
written informed consent was obtained (www.trialregister.nl; NTR1825; EudraCT 
nr.: 2008-002195-10).
This report describes the analysis of the samples that were taken prior to 
treatment. Patients were accrued between May 2009 and September 2015. 
Cytomorphology results were centrally reviewed and assessed according to the 
WHO 2001 (at study design the WHO 2008 and 2016 classifications were not yet 
established).1 Karyotyping and interphase FISH were performed in local certified 
cytogenetic laboratories. After central review, the data were collected at the 
HOVON data center, Rotterdam, The Netherlands. FC analysis was performed in 
the VU University Medical Center, Amsterdam, The Netherlands. SNP-arrays and 
NGS were performed at the Radboud University Medical Centre, Nijmegen, The 
Netherlands.
Patients
Two-hundred patients were randomized between study arm A and B. After 
randomization 16 patients were excluded by the review committee as they did not 
meet the inclusion criteria. One-hundred and eighty-two patients gave informed 
consent for the additional studies as described within this study. For these patients 
bone marrow samples to perform SNP-array, FC, and NGS were requested at the 
local sites. In 141 cases material was received (Table 1).
Karyotyping, FISH and SNP-array
Routine karyotyping was performed using standard methods and at least 
20 metaphases were analyzed according to the guidelines of the European 
cytogenetic association for acquired cytogenetics. Karyotypes were described 
according to the standardized ISCN2013 nomenclature system.19 In patients with 
less than 20 normal metaphases or less than 10 metaphases in the presence of 
a clonal abnormality, additional interphase FISH analyses for the detection of -5, 
5q-, -7, 7q- and +8 were performed using commercially available probes (Abbott 
Laboratories, Abbott Park, Illinois, USA).
Genomic array profiling was carried out in a central laboratory using the CytoScan 
HD array platform (Affymetrix, Inc., Santa Clara, CA, USA). Hybridizations were 
performed according to the manufacturer’s protocols. The data were analyzed 
using the Chromosome Analysis Suite software package (Affymetrix), using 
annotations of genome version GRCh37/hg19.
For a comprehensive interpretation of the SNP-based genomic array profiling 
data we used criteria previously described.20 According to these guidelines all 
segments larger than 5 Mb (resolution of conventional karyotyping), regardless 
of gene content, were denoted as true aberrations. Segments smaller than 5 
Mb, were included only if they coincided with known cancer genes (http://cancer.
sanger.ac.uk/cancergenome/projects/census/date of accession November 2012). 
Since paired control DNA was not used, alterations that coincided with normal 
genomic variants were excluded. For this approach the publicly available database 
‘Database of Genomic Variants’ (http://projects.tcag.ca/variation) and an in-house 
database in which CNVs are stored from ~1,000 healthy individuals run on the same 
CytoScan HD platform were used. Regions of CNLOH were only considered if they 
were >10 Mb in size and if they extended towards the telomeres of the involved 
chromosomes, as reported in.21 Focal CNAs in the immunoglobulin genes were 
excluded. All the data were also visually inspected to define alterations present 
in a lower proportion of cells (mosaics), and to eliminate alterations reported in 
regions with low probe density. Only aberrations fulfilling the above criteria were
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Table 1 Patient characteristics
Patient count
Study inclusion 200
































included in the genomic profiles, and were described according the standardized 
ISCN 2013 nomenclature system.
Flow Cytometry
Flow cytometry was conducted according to the guidelines concerning 
recommended methods for cell sampling, handling and processing, published by 
the ELNet Working Party on Flow Cytometry in MDS.22 Samples were processed 
within 24 hours. Mature erythrocytes were lysed using ammonium chloride-based 
erythrocyte lysing solution. Nucleated cells were pre-incubated with human 
serum immunoglobulins before staining. The antibody panels are provided in the 
supplementary file.
Due to technical developments a 4-color method was applied between 2009 
and 2012 (FACSCalibur; BD Biosciences, San Jose, CA), and an 8-color method 
(FACSCanto II; BD Biosciences) between 2012 and 2014. A total of 100,000 
leukocyte events were acquired, including a minimum of 250 CD45diminished/
CD34+ events.23 Data from the 4-color method were analyzed with CellQuestPro 
(BD Biosciences); data from the 8-color method were analyzed with Infinicyt 
software (Cytognos, Salamanca, Spain). Results were discussed within an expert 
MDS-flow cytometry team, with ≥3 researchers. Reference values for marker 
expression were established within normal age-matched controls; values two-
times the standard deviation above or below normal were considered aberrant.7
Integrated MDS-flow cytometric score (iFS)
The integrated flow cytometric score (iFS) was applied to summarize MDS-FC 
results [22]. This score integrates the four-parameter diagnostic score described 
by Della Porta and Ogata and separate cell lineage evaluations largely based on 
Wels et al.7,23 The diagnostic score comprises the percentage of CD34 positive cells, 
CD45 expression of myeloid progenitors, SSC of the granulocytes, and percentage 
of progenitor B cells. The erythroid lineage evaluation included evaluation of: 
CD71 expression and the coefficient of variation (CV), CD36 CV and percentage of 
CD117 within the CD45diminished-negative erythroid cell compartment.24,25
If there were no flow cytometric abnormalities the patient was categorized 
as ‘no MDS-related features’. If one cell compartment (progenitor, erythroid, 
or myeloid) was affected, the patient was categorized as ‘limited number of 
changes associated with MDS’, and if ≥2 cell lineages were affected the patient 
was categorized as ‘features consistent with MDS’. Additionally, patients with 
≥2 abnormalities according to the four-parameter diagnostic score altered the 
allocation to above mentioned categories: a patient within the ‘no MDS-related 
features’ category became ‘limited number of changes associated with MDS’; and 
patients categorized as ‘limited number of changes associated with MDS’ with ≥2 
abnormalities according to the diagnostic score were now categorized as ‘features 
consistent with MDS’.25
Next generation sequencing
DNA was isolated from bone marrow mononuclear cells using nucleospin 
columns (BioKe, The Netherlands). Sequencing was performed using Roche 454 
technology, largely as described.26 Amplicons covering all relevant regions in 20 
genes frequently affected in MDS (ASXL1, CBL, CSF1R, DNMT3A, ETV6, EZH2, FLT3, 
IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1 
and ZRSR2) were designed (Supplemental table S2. Primers contained a 10 bp 
barcode, Supplemental files). Pools were prepared for the emulsion PCR (emPCR) 
step. First, the pools were diluted to a concentration of 4x106 molecules per µl. 
Secondly, the libraries were processed using the GS FLX Titanium Series Lib-A SV 
method (Roche Applied Science). Forward (A beads) and reverse (B beads) reactions 
were carried out using 2,000,000 beads per emulsion oil tube. The copy per bead 
ratio used was 2.1. The amplification reaction, breaking of the emulsions and 
enrichment of beads carrying amplified DNA was performed using the workflow as 
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recommended by the manufacturer. However, A beads and B beads were separately 
processed during breaking and enrichment processes. Finally, samples were loaded 
on an 8-lane PicoTiterPlate (PTP) on the Genome Sequencer FLX System instrument 
(Roche Applied Science). All data were generated using the GS FLX Sequencer 
Instrument software version 2.3. Image processing and amplicon pipeline analysis 
was performed using default settings of the GS RunBrowser software version 2.3 
(Roche Applied Science).
Amplicons covering relevant regions of CSF1R, SF3B1, SRSF2 and U2AF1 (See 
Supplemental table S3 for primers) were also sequenced using Ion Torrent 
semiconductor technology, as described.27 PCRs were performed using conventional 
sequencing primers in a fully automated robotic work flow. PCR amplicons were 
subsequently pooled and sheared to 200-300 bp. Library preparation was performed 
in an automated fashion on a MicroLab Starlet Replicator Robot (Hamilton) by using 
the Ion Plus fragment library kit in combination with the Ion XpressTM barcode 
adapters 1–96 kit (both Life Technologies). Emulsion PCRs were performed on an 
Ion OneTouch system (Ion OT2 instrument, Life Technologies) using the Ion PGM 
Template OT2 200 kit. Enrichment of template-positive Ion sphere particles (ISPs) 
was performed on a OneTouch ES system (Life Technologies). The percentage of 
template-positive ISPs was measured with the use of the Ion Sphere Quality Control 
kit (Life Technologies) and a Qubit 2.0 Fluorometer (Invitrogen). Subsequently, ISPs 
coated with template were loaded on Ion 318TM sequencing chips (Life Technologies). 
The chips were sequenced on the PGM, with the use of the Ion PGM sequencing 200 
kit version 2.
Sequence alignment and variant detection was performed using the SeqNext module 
of Sequence Pilot software, version 4.1.2 (JSI medical systems, Germany). Within 
SeqNext, the sequencing reads were mapped to defined ROIs, and variant calling 
was performed using user-defined settings. Analysis parameters in combination with 
selective procedures were used to ensure high coverage and high sensitivity, thus 
taking specific sequencing technology–based limitations into account (e.g., bases with 
low base call quality and homopolymer topics). For the detection of variants, filters 
were set to display sequence variants occurring in more than 10% of bidirectional 
reads per amplicon. Mutations within introns and single nucleotide polymorphisms 
(SNPs; dbSNP build 131) were discarded.
Statistics
Results from FC and NGS were visualized in bar plots, and compared using the 
appropriate statistical tests. Correlations of scale outcomes between two or more 
patient groups were investigated by the Mann-Whitney U test. Correlations between 
two ordinal (three or more categories) outcomes were analyzed applying a chi-
square test. P-values below 0.05 were considered statistically significant. Correlation 
between two scale-outcomes were analysed by the Spearman Correlation test, were 
a correlation coefficient above 0.7 was considered a strong correlation. The analyses 
were performed using PASW Statistics version 20.0 (SPSS, Chicago, IL).
Results
Out of the 182 patients who gave approval for further analysis for additional laboratory 
studies, material from 141 patients was actually received. In 129 (91%) cases FC was 
performed (other cases concerned inadequate samples) or technical issues i.e. not 
enough events were acquired); 133 (94%) samples were suitable for SNP-array and 
NGS (not enough material in the remaining set). Median age of the 141 evaluated 
patients was 71 years (range 38-85 years), 80 were male (57%; Table 1).
Diagnosis of MDS according to WHO 2001
Accrual of patients in the clinical trial started before the WHO criteria of 2008 and 
2016 were established. Therefore, patients were classified according to the WHO 
2001 criteria.1 Diagnoses were: 3 patients with MDS-RA, 21 with MDS-RARS, 31 
with MDS-RCMD, 34 with MDS-RCMD-RS, 25 with MDS and isolated deletion of 
chromosome 5q, 3 with MDS-unclassifiable, 17 with MDS-RAEB-1 and 7 patients with 
a CMML-1 (Figure 1A).
SNP-array had a higher diagnostic yield than conventional karyotyping
Besides standard karyotyping and FISH analysis, SNP-based genomic arrays were 
performed. SNP-array was performed in 133 (94%) patients. This is an extended 
analysis of the study as previously published by Stevens-Kroef et al.20 In patients for 
whom both techniques were performed, a higher diagnostic yield for SNP-array was 
observed resulting in 55 (42%) abnormal cases, while an abnormal karyotype was 
found in only 35 (27%) patients. In 5 cases when karyotyping failed or in case of 
an inadequate number of metaphases, SNP-based array analysis was successful. Of 
interest, in 26 (20%) patients (including 18 with normal karyotype) small focal copy 
number abnormalities or regions of copy neutral loss of heterozygosity abnormalities 
were found that were out of the scope of karyotyping and FISH. The SNP-array 
showed a wide variety in type of mutations within a WHO category (Figure 1B). A 
deletion in chromosome 5q was the most observed mutation (20%), followed by 
a deletion in chromosome 4q (6%) and 7q (4%). A deletion of the Y-chromosome, 
which is frequently described as MDS-associated but also as age-associated, is rare 
in this cohort (1%). One patient had a monosomy 7 as single mutation. There were 






































































































Flow cytometry detects multilinear aberrancies in unilinear dysplasia cases
Flow cytometry was adequately performed in 129 (91%) patients. Analyses of the 
erythroid, progenitor and myeloid cell compartment showed MDS-associated 
aberrancies in 105 (81.4%) patients (Figure 1C). Only minimal aberrancies were 
found in 17 (13.2%) patients, and 7 (5.4%) patients were normal according to 
integrated FC score analyses.
Most MDS patients (78%) showed aberrant myeloid progenitors, a feature that 
cannot be assessed by cytomorphology. Erythroid dysplasia-associated aberrancies 
(most frequently found in MDS by cytomorphology) were also frequently found 
(86%). The presence of ring sideroblasts (irrespective to specific WHO category) 
correlated with an aberrant erythroid cell compartment (p = 0.015). There was no 
correlation between lineage aberrancies as assessed by FC and the WHO 2001 
category.25 To illustrate this, in 23/24 RA(RS) cases with unilinear dysplasia based 
on the WHO2001 criteria for cytomorphology, FC showed multilinear aberrancies. 
In one additional case cytomorphology described only dyserytropoiesis, whereas 
FC showed no erythroid aberrancies but dysgranulopoiesis.
Patients classified as MDS-unclassifiable show <10% dysplasia by cytomorphology 
per definition. Here, two out of three MDS-U patients showed multilineage FC-
aberrancies; one other showed only aberrant monocytes by FC. This means, that 
here FC can help to underline the diagnosis of MDS.
Next Generation Sequencing confirmed results of previous MDS studies
Sequencing was performed in 133 (94%) patients. Within this MDS patient cohort 
SF3B1 (43%) and TET2 (21%) were the most commonly affected genes, followed by 
DNMT3A (17%) and ASXL1 (16%; Figure 1D). As expected, mutations such as TP53, 
NRAS, KRAS and FLT3, were rare in this IPSS low-intermediate-1 cohort. Mutations 
concerned a splicing factor in 74 (56%) patients, an epigenetic regulator in 64 
(48%) patients, a transcription factor in 27 (20%) patients, and in 5 (4%) patients 
there was a mutation in a signal transduction gene. A single mutation was present 
in 35 patients (26%), more than one mutation was present in 64 (48%) patients, of 
whom 57 patients had a mutation in more than one mutational category (Table 1). 
Our data confirmed the correlation between the presence of ring sideroblasts and 
mutations in splicing factors (p<0.001). As reported before this correlation was not 
100%: some patients with ring sideroblasts lacked a SF3B1 mutation and some 
patients with a SF3B1 mutation lacked ring sideroblasts. Note, in our cohort four 
patients with ring sideroblasts, without an SF3B1 mutation had another splicing 
factor mutation, i.e. a SRSF2 mutation.
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Except for one patient, a mutation in a splicing factor was restricted to one type 
of splicing factor mutation confirming that mutations within this class are mutually 
exclusive (Figure S1). This was not the case for mutations in epigenetic regulators 
(i.e. DNMT3A), as they often coincided with other epigenetic regulator mutations. 
Furthermore, RUNX1 and JAK2 mutations were never seen as single mutations.
As described in the WHO 2016 criteria for MDS: 80% of CMML patients have a 
mutation in SRSF2, TET2 or ASXL1. In this cohort, all tested CMML patients had a 
mutation detected by NGS: 5/7 in ASXL1, and 3/7 in TET2 (Figure S1).
Flow cytometry and next generation sequencing identify MDS-associated 
abnormalities
In 122 patients both FC and NGS were performed; in 7 additional patients there 
was only FC data and in 11 additional patients there was only NGS data. In one 
patient neither FC or NGS could be performed. Flow cytometry identified 105/129 
(81%) patients with MDS-associated aberrancies. Next generation sequencing 
revealed at least one mutation in 99/133 (74%) patients (Table 1). In the 122 
patients where both techniques were performed, 80 (66%) patients were classified 
as MDS according to FC with additional MDS-related gene mutations. In 18 (14%) 
patients with MDS according to FC, no mutations by NGS were observed. In 12 
(10%) patients with MDS mutation were present by NGS but no aberrancies were 
observed according to FC. Finally, 12 (10%) MDS patients were not recognized by 
either FC or NGS.
By combining the results of both techniques 124/140 (89%) patients showed MDS-
associated abnormalities. The remaining 16 patients included 2 RA patients, 1 RARS 
patient, 6 RCMD patients, 1 RCMD-RS patient, 5 patients with an isolated deletion 
of chromosome 5q, and 1 RAEB-1 patient. In the latter FC was not performed; 
this patient showed an abnormal karyotype and was therefore recognized as 
MDS. Besides this RAEB-1 patient and the patients with an isolated deletion of 
chromosome 5, the patients that were not recognized by FC and/or NGS showed 
also no abnormalities according to SNP-array. Thus, in 10 patients the diagnosis 
MDS was established solely based on the presence of a cytopenia and dysplasia 
by current standard conventional cytomorphology criteria.
Mutations in transcription factors correlate with an aberrant phenotype
A heterogeneous landscape of FC aberrancies and anomalies as assessed by 
SNP-array and NGS was identified in this low/intermediate-1 risk MDS population 
(summarized in Figure S1). In 122 patients we were able to investigate correlations 
between FC aberrancies and NGS. There was a minor but significant positive 
correlation between the number of FC aberrancies and the amount of mutations 
detected by NGS (r = 0.24; p=0.01). The number of cases per anomaly found by 
SNP-array were too small to perform proper statistics.
Due to small patient numbers per mutational subcategory, correlations between 
aberrant cell compartments by FC and mutations were analyzed per mutational 
category. There was a significant correlation between mutations in transcription 
factors and aberrant myeloid progenitors, granulocytes and monocytes according 
to FC (Table 2). There was also a significant correlation between mutations in 
an epigenetic regulator and presence of aberrant myeloid progenitors, and a 
correlation between signal transduction factors and aberrant granulocytes. FC did 
not correlate with splicing factor mutations.




Splicing ns* ns Ns ns
Epigenetic ns R 7.95; P = 0.005 Ns ns
Transcription 
factors
ns R 6.89; P = 0.009 R 3.96; P = 0.05 R 5.08; P = 0.02
Signal 
transduction
ns** ns** R 5.32; P = 0.02** ns**
Abbreviations NS: not significant; *Chi-square test: correlation coefficient; p=value; df(4).
** Note, based on N= 3 cases
No correlation between flow cytometric aberrancies and the IPSS score
Since this study initiated patient accrual in January 2008, we applied the IPSS 
instead of the now widely applied IPSS-revised prognostic scoring system. Patients 
with low/intermediate-1 risk MDS were included. Results of FC and NGS were 
rather heterogeneous within the risk groups. No correlations were observed 
between the iFS and IPSS or a particular mutational group and IPSS. This might 
suggest that both techniques may have prognostic value within IPSS subgroups.
Discussion
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow 
diseases. Heterogeneity is reflected by the WHO classification of MDS as well as by 
the landscape of flow cytometric (FC) and molecular aberrancies. In addition, the 
diversity in the natural course of the disease and response to current treatment 
modalities emphasize huge variability in the spectrum of bone marrow failure 
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syndromes such as MDS. As more treatment modalities become available the need 
for better and more directive diagnostic and prognostic tools is growing which 
might select patients for precision medicine. The combined use of techniques 
such as SNP-array, FC and targeted next-generation sequencing (NGS) might help 
to i) improve the diagnosis of patients with MDS; ii) add prognostic information, 
and iii) ultimately assist in choosing the most appropriate therapy. The current 
study addressed the role of these emerging technologies in diagnostics by the 
description of a cohort with 141 low and intermediate-1 risk MDS patients, treated 
within the HOVON89 study protocol. Patients were analyzed by morphology, 
conventional karyotyping, SNP-array, FC and NGS.
An abnormal karyotype was found in 35 patients. SNP-array detected 55 (41%) 
abnormal cases. FC detected 105 (81%) aberrant cases. NGS detected mutations 
in 99 (74%) patients. By adding the results of FC and NGS 88% patients showed 
MDS-associated abnormalities. Interestingly, in a total of 11 patients, the diagnosis 
MDS was established solely based on presence of a cytopenia and >10% dysplasia 
by standard conventional cytomorphology, without other criteria. This is an 
interesting group for long-term follow-up. One might expect that these patients 
have a higher overall survival than patients with multiple aberrancies or mutations. 
The correlation between standard karyotyping and SNP-array was previously 
published.20 Here we extended this analysis confirming that there is a higher 
diagnostic yield for SNP-array compared to standard karyotyping, except for 
mutations without loss of heterogeneity. Seventy-five percent of these only low to 
intermediate-1 risk MDS patients had one or more mutations (Figure S1), somewhat 
lower than reported in previous research reports where 80-90% was reported in 
low to high risk MDS patients. Sequencing was performed in 133 (94%) patients. 
In 99 (74%) patients a mutation was present. Within this low-intermediate-1 risk 
MDS patient cohort SF3B1, TET2, DNMT3A and ASXL1 were the most commonly 
affected genes. We found a mutation in a splicing factor in 56% of the cases, 
corresponding with the previously described 60% in a similar cohort of lower risk 
MDS.2 In line with previous reports, the majority of patients with splicing factor 
mutations showed restriction to one type of splicing factor mutation. This was not 
the case for mutations in epigenetic regulators, were epigenetic regulators appear 
to coincide. In addition, DNMT3A, a mutation commonly seen as a single mutation 
in clonal hematopoiesis of indeterminate potential (CHIP), often observed in the 
elderly, was rarely seen as single mutation in this cohort (only in one case). This 
mutation may be of limited leukemic potential as a single mutation co-occurs with 
other mutations in MDS. RUNX1 (N=12) and JAK2 (N=3) were never seen as single 
mutation as previously described.13,28
Sato and colleagues described ‘pre-leukemic stem cells’ that will either propagate 
to a malignant state or will never lead to leukemic evolution.29 Of note, the patients 
in this cohort are all refractory or are unlikely to respond to erythropoietin at 
inclusion in the study. This means that our analysis was not performed in de novo 
MDS, which may imply the presence of additional mutation due to clonal evolution. 
This may explain why high-risk mutations (mutation correlated with poor survival) 
were relatively frequent in our cohort, i.e. ASXL1 was found in 21 (16%) cases 
as compared to other studies. Also other mutations such as TP53, EZH2, ETV6, 
RUNX1 and SRSF2 were more frequently seen then previously reported in a 
low/intermediate-1 risk cohort.2 Identification of type, function, and moment of 
occurrence of a certain mutation with or without abnormal phenotype will give 
more answers to why MDS is such a heterogeneous disease.
As described in the WHO 2016 criteria: 80% of CMML patients have a mutation in 
SRSF2, TET2 or ASXL1. In this cohort with only a small subset of CMML patients, all 
patients had a mutation in one of these genes (Figure S1). All CMML patients had 
multilineage aberrancies by flow cytometry.
Cytopenias do not always correlate with the lineage affected with dysplasia. In 
addition, our study showed that the lineage affected by dysplasia as assessed 
by cytomorphology did not show an 1:1 correlation with FC results (figure 1C). 
Most patients with unilineage dysplasia according to cytomorphology could have 
multilineage aberrancies by FC. Phenotype is a result of genotype. Therefore, 
we expected to find correlations between FC aberrancies and mutations. In 122 
patients, we were able to investigate correlations between FC aberrancies and 
NGS, irrespective of WHO classifications. First, we found a minor but significant 
positive correlation between the number of FC aberrancies and the number of 
mutations detected by NGS. This confirms the phenotype-genotype link which 
might imply a disease-risk association. As most of these were all low risk patients, 
those patients with multiple aberrancies and additional mutations might identify 
a higher risk disease despite the low risk IPSS category, or clonal evolution during 
the course of the disease since most of these patients were not analyzed upfront 
but after being refractory to erythropoietin as first line of treatment. 31 Note, that 
in some subcategories patient numbers were small (i.e. only 3 patients with a 
mutation in a signal transduction gene). Therefore, patients were analyzed in 
(sub)categories to increase group size. Overall, mutations in transcription factors 
correlated with an aberrant immunophenotype (aberrant myeloid progenitors, 
granulocytes and monocytes). Furthermore, mutations in epigenetic regulators 
correlated with aberrant myeloid progenitors. Because of the heterogeneity 
observed, large patient numbers are required per mutational category to draw 
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solid conclusions. Large, multicenter patient cohorts are required to validate the 
correlations that were found, and to identify possible new correlations. Overall, 
these results might reflect the heterogeneity in disease manifestation, prognosis 
and response to therapy in MDS patients.
We demonstrated that MDS-FC and NGS were complementary to cytomorphology 
(the gold standard) in a diagnostic setting. Patients classified as MDS-U, a 
challenging diagnosis by cytomorphology (lacking dysplasia), showed clear MDS-
FC aberrancies (even multilinear dysplasia in one case).
In summary, this study reveals very heterogeneous with respect to FC aberrancies 
and SNP-array and NGS abnormalities within the distinct WHO categories. By 
combining the results of FC and NGS, 88% of patients showed MDS-associated 
abnormalities. There was a significant positive correlation between the number 
of FC aberrancies and the number of mutations detected by NGS. Mutations 
in transcription factors and epigenetic regulators correlated with presence of 
aberrant myeloid progenitors, granulocytes and/or monocytes by FC. With the 
availability of new, more advanced diagnostic tools, the classification of MDS is still 
heavily weighted on cytomorphology and cytogenetics. Although in the WHO 2016 
criteria assessment of SF3B1 in patients with ring sideroblasts is now added, this 
is just the beginning of improvement of MDS classification. MDS-FC can be used 
to identify multilineage aberrancies in single lineage dysplasia by cytomorphology. 
The diagnostic value of NGS is still under consideration. Mutation are described 
as frequent, yet their impact on therapy and prognosis is unknown.32 This study 
demonstrates that MDS-FC and NGS are able to identify a divers landscape 
within the well-established WHO categories. More research on the impact of 
these techniques and the prediction of overall survival and treatment response 
is ongoing.
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Table S1A The applied 4-color (panel A) and 8-color (panel B) markers.































































































































































Per antibody CD number, (clone), and manufacturer are depicted. DAKO: 
DakoCytomation, Glostrup, Denmark; BD: BD Biosciences, San Jose, CA, USA. 
BL: BioLegend, San Diego, Ca, USA. Sanquin, Amsterdam, The Netherlands. BC: 
Beckman Coulter, Miami, FL, USA. IS: Immunostep, Salamanca, Spain.
Table S2 The applied next-generation sequence panel.
Table X: Composition of sequencing panel
Gene Genic regions covered Gene function
1 ASXL1 E13 Epigenetic regulation
2 CBL E8, E9 Signal transduction
3 CSF1R E7, E22 Growth factor receptor
4 DNMT3A all coding exons (E2-E23) Epigenetic regulation
5 ETV6 all coding exons (E1-E8) Transcription factor
6 EZH2 all coding exons (E2-E20) Epigenetic regulation
7 FLT3 E14-E15, E20 Growth factor receptor
8 IDH1 E4 Epigenetic regulation
9 IDH2 E4 Epigenetic regulation
10 JAK2 E12, E14 Signal transduction
11 KRAS E2, E3 Signal transduction
12 NPM1 E11 Nuclear import, apoptosis
13 NRAS E2, E3 Signal transduction
14 RUNX1 all coding exons (E1-E6) Transcription factor
15 SF3B1 E6, E8, E13-E16 Splicing factor
16 SRSF2 E1 Splicing factor
17 TET2 all coding exons (E3-E11) Epigenetic regulation
18 TP53 all coding exons (E2-E11) Transcription factor, apoptosis
19 U2AF1 E2 Splicing factor
































































































































































































































































































































































































































































































































Figure S1 the diagnostic landscape in low risk MDS. 
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chapter 7
Transfusion dependency in MDS
About 80% of the MDS patients will present with an anemia, of which 40% will be 
treated with supportive care. This means erythropoietin and granulocyte-colony 
stimulating factor with or without red blood cell transfusions.1,2 Red blood cell 
transfusions decrease anemia-related symptoms and prevent ischemic organ 
damage. However, every unit of red blood cells contains about 200-250 mg of 
iron, 100 times the normal daily amount. There is no physiological mechanism 
to erase this overload of iron from the body. This means that multiple blood cell 
transfusions might lead to a secondary hemochromatosis.
The only potential curative treatment for MDS is allogeneic stem cell transplantation. 
Here, high transfusion dependency predicts a poor treatment outcome.3 If this is 
caused by the deleterious effect of iron, or that transfusions are only a reflection 
of the depth of the bone marrow disease, is unknown.
Pathophysiology of secondary hemochromatosis
The main regulator of iron homeostasis is hepcidin, a peptide hormone produced 
by the liver. Hepcidin breaks down the ferroportin, a membrane-bound iron 
transporter, through which iron is normally capable to leave the enterocytes and 
macrophages.
In case of an iron deficiency the hepcidin level in the blood is low, this leads to an 
increased iron absorption in the gut via the DMT1 transporter (Fe2+) and HCP1 
transporter (heme). Subsequently, iron reaches the circulation via ferroportin 
(Figure 1). A low hepcidin level will also cause release of stored iron from the 
macrophages of the reticulo-endothelial system (stored after erythrocyte 
degradation; under normal circumstances 20mg/day).1
Figure 1 Iron homeostasis. 
In patients with MDS-RARS the erythropoiesis is increased but ineffective. In MDS-
RARS patients hepcidin blood levels are significantly reduced. This is probably caused 
by release of humoral factors during the ineffective erythropoiesis, which suppresses 
the production of hepcidin. In MDS-RAEB patients an increased hepcidin blood level 
is found, mainly as a result of many red blood cell transfusions which lead to an 
increased iron in the circulation.4,5 Each transfused unit of erythrocytes provides 
200-250 mg of iron directly to the macrophages. The body has no active mechanism 
to remove excess of iron, but can passively remove 1-2 mg of iron per day through 
feces and sweat. Multiple transfusions will therefore lead to iron accumulation.
Iron is transported bound to transferrin. A small part is bound to ferritin and heme. 
The physiological storage possibilities are binding to ferritin in epithelial cells and 
macrophages. When the binding capacity of ferritin and transferrin is exceeded, 
iron occurs in the blood as ‘non-transferrin bound iron’ (NTBI). This means that 
the iron binds to other circulating molecules such as citrate, acetate and albumin. 
These bindings are less stable than the bindings to transferrin, ferritin or heme. The 
most reactive form of NTBI is called labile plasma iron (LPI). LPI easily passes the cell 
membrane and initiates cell damage in organs due to an increase in reactive oxygen 
species (ROS; oxygen free radicals) via the Fenton reaction (breakdown of H2O2 by 
reaction with an iron (II) ion). Oxidative stress and ROS-induced damage is a potential 
trigger for the increased apoptosis of the erythroid precursors in MDS by increasing 
of the Fas receptor (and the corresponding ligand FasL). This has a possible negative 
influence on survival. However, more research is needed to explain the direct toxic 
effects of red blood cell transfusions.6,7
Clinical effects of secondary hemochromatosis
As mentioned, the iron status becomes misbalanced after each transfused unit 
of red blood cells.8 As a result, secondary hemochromatosis will arise in patients 
who have received multiple red blood cell transfusions. The described negative 
effect of transfusion dependence on survival can be explained in two ways: i) as 
a reflection of the degree of bone marrow failure; ii) as a result of iron toxicity 
caused by transfusions. Bone marrow failure may lead to a higher risk of infection, 
hemorrhages and the negative effects of a prolonged-existing anemia, such 
as reduced quality of life, the risk of heart failure, and tissue ischemia (Figure 1). 
Studies on long-term transfusion-dependent patients with thalassemia revealed 
that heart, liver and endocrine organs are the most commonly affected organs by 
iron overload. Correlations between these complications and transfusion-caused 
iron overload are difficult to interpret as i) MDS is a very heterogeneous disease; ii) 
in general, MDS patients are elderly persons, usually with age-related comorbidities; 
iii) the mortality rate is heavily influenced by age. This makes it difficult to correlate 
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morbidity and mortality, solely with transfusion dependency. Described transfusion-
related complications in MDS are: liver cirrhosis by iron accumulation in the liver, 
diabetes mellitus due to iron overload in the pancreas, vascular damage caused 
by direct toxic damage of free iron in the blood and cardiac failure as a result of 
iron overload in the hart, and reduced quality of life.6,9 However, it remains complex 
to rule out other causes such as high age, pre-existing cardiovascular comorbidity 
and/or underlying chronic anemia due to chronic illnesses, especially in vascular 
diseases or cardiac failure.
Influence on (leukemic-free) survival
In untreated patients with very low and low risk MDS, the median survival is 8.8 
(IPSS-R). This means that in transfusion-dependent patients, iron accumulation takes 
place over a long period. A prospective analysis within the European LeukemiaNet 
MDS-registry showed progression to AML in 5% of the low- and intermediate-1-
risk (IPSS) MDS patients within 5-years; 12% died due to another cause.10  The 
most common causes of death in this group were infections and cardiovascular 
complications. Transfusion-dependent patients without disease progression had 
a four-times higher risk of death within 2 years, when compared to transfusion-
independent patients. In contrast, there was no difference in survival between 
patients with disease progression, with or without transfusion dependency.
Patients with high-risk MDS are expected to show fast progression to AML. So far, 
the only potentially curative therapy for high-risk patients is allogeneic stem cell 
transplantation (allo-SCT). Retrospective studies in this patient population showed 
that patients with high ferritin levels before the transplantation have a higher 
transplant-related mortality than patients with low-to-normal ferritin levels.11,12 
However, a recent prospective evaluation showed that iron overload, measured by 
T2-weighted MRI, had no impact on treatment-related mortality or overall survival 
after allo-SCT.13 Although there are indications that transfusion dependency and 
associated iron overload have a negative effect on allo-SCT outcome, clear evidence 
for a positive effect of iron-reducing therapy (via chelation drugs or phlebotomies) 
in a transplantation setting is lacking. However, it is advised to measure the degree 
of iron accumulation in allogeneic SCT candidates.14
Aim of the thesis – part 2
The aims of the second part of the thesis are to investigate the deleterious effect of 
transfusion-related iron toxicity in patients with high risk MDS treated with allo-SCT 
and to investigate a rationale for iron chelation therapy in an allo-SCT setting.
Chapter 9 and chapter 10 describe results of clinical trials conducted within the 
Chronic Malignancies Working Party (CMPW) of the European Society for Blood and 
Marrow Transplantation (EBMT). Chapter 9 describes the retrospective investigation 
of prognostic factors in MDS patients who were treated upfront with an allo-
SCT. Chapter 10 describes a prospective analysis of the influence of transfusion 
dependency on treatment outcome in MDS patients also treated upfront with allo-
SCT.
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Many pre-transplant factors are known to influence the outcome of allogeneic 
stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS). 
However, patient cohorts are often heterogeneous by disease stage and 
treatment modalities, which complicates interpretation of the results. This study 
aimed to obtain a homogeneous patient cohort by including only de novo MDS 
patients who received upfront allogeneic SCT after standard high dose myelo-
ablative conditioning. The effect of pre-transplant factors such as age, disease 
stage, transfusions, iron parameters and comorbidity on overall survival (OS), non-
relapse mortality (NRM) and relapse incidence (RI) was evaluated in 201 patients. 
In this cohort, characterized by low comorbidity and a short interval between 
diagnosis and transplantation, NRM was the most determinant factor for survival 
after SCT (47% after 2-year follow-up). WHO-classification and transfusion burden 
were the only modalities with a significant impact on overall survival after SCT. 
Estimated Hazard Ratios (HR) showed a strongly increased risk of death, NRM 
and RI, in patients with a high transfusion-burden (HR 1.99; P=0.006, HR of 1.89; 
P=0.03 and HR 2.67; P=0.03). The HR’s for ferritin level and comorbidity were not 
significantly increased.
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid bone 
marrow disorders characterized by clonal hematopoiesis, impaired differentiation, 
peripheral cytopenias, and an increased risk of progression to acute myeloid 
leukemia (AML).1 Allogeneic hematopoietic stem cell transplantation (SCT) 
is considered the only modality with proven curative potential, but leads to 
considerable treatment-related morbidity, mortality and decreased quality of life.2-5
Most MDS patients receive red blood cell (RBC) transfusions during the course 
of their disease.6 Transfused patients are prone to long-term accumulation of 
iron due to red blood cell (RBC) transfusions as well as susceptible to direct iron 
toxicity due to the formation of reactive oxygen species (ROS).7 Iron accumulation 
in MDS may start before patients become transfusion-dependent because of 
ineffective erythropoiesis, which blocks hepcidin production and subsequently 
increases iron absorption from the gut. Myelosuppressive therapy blocks 
erythropoiesis immediately and may result in direct iron toxicity.8 Elevated toxic 
iron radicals may lead to an increased risk of infections, higher SCT mortality, 
leukemic transformation, and tissue damage.9-11 Many studies described the 
negative impact of transfusion-dependency and associated iron accumulation on 
treatment outcome after SCT. Serum ferritin has often been used as a surrogate 
marker for iron overload. It is associated with an adverse effect on overall survival 
(OS), non-relapse mortality (NRM) and relapse incidence (RI).4, 12-15 However, ferritin 
levels are also associated with advanced stages of MDS, number of prior regimens 
and infections.16 Therefore, pre-transplant ferritin levels are less suited to evaluate 
iron toxicity caused by transfusions and ineffective erythropoiesis in MDS.
High dose chemotherapy decreases erythropoiesis and utilisation of iron, which 
leads to an increased iron load.17 High dose myeloablative preparative regimens 
cause more serious organ toxicity, higher risk of infections and acute graft-versus-
host disease (GvHD) than non-myeloablative regimens.18 Therefore, this study 
aimed to analyse a homogeneous group of MDS patients only treated with high 
dose chemotherapy as part of the transplant conditioning, without previous anti-
leukemic treatment (to minimize comorbidity). This allows more insight in the role 
of transfusion-burden and associated iron accumulation during SCT procedures. 
Insight in factors contributing to NRM may lead to better treatment approaches in 




The Chronic Malignancies Working Party (CMWP) of the European Group of Blood 
and Marrow Transplantation (EBMT) collected retrospective data of adult patients 
with proven MDS according to the WHO-classification, who received allogeneic 
SCT after high dose conditioning. Centers who had transplanted more than 4 MDS 
patients between 2000 and 2005 were invited to participate in this survey. Due to 
strict inclusion criteria 34 centers were selected to participate; leading to a cohort 
of 243 patients (range: 1 to 19 per center). The data were checked on diagnosis, 
primary origin, and previous treatment with intensive chemotherapy. With this
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primary origin, and previous treatment with intensive chemotherapy. With this 
procedure 24 patients were excluded because of secondary origin, 18 patients 
because of missing relevant transplantation data. The additional survey collected 
data which are not routinely recorded in the EBMT registry, including ferritin 
levels, serum iron levels, transferrin saturation and number of RBC-transfusions. 
Patients’ health status, including co-morbidities, was recorded through follow-up 
forms up to 5 years post-transplant. All clinical variables were measured at time of 
transplantation in patients undergoing upfront SCT, without other pre-transplant 
anti-leukemic treatment. Patients were analyzed according to patient and donor 
characteristics, WHO-classification, number of RBC units transfused, presence 
of comorbidity, iron parameters including ferritin, transferrin and plasma iron, 
and cytogenetic risk category according to the International Prognostic Scoring 
System (IPSS) risk categories.5, 19 Patients were diagnosed and classified prior 
to the introduction of the revised IPSS, therefore the IPSS was applied. Data on 
extra-hematologic comorbidities, that can influence the outcome of treatment 
were calculated using the Sorror co-morbidity index.18 The procedures were in 
accordance with the ethical standards with the Declaration of Helsinki.
End points and statistical analysis
Primary end-points were OS, NRM, and RI. OS was defined as the probability of 
survival since transplantation; death from any cause was considered as an event. 
Patients alive at time of last follow-up were censored at this date. NRM was defined 
as the probability of any death in the absence of relapse since SCT. RI was defined 
as the probability of hematologic relapse (definition: cytological and/or histological 
evidence of the disease in the marrow-blood and/or in extramedullary sites after 
SCT). For NRM and RI, patients were censored if relapse free and alive at time of 
last follow-up.
The probabilities of OS were estimated using the Kaplan-Meier product limit 
method. Estimates of NRM and RI were calculated using cumulative incidence 
curves to accommodate competing risks (relapse, considered a competing risk 
for NRM and vice versa). Univariate comparisons were based on the Kaplan-Meier 
method for OS, and on non-parametric cumulative incidence curves for RI and 
NRM. All significance tests are Cox-model based score tests (corresponding to the 
usual log-rank tests for OS and NRM).
Cox proportional hazards regression was used to assess the impact of potential 
prognostic factors in multivariate analyses. The impact of these factors on OS, NRM 
and RI was modeled by means of cause-specific hazards. For each outcome, we 
created 3 models. The first model contained baseline (expected) predictive factors: 
WHO-classification, age, donor type, sex-match (a female donor-male recipient 
combination has been described as a negative influence on SCT outcome)20, time 
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between diagnosis and SCT and cytogenetic abnormalities (model 1; see table 2).6, 
21 Then we added RBC-transfusions, and comorbidity, respectively (models 2-3).
We checked the impact of missing values for the key variables RBC-transfusions and 
comorbidity score on the outcomes both in the univariate and in the multivariate 
analyses. Since we concluded that the estimates of the coefficients of interest 
were not influenced significantly by the presence or absence of the patients with 
missing values for each of these key variables in turn, we presented the results 
based on different subsets of our data set with non-missing information.
Analyses were performed using PASW Statistics version 18.0 (SPSS, Chicago, IL). 
Cumulative incidences were calculated by means of SPSS macros developed by 
the Department of Medical Statistics and Bioinformatics of the Leiden University 
Medical Center (Leiden, the Netherlands); they are based on the hazard estimates 
from the Cox models. All P-values are two-sided and P<0.05 was considered 
significant. The dataset for analysis was closed in March 2011.
Results
A total of 201 patients underwent allogeneic SCT after high dose conditioning for 
untreated MDS between 2001-2005. Table 1 describes patients’ characteristics. 
The median age was 49 years (range 18-70) and 119 patients were male.
Due to the selection criteria of upfront SCT without prior treatment, the group of 
patients with refractory anemia (RA), refractory anemia with ringed sideroblasts 
(RARS) or isolated deletion of the 5q chromosome (5q-) population was relatively 
large (36%) in comparison to other reports 1. It is important to realize that this study 
was conducted prior to the introduction of lenalidomide and hypo-methylating 
agents. Treatment regiments were high dose myeloablative regimens, most 
commonly based on Busulfan (N=82), Treosulfan (N=15) and Melfalan (N=15) or 
total body irradiation (TBI; N=62) in dosages used in myelo-ablative schedules.22, 
23 GvHD prophylaxis regimens comprised of Cyclosporin (N=159), methotrexate 
(N=107), mycophenolate mofetil (N=24) and/or ATG (N=65). Median time between 
diagnosis and SCT was 8 months. Pre-SCT comorbidity was present in 34% of 
the patients. Of the patients transfused, 23% received >20 RBC units. Mean pre-
transplant iron parameters were: ferritin 1288ng/mL (N=62; range 72-9695 ), 
transferrin 233 mg/dL (N=30; range 56-538), transferrin saturation 29% (N=23; 
range 7-160 ), serum iron 171 mg/dL (N=43; range 30-467). Six patients received 
iron chelation post-SCT. The Sorror comorbidity index (HCT-CI) subdivided patients 
in ‘no comorbidity’ (HCT-CI: 0) 66%, ‘mild/moderate comorbidity’ (HCT-CI of 1-2) 
25%, or ‘severe comorbidity’ (HCT-CI of ≥3) 9%.
The OS, NRM and RI at 2 years post-SCT were 47%, 41% and 14%, respectively. Figure 
1 illustrates the OS stratified for WHO-classification, RBC-transfusions, ferritin level, 
and comorbidity. In univariate analyses, WHO-classification significantly affected 
OS (P=0.04) and RI (P=0.003), but did not affect NRM (P=0.38). Age, cytogenetics, 
donor type, match sex recipient-donor, and time between diagnosis and SCT did 
not have a significant impact on OS, NRM and RI in univariate analyses (data not 
shown).
Treatment outcome according to transfusion-burden
To examine the influence of transfusion-burden, patients were subdivided into 
2 groups depending on the amount of RBC units received pre-SCT, ≤20 and >20 
RBC-transfusions. Patients with a low transfusion burden had a significantly (P 
= 0.006) higher 2-year OS than patients with a high transfusion-burden (52% 
versus 31%), which was mainly explained by a higher NRM for patients with >20 
RBC transfusions. The 2-year NRM was different in both groups: 54% for patients 
with >20 RBC-transfusions, compared to 36% for the patients with less RBC-
transfusions (P=0.02). The RI was comparable in both groups: 17% and 15% at 2 
years (P=0.20).
Treatment outcome according to ferritin levels
Ferritin levels prior to transplantation were reported in a minority of patients 
(N=62). Based on ferritin levels patients were subdivided into two categories: 
<1000ng/ml (N=35) and ≥1000ng/ml (N=27). Patients with a higher ferritin level 
had a 14% lower 2-year survival than patients with a normal ferritin level (37% 
versus 51%; Figure 1) (P=0.23). The 2-year NRM and RI were 44% and 19%, in 
patients with a ferritin level ≥1000ng/ml, compared to 43% and 9%, in patients 
with a ferritin level below 1000ng/ml. The differences between the RI of both 
groups were not significant.
Treatment outcome according to comorbidity
Since the number of patients with co-morbidities was too small to subdivide 
the patients according to Sorror comorbidity index, presence and absence of 
comorbidities was used. The Kaplan Meier curves showed a 10% decrease in 
2-year survival for the patients with comorbidity (40% versus 50%). However, the 
difference in OS was not significant (P=0.15). RI was equal in both groups (16% vs 
14%; P=0.63). NRM for patients with a comorbidity was 48%, compared to 37% for 
patients without comorbidity (P=0.12).
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Multivariate analysis of pre-transplant factors
Cox models were built for the multivariate analysis (see patients and methods). 
The baseline model, which included expected prognostic factors showed that 
transplantation with an unrelated donor had a very significant impact on the HR 
for RI (HR 0.28; P=0.002) but no influence on survival (HR 1.03; P=0.89) (table 2). 
Although other studies used 40 years of age as a cut-off point, we decided to use 
50 years since this was closer to the median.2 Poor risk cytogenetic abnormalities 
(≥3 abnormalities or an abnormal chromosome 7) had a significant impact on 
the HR for RI (HR 3.01; P=0.009). This did not influence survival significantly (HR 
1.31; P=0.29). WHO-classification influenced the outcome significantly (table 
2). In comparison to RA/RARS patients, patients with a refractory cytopenia 
with multilineage dysplasia (RCMD) had a statistically decreased survival (HR 
3.12; P=0.001) and high HR for NRM (HR 2.80; P=0.006). This impact remained 
significantly increased in all models. In comparison to RA/RARS patients, patients 
with a refractory anemia with excess blast-1 (RAEB-1) and patients with MDS 
transformed into AML (MDS/AML) had a significantly higher risk of relapse, HR 
5.95 (P=0.001), and HR 5.66 (P=0.003), respectively, leading only to a significantly 
decreased survival in MDS/AML patients (HR1.85; P=0.03).
Age, sex match donor-recipient, and interval between diagnosis and transplantation 
had no significant prognostic impact on OS, NRM and RI in the baseline model 
(table 2).
The Cox models built for transfusion-burden showed that a high transfusion-
burden resulted in an inferior outcome for OS, NRM and RI, with a HR of 1.99 
(P=0.006), 1.89 (P=0.03), and 2.67 (P=0.03) respectively (model 2). The presence 
of comorbidity was associated with a non-significant increased risk of death (1.43; 
P=0.15) and NRM (HR 1.67; P=0.08) but no impact on RI (HR 0.71; P=0.44) (table 
2; model 3).
Discussion
Several studies addressed the impact of transfusion-dependency, transfusion-
burden and iron overload/toxicity after transplantation in MDS patients. However, 
data from these retrospective studies should be interpreted carefully because 
patient cohorts are often heterogeneous with regards to disease status, comorbidity, 
and treatment modalities.19, 24 High risk patients frequently receive cytoreductive 
therapy (intensive chemotherapy or hypomethylating agents) prior to the 
transplant conditioning, sometimes as part of bridging. The value of cytoreductive 



































































































































































































































































































































   







































































































































































































































































































































































































































































































We have chosen this this homogeneous population with a relative low relapse 
risk after transplantation and a long median follow-up of 5 years. Both in AML and 
in MDS, ferritin levels had a pronounced influence on OS in heavily pretreated 
patients.12, 16 Since ferritin is an acute phase reactant, we postulate that elevated 
ferritin levels are heavily influenced by stage of disease and by recently applied 
intensive chemotherapy and associated invasive infections. Therefore, the 
homogeneity of this cohort may provide more insight in the impact of relevant 
prognostic factors in the setting of SCT. In addition, we focused on obtaining a 
complete pre-transplantation transfusion history to be able to accurately analyze 
the impact of transfusion burden rather than using ferritin levels as surrogate 
marker.
In this study NRM was the most determinant factor for survival post-SCT, probably 
due to the large number of patients with <5% blasts (36%). The favorable OS of the 
large RA/RARS group may explain the lack of prognostic impact of several putative 
prognostic factors, including age, sex-match donor-recipient, time between 
diagnosis and SCT and cytogenetic abnormalities.19 Cytogenetic abnormalities did 
have an impact on RI, but not on OS since NRM was the driving force of death 
in this study. In all models age had no impact on outcome. The low incidence 
of comorbidities may explain the loss of the prognostic impact by age in this 
patient cohort. As expected WHO-classification had a major impact on outcome 
(P=0.04). In comparison to RA/RARS patients, RCMD patients showed a significantly 
decreased survival (HR 3.12; P=0.001). The HR’s of RCMD for OS and NRM remained 
significantly increased after adding transfusion-burden, and comorbidities to the 
models. The increase of the HR after adding number of transfusions and co-
morbidity suggests that the impaired survival is intrinsic to this MDS category. 
However, this unique observation needs confirmation by additional studies. As 
expected, RAEB-1 and MDS/AML patients had a significantly higher risk on RI, 
5.95; P=0.001, and HR 5.66; P=0.003, compared to RA/RARS patients, leading to a 
significantly decreased survival in MDS/AML patients (HR1.85; P=0.03).
 
Transfusion dependency appeared to have a major prognostic impact on outcome. 
Multivariate analysis showed a significantly decreased OS in patients who received 
>20 RBC-transfusions prior to conditioning (HR 1.99; P=0.006), due to an increased 
NRM and RI with a HR of 1.89 (P=0.03) and HR 2.67 (P=0.03) respectively. A 
higher transfusion-dependency may indicate a more pronounced marrow failure 
which may be associated with a decreased survival. In addition toxicity caused 
by RBC-transfusions might be deleterious either because of increasing iron load 
or because of other adverse effects e.g. transfusion related immunomodulation 
(TRIM) and the effect of stored blood on the microcirculation hemodynamics and
Fig 1. Overall survival stratified for WHO-classification (A), transfusion burden (B), iron load 
(C), and comorbidity (D) (Kaplan-Meier curves). P-values are based on the two-sided log-
rank test.
tissue oxygenation.26, 27 A more challenging explanation is given by Hod et al.28 
They described that RBC-transfusions with stored blood give a sudden rise in non-
transferrin bound iron (NTBI), due to a rapid clearance of the damaged blood cells. 
This sudden increase in NTBI may enhance transfusion-related complications.9, 
10 To minimize transfusions toxicity they advised to use fresh erythrocytes for 
transfusions, which will have a major impact on the logistics of clinical practice. 
Iron chelating therapy before and after SCT might be a good alternative. Chelation 
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therapy may improve hemoglobin levels and reduce transfusion requirement in 
a minority of patients with MDS.29 Reduction of the interval between diagnosis 
and transplantation minimizes the exposure time to ineffective erythropoiesis, 
transfusion-dependent period and the number of transfusions. Comorbidity in 
this studied population was limited, which may explain the absent prognostic 
impact in contrast to other studies.3 A prospective non-interventional study within 
the CMWP of the EBMT, to look at the influence of iron toxicity and transfusions 
on treatment outcome after allogeneic SCT in MDS patients has been completed 
and the analysis of the data is ongoing.
In summary, in this homogeneous patient cohort, NRM was the most determinant 
factor for survival after SCT. WHO-classification and transfusion-burden were 
the only pre-transplant factors with a significant impact on survival. Cytogenetic 
abnormalities had only a significant influence on the HRs for RI. More research on 
the influence and pathophysiology of transfusion toxicity is mandatory in particular 
the role of iron chelation before SCT and phlebotomies and/or iron chelation after 
SCT.
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Most patients with myelodysplasic syndromes (MDS) present with anaemia and 
receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron 
overload-related comorbidity and mortality, and may influence outcome after 
allogeneic HSCT. This prospective non-interventional study evaluated 222 patients 
with MDS and CMML who underwent upfront HSCT. Overall survival (OS), relapse-
free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 
months were 52%, 44%, 25% and 31%, respectively. Age, percentage of marrow 
blasts and presence of severe comorbidities impacted OS (p=0.002, p=0.002, and 
p=0.02 respectively). RFS  was significantly associated with RBCT burden prior 
to HSCT (HR 1.7; p=0.02) in the multivariable analysis. High ferritin levels had a 
significant negative impact on OS and RI, but no impact on NRM. Administration of 
iron chelation therapy prior to HSCT did not influence outcome, but iron reduction 
after HSCT either by phlebotomies or by iron chelation improved relapse-free 
survival significantly, if started before 6 months after transplantation.
This study illustrates the impact of RBCT and related parameters on outcome after 
transplantation. Patients with an expected prolonged survival after transplantation 
may benefit from early iron reduction therapy after transplantation.
Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) is the most potent 
curative therapeutic option in patients with myelodysplastic syndromes (MDS).1 
Due to high treatment-related morbidity and mortality, combined with a high 
relapse risk, the current long-term overall survival rate is around 35%.2-4 Non-
relapse mortality (NRM) has decreased after introduction of reduced intensity 
regimens (RIC) for the elderly and more frail patients with MDS.5,6 Many parameters 
such as age, comorbidity, advanced disease stage and cytogenetic risk category 
according to the (revised)-International Prognostic Scoring system (IPSS-R) have 
been reported to impact treatment outcome.4,7-10 Around 80% of patients with 
MDS present with anaemia and  many of these patients receive multiple red blood 
cell transfusions (RBCT) during the course of their disease.11 RBCT and associated 
iron overload may cause iron toxicity related comorbidity and mortality, and 
influence HSCT outcome.12-15 Most studies are retrospective and selection bias 
and lack of detailed data about treatments, outcomes and potentially confounding 
risk factors  might have influenced conclusions.
The Chronic Malignancies Working Party (CMWP) of the EBMT performed a large 
prospective, non-interventional study to evaluate prognostic pre-transplant factors 
in MDS and chronic myelomonocytic leukaemia (CMML). The primary objective of 
this study was to evaluate the relation between iron toxicity and treatment-related 
mortality after allogeneic HSCT in adult MDS and CMML patients. As previous 
intensive chemotherapy might have an impact on pre-HSCT co-variables, including 
stage of disease, patients treated with intensive chemotherapy were excluded 
from this study. This approach is expected to be associated with a reduced pre-
treatment related morbidity, and a reduction of the interval between diagnosis and 
HSCT. Secondary objectives were i) description of treatment outcomes defined by 
NRM, OS, relapse incidence (RI) and relapse-free survival (RFS); ii) impact of RBCT 
and surrogate iron markers that may reflect iron burden, including ferritin levels, 
on treatment outcome. Data on iron reduction therapy prior and post HSCT was 
collected, to evaluate its impact on treatment outcome.
Patients and Methods
Two hundred twenty-two adult (age >=18 years at HSCT) patients with de-novo 
MDS, AML-MDS with 20 to 30% marrow blasts (formerly RAEBt), patients with AML 
after MDS (AML-MDS) or patients with CMML who received upfront HSCT after 
bone marrow ablative or reduced intensity regimens were included prospectively 
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between January 2009 and January 2014. Patients had an ECOG performance 
status between 0 and 2. Exclusion criteria included previous intensive anti-
leukaemic chemotherapy, patients with juvenile CMML, patients with therapy-
related MDS, AML or CMML after treatment with immunosuppressive or cytotoxic 
treatment for a non-myeloid malignancy, patients who had received auto-HSCT, 
candidates for cord blood HSCT or syngeneic HSCT, inadequate renal function 
(ECC <60 ml/min and/or creatinine >2.5 times upper limit of normal value), 
inadequate hepatic function (transaminases >2.5 times upper limit of normal 
value), history of seizures, pregnancy and women of child-bearing potential and 
not using adequate contraceptives, uncontrolled hypertension. The research was 
conducted according to the Declaration of Helsinki and written informed consent 
was obtained from each participating patient. Trial registered at Clinicaltrial.gov 
Identifier: 842205547.
Data were collected by survey at diagnosis, at transplantation and 6 weeks, 100 
days, 1 year and annually thereafter. Missing data was collected by follow-up 
surveys. Based on the study objectives the following variables were collected: 
age, gender, comorbidities, WHO classification, cytogenetic characteristics 
according to IPSS-R, number of transfusions, ferritin levels, haemoglobin levels, 
C-reactive protein (CRP), donor type, female-donor/male recipient versus other 
combinations, interval diagnosis and HSCT, HSCT conditioning agents and types, 
T-cell depletion, acute and chronic graft versus host disease (GvHD), and data 
concerning treatment with iron chelation or phlebotomy.
Primary end-points were overall survival (OS), relapse-free survival (RFS), relapse 
incidence (RI), and non-relapse mortality (NRM), evaluated at 36 months after 
transplant. The median follow-up was estimated using the reverse Kaplan-Meier 
method. Additionally, acute GvHD grade I-II and III-IV and limited and extensive 
chronic GvHD were evaluated at 100 days and 36 months after transplant 
respectively. OS and RFS were estimated using the Kaplan-Meier product limit 
estimation method, and differences in subgroups were assessed by the Log-Rank 
test. Cumulative incidences of relapse and NRM,  were analyzed in a competing 
risks framework. The cumulative incidences of acute GvHD grade I-II and III-
IV were estimated as competing risks, considering as competing event death 
before aGvHD. The cumulative incidences of limited and extensive cGvHD were 
estimated equivalently. Subgroup differences were assessed by Gray’s test. Cox 
proportional hazards regression was used to assess the impact of potential risk 
factors in univariable and multivariable analyses. Multivariable analyses of RI and 
NRM were performed using Cox cause-specific hazards models. The impact of 
post-transplant iron reduction therapy was investigated using landmark analyses 
at 6, 12 and 24 months. The landmark population was defined as patients alive 
(event = death) and event free (event = death and/or relapse) at the respective 
landmark time points. All p-values were two-sided and p<0.05 was considered 
significant
Results
Demographic and transplantation data
The study included 181 patients with MDS, 16 patients with AML-MDS, and 25 
patients with CMML from 29 European transplant centres (for details, see table 1). 
The median age was 59 years (range 19-76 years). WHO-classifications at time of 
transplantation were 20 patients with a RA/RARS, 36 with RCMD/RCMD-RS, 1 with 
5q-, 50 with RAEB-1, 74 with RAEB-2, 25 with CMML and 16 with AML-MDS. In total, 
70% of the patients had received red blood cell transfusions (RBCT) prior to HSCT. 
Median number of RBC units transfused before transplantation: 12 units (range: 
1-146 units); median ferritin levels: 700 ng/ml (range 8-9033 ng/ml). Median 
interval between diagnosis and HSCT was 10 months (range 1-128 months). Time 
between diagnosis and HSCT was <6 months for 56 patients and >6 months for 
166 patients. A total of 99 patients received standard conditioning (MAC) and 123 
received a reduced intensity (RIC) regime. After conditioning 70 patients received 
stem cells from a sibling, 4 from a mismatched relative and 148 patients from an 
unrelated donor. The incidence of acute GvHD grade I-II and grade III-IV at 100 
days was 1% (25-37%) and 14% (9-18%) respectively.  The incidence of limited 
or extensive chronic GvHD at 36 months was 47% (40-54%) and 20% (15-26%) 
respectively.
Univariable analysis of relevant factors on primary end points
The median follow-up of the 222 registered patients after HSCT was 39 months 
with 95% confidence intervals (CI) ranging from 36 to 44 months. OS, RFS, NRM and 
RI at 36 months were 52% (95% CI: 45-59%), 44% (95% CI: 37%-51%), 25% (95% CI: 
19%-32%) and 31% (95% CI: 24%-37%), respectively. Age had a significant impact 
on OS when analysed as continuous variable per decade (HR 1.4, 95%CI 1.1-1.8; 
p=0.002) also on RFS (HR 1.4, 1.1-1.8; p=0.002), and a borderline impact on NRM 
(HR 1.4, 1.0-1.8; p=0.05) and on relapse incidence (HR 1.3, 1.0-1.7; p=0.07). To 
evaluate the impact of WHO-classification on treatment outcome, patients were 
divided in 4 subgroups: patients with 5% marrow blasts or less at time of HSCT 
(RA, RARS, RCMD, RCMD-RS, 5q-), patients with 6-19 marrow blasts (RAEB1 and 
RAEB2), patients with >20 % marrow blasts (AML-MDS) and patients with CMML. 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Cytogenetics according to IPSS-R categories, had no significant impact on 
treatment outcome. However, the group with very poor-risk cytogenetics could not 
be analysed separately due to its small size (n=9) (details provided in Table I). Only 
11 patients were transplanted with bone marrow as stem cell source. Therefore, 
the impact of stem cell source has not been analysed separately. Transfusion 
burden (<20 RBCT versus >20 RBCT) did not have a significant impact on any of the 
outcome parameters. Ferritin levels (>1000 ng/ml) had a non-significant negative 
impact on NRM and OS after HSCT, but elevated CRP levels (> 10 mg/l) influenced 
OS significantly (p=0.02).
Figure 1 Overall survival according to WHO Categories. Kaplan-Meier plot for OS in the 
whole cohort, grouped by WHO categories. The corresponding 95% confidence intervals 
are indicated by the gray regions. The Log-rank p-value is indicated.
Correlations  of potentially confounding factors for the multivariable analyses
Patients with more than 5% bone marrow blasts received a low number of red 
blood cell units (0-20 RBCT) before HSCT more frequently than patients with less 
than 5% bone marrow blasts (p = 0.01), mainly explained by a shorter duration 
of the interval between diagnosis and HSCT in patients with more advanced MDS 
according to WHO-classification (data not shown). The number of RBCT before 
HSCT was not associated with the cytogenetic risk category according to IPSS-R (p 
= 0.7) nor with interval between diagnosis and actual HSCT of the whole cohort, 
including patients with less than 5% marrow blasts (<6 vs >6 months) (p = 0.2). 
As expected, ferritin levels (>1000 ng/ml versus <1000 ng/ml) were influenced by 
number of administered RBCT prior to HSCT (p<0.001). Ferritin levels, measured 
as units of 1,000 mg/L were associated with elevated CRP levels (p=0.03) in this 
study. Co-morbidities and intensity conditioning (MAC versus RIC) were significantly 
associated (p<0.001).
Multivariable Cox models
The basic model was restricted to the traditional variables indicating a potential 
prognostic impact, as known from the literature and as indicated by the univariable 
analyses (Table II). Therefore, only WHO-classification, age at HSCT, donor type, 
sex-match, and intensity of conditioning regimen were included in the model. We 
added one by one the other variables of specific interest in the current study: 
RBC transfusions, CRP levels, ferritin levels (continuous in units of 1000 ng/ml) 
and comorbidities. This approach was necessary due to the highly correlated 
nature of these variables. The transfusion burden prior to HSCT influenced RFS 
significantly (HR 1.7; p = 0.02). The impact of pre-HSCT ferritin levels was minor but 
significant on OS (HR 1.2; p = 0.05) and RI (HR 1.3; p = 0.04).   Presence of severe 
comorbidities influenced OS after HSCT (HR 1.8; p 0.04). Elevated CRP-levels (>10 
mg/L) had a borderline negative impact on survival (HR 1.6; p=0.06).
Impact of iron chelation before HSCT on outcome
Thirty-one (14%) patients received iron chelation prior to HSCT and ferritin levels 
at HSCT were available in 28 patients of them. The median duration of chelation 
prior to HSCT was 4 months (range: 0 to 40 months). The median ferritin levels 
at HSCT was 1598 ng/ml, 9 chelated patients had ferritin levels < 1000 ng/ml at 
time of HSCT. Sixteen chelated patients had received >20 units of RBCT prior 
to HSCT. The outcome of the patients chelated prior to transplant conditioning 
was compared with a non-chelated control group of 70 patients who had ferritin 
levels >1000 ng/ml at HSCT  or  who had received >20 units of RBCT prior to HCT 
conditioning. The overall 3-year survival in the chelated group was 44% (21-67%) 
similar to the survival in control group 45% (33-57%, p = 0.6; Figure 2A). The RFS, RI 
and NRM were also similar in both groups: 33% (13-54%) in the chelated patients 
versus 38%  (26-50%) in the non-chelated patients, 34% (15-53%) versus 33% (22-
44%), and 32% (13-53%) versus 29% (18-40%), respectively (Figure 2B).
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Impact of phlebotomies or iron chelation after HSCT on outcome
Twenty patients have been treated with phlebotomies after HSCT. Most patients 
(80%) started phlebotomies during the first year after HSCT. The median ferritin 
levels before starting phlebotomies was: 3134 ng/ml (range: 937 – 9985 ng/ml). 
The number of phlebotomies was available in 16 patients: 9 patients underwent 
<10 phlebotomies and 7 patients 10 or more phlebotomies. The ferritin levels 
decreased to levels <1000ng/ml in 10 out of 19 patients at time of completion of 
phlebotomies or at 24 months after HSCT and decreased more than 50% in five 
additional patients. In the remaining 5 patients the effect was not evaluable mainly 
due to insufficient follow-up after starting phlebotomies.
Sixteen patients have received iron chelation (deferasirox only) after HSCT. Nine 
patients started chelators during the first 6 months after HSCT and 13 patients 
during the first year after HSCT. The median interval between HSCT and starting 
chelation was 5 months (range: 1-18). The median ferritin level before starting 
chelation was: 3122 ng/ml (range: 69 – 9040 ng/ml). The median duration of iron 
chelation was 4 months (range: 0.5 to 40 months). The ferritin levels decreased 
to levels <1000 ng/ml in 3 out of 16 patients during iron chelation and decreased 
more than 50% in four additional patients. In the remaining patients the effect was 
not evaluable due to missing ferritin levels (5 patients) or too short duration of 
chelation (7 patients). The median duration of iron chelation in the 5 responding 
patients was 4 months (range: 1.5 to 7 months).
We combined the data of both interventions, because the number of patients 
who were treated with either chelation or phlebotomies was relatively small, and 
both interventions are aiming at reducing the iron overload.  Fourteen patients 
started treatment with either phlebotomies or chelation during the first  6 months 
after HSCT, and 27 patients started these interventions within the first 12 months 
after HSCT. The outcome of the patients treated with iron reductive interventions 
was compared with the untreated control groups with ferritin levels >1,000 ng/
ml alive and relapse free at the landmarks of 6, 12 and 24 months respectively 
(Table III).  Only patients who received iron reductive therapy within 6 months 
after HSCT had a significantly improved 3 year RFS compared to the non-treated 
patient population (90% (71-100%) vs 56% (46-67%); p=0.04 Figure 3, table III). 
The survival at this landmark analysis was moderately reduced compared to the 
control group with an 3-year OS of 90% (71-100%) versus 65% (54-75%) in the 
control group (Table III). The outcomes at later landmark analyses did not indicate 
relevant differences with the exception of a moderate difference of the NRM at 































































































































































































































































































































































































































































































































































































































































































































































Figure 2 Overall survival (2A) and relapse free survival (RFS) according to iron reduction 
therapy prior to Transplantation(2B). Kaplan-Meier plot for OS (2A) and RFS (2B) in 
patients who either received chelation therapy or could have received chelation therapy 
based on their increased ferritin levels or received transfusions, prior to transplant. The 
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Figure 3 Overall survival and relapse-free survival of patients alive and relapse-free at 6 
months after transplantation, stratified in 2 groups according to iron reduction therapy 
given during the first 6 months after transplantation or not.  Landmarked Kaplan-Meier plot 
for OS and RFS in patients who either received iron reduction therapy or could have received 
iron reduction therapy based on their increased ferritin levels or received transfusions. 
Patients were selected based on ferritin levels >1000 ng/ml. The landmark time-point is 
indicated by the vertical dashed line. Only patients alive and relapse-free at 6 months are 
included. The corresponding 95% confidence intervals are indicated by the gray regions.
Discussion
Allogeneic haematopoietic stem cell transplantation (HSCT) is considered the most 
potent curative option in myelodysplastic syndromes (MDS). Many retrospective 
analyses evaluated relevant prognostic parameters, to enable adequate patient 
selection for treatment16,17 and reviewed in.18 This large prospective observational 
study collected detailed information on several relevant prognostic factors, 
including specific patient characteristics, disease modalities, transfusion data and 
iron parameters in patients with MDS undergoing HSCT. Age, BM blast percentage 
and comorbidity at time of HSCT had a significant influence on outcome after 
HSCT. The data of this study showed that intensity of conditioning regimen had 
no impact on overall survival, confirming several other  retrospective studies.5,6,19,20
The primary objective of this study was to study the impact of iron overload and 
iron toxicity on outcome after HSCT. As expected21, the data showed a significant 
association between transfusion burden and ferritin levels (p<0.001). A high RBCT 
burden, higher than 20 units prior to transplantation, was significantly associated 
with a decreased relapse-free survival (HR 1.7; P=0.02). Although it is difficult to 
separate the impact of transfusion load as an independent prognostic marker 
from progression of bone marrow failure and increased tumour burden, several 
studies showed a significant impact of transfusion burden on HSCT outcome17,22,23, 
including our own retrospective study.24 In this study the impact of high transfusion 
burden on overall survival was less explicit (HR 1.5; P=0.09), in contrast to the 
significantly reduced RFS, which can be explained by the smouldering nature of 
less advanced MDS patients in this cohort (only 16 patients had AML-MDS at time 
of transplantation). This may result in a prolonged survival after relapse.
Ferritin is an acute-phase protein, elevated in case of infection, inflammation 
or high tumour burden.25 To correct for this confounding factor we analysed 
CRP levels, another acute phase protein, which was significantly correlated with 
ferritin levels. Both ferritin levels and elevated CRP levels had an impact on overall 
survival, but only ferritin levels had an significant impact on relapse incidence. On 
the other hand, the impact of elevated CRP levels on NRM was more pronounced 
compared to the impact of elevated ferritin levels, confirming data from a large 
HSCT study in AML and MDS.26 Ferritin levels are sometimes used as a marker 
of transfusion burden,27 but in the multivariable analysis of that study only co-
morbidities and percentage of marrow blasts at time of HSCT predicted OS.27 
Therefore, it has been postulated that transferrin saturation, NTBI and LPI are 
better parameters to monitor and to study iron toxicity during conditioning for 
HSCT and the first two weeks after HSCT.28 When transferrin saturation exceeds 
85%, species of non-transferrin-bound iron (NTBI), and its redox active component 
labile plasma iron (LPI), become detectable in the plasma.29,30 Transferrin becomes 
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saturated immediately during transplant conditioning and remains elevated until 
engraftment.30 These redox active components lead in various steps to associated 
tissue damage, mostly cardiac, endocrine and liver tissue and may also affect clonal 
evolution in MDS.31 Reduction of iron stores, may alleviate long-term effects of 
iron toxicity in transfusion dependent patients with MDS.32 Consensus statements 
advice to administer iron chelation therapy in those patients with an expected 
long-term survival.33,34 In high-risk MDS, patients might not live long enough to 
endure the toxic effects of transfusional therapy. Research of the impact of iron 
chelation in a transplant setting is ongoing.35
In the current study we were able to investigate the impact of iron reduction 
therapy on outcome after HSCT. Iron overload in the transplant setting may be 
reduced both by iron chelation therapy36,37 and by phlebotomies.38 Administration 
of iron chelation therapy prior to HSCT had no influence on treatment outcome in 
this study. However, the ferritin levels of the chelated patients at HSCT were still 
elevated with a median level of 1772 ng/ml, and only 8 out the 28 chelated patients 
with available ferritin levels had ferritin levels <1000 ng/ml at HSCT. This indicates 
that iron chelation was insufficient in the majority of cases, probably reflecting the 
short period of iron chelation prior to HSCT. Patients with MDS may also receive 
iron reduction interventions to reduce iron overload after HSCT.39 We were able 
to evaluate the influence of iron reduction therapy after HSCT in a subgroup 
of 35 patients, consisting of iron chelation in 16 patients and/or phlebotomies 
in 20 patients (one patient received bot phlebotomies and iron chelation). Iron 
reduction by phlebotomies started  within one year after HSCT in 80% and by iron 
chelation in 81% of the patients receiving the respective therapies. The efficacy 
of reducing ferritin levels by phlebotomies was excellent with more than 50% 
reduction in 74% of the patients and 28% after chelation, probably reflecting the 
short period of chelation (median 4 months). Most events (relapse or death by any 
cause) occurred within the 6 months after transplantation in our study. Therefore, 
iron reduction therapy is expected to have more impact on outcome, if initiated 
within 6 months after HSCT, as shown in our study. The patient population who 
received iron chelation therapy or phlebotomies within 6 months after HSCT had 
a significantly improved RFS compared to non-chelated patient population with 
ferritin levels >1000 ng/ml or having received transfusions before HSCT (P = 0.04), 
while the OS at this landmark was moderately (P=0.08) improved. Selection of the 
patients for either of the interventions cannot be ruled out, but the data in the 
supplementary table do not show remarkable differences in the both groups.
In conclusion, analysis of this non-interventional prospective data from MDS 
patients, not pre-treated with intensive chemotherapy before undergoing 
allogeneic HSCT, demonstrated that transfusion burden prior to HSCT influenced 
progression free survival, without a significant effect on survival. Outcome might 
be predicted by serum ferritin levels, irrespective to CRP levels. Administration 
of iron reduction prior to HSCT had no impact on primary outcome, but iron 
reduction therapy after HSCT increased relapse-free survival, if initiated within 6 
to 12 months after HSCT.
Acknowledgements: We would like to thank all centres which have participated 
in this study.
E.C. coordinated the study, analysed the data and wrote the paper. T.d.W. analysed 
the data, designed the research, and co-authored the paper. L.d.W., D.E. and 
D.Z performed the statistical analysis, and co-authored the paper. E.K and A.v.B. 
collected the data. J.F., D.B., G.S., A.N.., G.K., L.V., T.G., J.S., Y.B., G.S., P.L., and A.A., 
admitted a substantial amount of patients and critically reviewed the paper. M.R. 
and N.K. chaired the CMWP meetings during which the progress of the study and 
this manuscript was discussed, they also reviewed the paper.




1. Gangat N, Patnaik MM, Tefferi A. Myelo-
dysplastic syndromes: Contemporary re-
view and how we treat. Am J Hematol. 
2016;91(1):76-89.
2. Kroger N. Allogeneic stem cell transplanta-
tion for elderly patients with myelodysplastic 
syndrome. Blood. 2012;119(24):5632-5639.
3. Damaj G, Mohty M, Robin M, et al. Upfront 
allogeneic stem cell transplantation after 
reduced-intensity/nonmyeloablative con-
ditioning for patients with myelodysplastic 
syndrome: a study by the Societe Fran-
caise de Greffe de Moelle et de Therapie 
Cellulaire. Biol Blood Marrow Transplant. 
2014;20(9):1349-1355.
4. Koenecke C, Gohring G, de Wreede LC, 
et al. Impact of the revised International 
Prognostic Scoring System, cytogenetics 
and monosomal karyotype on outcome af-
ter allogeneic stem cell transplantation for 
myelodysplastic syndromes and secondary 
acute myeloid leukemia evolving from my-
elodysplastic syndromes: a retrospective 
multicenter study of the European Society of 
Blood and Marrow Transplantation. Haema-
tologica. 2015;100(3):400-408.
5. Martino R, Iacobelli S, Brand R, et al. Retro-
spective comparison of reduced-intensity 
conditioning and conventional high-dose 
conditioning for allogeneic hematopoietic 
stem cell transplantation using HLA-iden-
tical sibling donors in myelodysplastic syn-
dromes. Blood. 2006/8/1;108(3):836-846.
6. Martino R, Henseler A, van Lint M, et al. 
Long-term follow-up of a retrospective com-
parison of reduced-intensity conditioning 
and conventional high-dose conditioning for 
allogeneic transplantation from matched re-
lated donors in myelodysplastic syndromes. 
Bone Marrow Transplant. 2017;52(8):1107-
1112.
7. Sorror ML, Martin PJ, Storb RF, et al. Pre-
transplant comorbidities predict severity of 
acute graft-versus-host disease and subse-
quent mortality. Blood. 2014;124(2):287-295.
8. Greenberg PL, Tuechler H, Schanz J, et al. 
Revised international prognostic scoring sys-
tem for myelodysplastic syndromes. Blood. 
2012;120(12):2454-2465.
9. Schanz J, Tuchler H, Sole F, et al. New com-
prehensive cytogenetic scoring system for 
primary myelodysplastic syndromes (MDS) 
and oligoblastic acute myeloid leukemia af-
ter MDS derived from an international da-
tabase merge. J Clin Oncol. 2012;30(8):820-
829.
10. Scheid C, de Wreede L, van Biezen A, et al. 
Validation of the revised IPSS at transplant 
in patients with myelodysplastic syndrome/
transformed acute myelogenous leukemia 
receiving allogeneic stem cell transplanta-
tion: a retrospective analysis of the EBMT 
chronic malignancies working party. Bone 
Marrow Transplant. 2017;52(11):1519-1525.
11. Arber DA, Orazi A, Hasserjian R, et al. The 
2016 revision to the World Health Organiza-
tion classification of myeloid neoplasms and 
acute leukemia. Blood. 2016;127(20):2391-
2405.
12. Waszczuk-Gajda A, Madry K, Machowicz R, et 
al. Red Blood Cell Transfusion Dependency 
and Hyperferritinemia Are Associated with 
Impaired Survival in Patients Diagnosed with 
Myelodysplastic Syndromes: Results from 
the First Polish MDS-PALG Registry. Adv Clin 
Exp Med. 2016;25(4):633-641.
13. Alessandrino EP, la Porta MG, Bacigalupo A, 
et al. Prognostic impact of pre-transplanta-
tion transfusion history and secondary iron 
overload in patients with myelodysplastic 
syndrome undergoing allogeneic stem cell 
transplantation: a GITMO study. Haemato-
logica. 2010/3;95(3):476-484.
14. Armand P, Sainvil MM, Kim HT, et al. Pre-
transplantation iron chelation in patients 
with MDS or acute leukemia and iron over-
load undergoing myeloablative allo-SCT. 
Bone Marrow Transplant. 2013;48(1):146-
147.
15. Bazuaye GN, Buser A, Gerull S, Tichelli A, 
Stern M. Prognostic impact of iron param-
eters in patients undergoing allo-SCT. Bone 
Marrow Transplant. 2012;47(1):60-64.
16. Santini V, Girelli D, Sanna A, et al. Hepcidin 
levels and their determinants in different 
types of myelodysplastic syndromes. PLoS 
One. 2011;6(8):e23109.
17. Alessandrino EP, la Porta MG, Bacigalupo A, 
et al. WHO classification and WPSS predict 
posttransplantation outcome in patients with 
myelodysplastic syndrome: a study from the 
Gruppo Italiano Trapianto di Midollo Osseo 
(GITMO). Blood. 2008/8/1;112(3):895-902.
18. de Witte T, Bowen D, Robin M, et al. Alloge-
neic hematopoietic stem cell transplanta-
tion for MDS and CMML: recommendations 
from an international expert panel. Blood. 
2017;129(13):1753-1762.
19. Lim Z, Brand R, Martino R, et al. Allogeneic he-
matopoietic stem-cell transplantation for pa-
tients 50 years or older with myelodysplastic 
syndromes or secondary acute myeloid leu-
kemia. JClinOncol. 2010/1/20;28(3):405-411.
20. Festuccia M, Deeg HJ, Gooley TA, et al. Minimal 
Identifiable Disease and the Role of Condi-
tioning Intensity in Hematopoietic Cell Trans 
plantation for Myelodysplastic Syndrome 
and Acute Myelogenous Leukemia Evolving 
from Myelodysplastic Syndrome. Biol Blood 
Marrow Transplant. 2016;22(7):1227-1233.
21. Sahlstedt L, Ebeling F, von Bonsdorff L, Park-
kinen J, Ruutu T. Non-transferrin-bound iron 
during allogeneic stem cell transplantation. 
Br J Haematol. 2001;113(3):836-838.
22. Pereira A, Nomdedeu M, Aguilar JL, et al. 
Transfusion intensity, not the cumulative red 
blood cell transfusion burden, determines 
the prognosis of patients with myelodysplas-
tic syndrome on chronic transfusion sup-
port. Am J Hematol. 2011;86(3):245-250.
23. Malcovati L, Germing U, Kuendgen A, et al. 
Time-dependent prognostic scoring system 
for predicting survival and leukemic evolu-
tion in myelodysplastic syndromes. JClinOn-
col. 2007/8/10;25(23):3503-3510.
24. Cremers EM, van Biezen A, de Wreede LC, et 
al. Prognostic pre-transplant factors in my-
elodysplastic syndromes primarily treated 
by high dose allogeneic hematopoietic stem 
cell transplantation: a retrospective study of 
the MDS subcommittee of the CMWP of the 
EBMT. Ann Hematol. 2016;95(12):1971-1978.
25. Kanda J, Mizumoto C, Ichinohe T, et al. Pre-
transplant serum ferritin and C-reactive pro-
tein as predictive factors for early bacterial 
infection after allogeneic hematopoietic cell 
transplantation. Bone Marrow Transplant. 
2011;46(2):208-216.
26. Artz AS, Logan B, Zhu X, et al. The prognos-
tic value of serum C-reactive protein, fer-
ritin, and albumin prior to allogeneic trans-
plantation for acute myeloid leukemia and 
myelodysplastic syndromes. Haematologica. 
2016;101(11):1426-1433.
27. Platzbecker U, Bornhauser M, Germing U, 
et al. Red blood cell transfusion depend-
184 185
chapter 9
ence and outcome after allogeneic pe-
ripheral blood stem cell transplantation in 
patients with de novo myelodysplastic syn-
drome (MDS). Biol Blood Marrow Transplant. 
2008;14(11):1217-1225.
28. Hilken A, Langebrake C, Wolschke C, et al. 
Impact of non-transferrin-bound iron (NTBI) 
in comparison to serum ferritin on outcome 
after allogeneic stem cell transplantation 
(ASCT). Ann Hematol. 2017;96(8):1379-1388.
29. de Swart L, Reiniers C, Bagguley T, et al. La-
bile plasma iron levels predict survival in 
patients with lower-risk myelodysplastic syn-
dromes. Haematologica. 2018;103(1):69-79.
30. Pullarkat V. Iron toxicity in hematopoietic 
stem cell transplantation: Strike while the 
iron is labile. Acta Haematol. 2014;131(4):220-
221.
31. Hod EA, Zhang N, Sokol SA, et al. Trans-
fusion of red blood cells after prolonged 
storage produces harmful effects that are 
mediated by iron and inflammation. Blood. 
2010/5/27;115(21):4284-4292.
32. Gattermann N, Finelli C, Della Porta M, et al. 
Hematologic responses to deferasirox ther-
apy in transfusion-dependent patients with 
myelodysplastic syndromes. Haematologica. 
2012;97(9):1364-1371.
33. Porter JB, de Witte T, Cappellini MD, Gatter-
mann N. New insights into transfusion-relat-
ed iron toxicity: Implications for the oncolo-
gist. Crit Rev Oncol Hematol. 2016;99:261-
271.
34. Malcovati L, Hellstrom-Lindberg E, Bowen 
D, et al. Diagnosis and treatment of primary 
myelodysplastic syndromes in adults: rec-
ommendations from the European Leukemi-
aNet. Blood. 2013;122(17):2943-2964.
35. Sivgin S, Eser B. The management of iron 
overload in allogeneic hematopoietic stem 
cell transplant (alloHSCT) recipients: where 
do we stand? Ann Hematol. 2013;92(5):577-
586.
36. Lee JW, Kang HJ, Kim EK, Kim H, Shin HY, 
Ahn HS. Effect of iron overload and iron-
chelating therapy on allogeneic hematopoi-
etic SCT in children. Bone Marrow Transplant. 
2009;44(12):793-797.
37. Jaekel N, Lieder K, Albrecht S, et al. Efficacy 
and safety of deferasirox in non-thalas-
semic patients with elevated ferritin levels 
after allogeneic hematopoietic stem cell 
transplantation. Bone Marrow Transplant. 
2016;51(1):89-95.
38. Eisfeld AK, Krahl R, Jaekel N, Niederwieser D, 
Al-Ali HK. Kinetics of iron removal by phlebot-
omy in patients with iron overload after al-
logeneic hematopoietic cell transplantation. 
Am J Blood Res. 2012;2(4):243-253.
39. Sivgin S, Eser B, Bahcebasi S, et al. Efficacy 
and safety of oral deferasirox treatment in 
the posttransplant period for patients who 
have undergone allogeneic hematopoietic 








General discussion and future perspectives
Myelodysplastic syndromes is a heterogeneous group of clonal hematopoietic 
bone marrow disorders, characterized by cytopenias and increased risk of 
leukemic transformation. The diagnosis is established on the presence of specific 
cytomorphological (CM) findings, the presence of MDS-associated cytogenetic 
abnormalities or presence of a mutation in the splicing chromosome SF3B1 (in 
the context of presence of ring sideroblasts).1–3 In patients with cytopenia(s), 
distinction between clonal and non-clonal diseases can be challenging due to 
many reasons. On one hand, MDS cases might present with minimal dysplastic 
features, no increased percentage of blasts and normal cytogenetic analysis. 
On the other hand, dysplasia is not restricted to MDS, it is also seen in reactive 
conditions. Furthermore, cytogenetic abnormalities are absent in around 50% 
of the MDS cases and rarely MDS-specific.4 The diagnostic guidelines for MDS 
established by the European LeukemiaNet (ELN) recommend the addition of FC, 
and suggest additional molecular techniques to support the diagnosis of MDS.5 
As described in the first two chapters FC is ready for clinical implementation in 
the diagnostic work-up in MDS, especially in excluding clonal disorders in patients 
with minimal dysplastic features and normal cytogenetics. The specificity (true 
negative) of MDS-FC analysis calculated after one year follow-up was 95%. This 
means that MDS-FC was very specific in excluding development of MDS within one 
year. The aim of the first part of this thesis was to evaluate and improve currently 
applied MDS-FC algorithms and investigate the efficacy of novel diagnostic tools in 
the diagnostic work-up in MDS.
This thesis provides recommendations for improvement of current applied 
MDS-FC panels. The first step was to review currently used MDS-FC approaches. 
Overall, the most commonly used diagnostic MDS-FC models have a sensitivity of 
71% and specificity of 93%.6,7 Due to wide availability of CD-markers that describe 
the granulocytic differentiation and maturation, this cell compartment forms the 
cornerstone of FC algorithms.8,9 Our study focused on the differences between 
MDS and pathological controls, all patients with cytopenias. The most concise 
panel for proper distinction between these patient groups included: CD34, CD117, 
CD11b, CD13, CD16 and CD56. Most markers are already present in the proposal 
for AML/MDS analysis by the EuroFlow Consortium. In combination with CD56, this 
might provide a highly specific MDS-FC panel. The sensitivity of these parameters 
can be calculated after addition of the other cell compartments, as MDS is not 
diagnosed solely based on abnormal neutrophils. The lower sensitivity (around 
71%) of most commonly used diagnostic MDS-FC models is partially caused by 
the absence of the erythroid cell compartment in these models. Therefore, we 
developed and validated the erythroid lineage evaluation and added it to applied 
MDS-FC algorithms. Only four parameters based on three markers (CD117, CD71, 
CD36) were sufficient to achieve an increased diagnostic sensitivity to 80%, without 
effecting the specificity (95%). To further increase the sensitivity from MDS-FC 
the megakaryocytic lineage should be added. Evaluation of the megakaryocytic 
lineage still faces technical challenges. However, the evaluation of CD34, CD36, 
CD42a an CD61 are very promising. 10 Note that this means that addition of only 2 
markers to the panel suggested above is sufficient. The megakaryocytic evaluation 
is currently under development within the ELNet MDS Flow Cytometry
To keep, and improve the specificity, the same analysis as preformed for the 
granulocytes should be performed for the monocytes. There are multiple 
markers, that describe the monocytic cell population. The challenge here is to 
identify markers that distinct MDS from other clonal diseases such as chronic 
myelomonocytic leukemia and myeloproliferative disorders. Others suggest 
panels including CD14, CD16, HLA-DR, CD64, CD56.8,11
Overall, evaluation of endless lists of CD-markers should be avoided. Shorter 
panels that evaluate the erythroid, myeloid progenitors, neutrophils, monocytes, 
and megakaryocytes, will lead to an overall higher specificity. FC can underline 
the diagnosis in indifferent cases, or even predict development of MDS in the 
near future. The role of other cell subsets such as dendritic cells (although 
very promising), and lymphocytes (except progenitor B cells) still need further 
investigation before introducing them in current standardized diagnostic panels, 
as their role in the identification of MDS is unclear. Aim should be to develop a 
standardize single tube multicolour FC analysis, which can be performed widely, 
and does not require high levels of expertise. Here new software can help to 
simplify the procedures. Panels need to be concise, easier to apply, less time 
consuming and cheaper.
Flow cytometry is described as an additional diagnostic tool to complement 
CM and cytogenetic analysis in suspected MDS. Note that, FC and CM evaluate 
different cell properties/aspects/features and therefore not necessarily correlate 
with one another. A big challenge in this thesis, and also in other studies regarding 
FC in MDS, is that FC results are always correlated to the gold standard. And 
here, the gold standard is CM features, in some cases supplemented by genetic 
abnormalities. Note that the goal of the current research is not to replace CM by 
other techniques but to complement or improve the diagnostic work-up. Because, 
as we demonstrate in Chapter 6, the current diagnostic subgroups described 
by the WHO classifications are very heterogeneous in many aspects (features 
described by the different tools). Therefore, we like to suggest that for future 
research of novel diagnostic tools such as FC, SNP-arrays, and next-generation 
sequencing, results should be correlated to other parameters such as clinical 
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features (i.e. presence of cytopenias, auto-immune phenomena, etc.) or prognosis 
(overall survival, time until leukemic evolution, therapy response, etc.).
Other pitfall in MDS analysis is that MDS is a clonal disease, and during the course 
of the disease the clonal cell population modifies due to disease, patient or 
treatment influences. Here studies that compare early onset MDS patients (based 
on high specific MDS-FC models that predict clonal development) to high risk 
highly aberrant MDS patients are needed. Also long-term follow-up of patients 
is mandatory to gain more insights in disease development. Identification of 
type, function, and moment of occurrence of a certain mutation with or without 
abnormal phenotype will provide better models that can predict prognosis or 
even treatment response.
By exploring the data in chapter 6, we found correlations between specific FC 
aberrancies and mutational status irrespective to the WHO diagnosis. We found 
that mutations in epigenetic regulators and transcription factors lead to aberrant 
myeloid progenitors, granulocytes or monocytes according to FC. What is the 
clinical impact of these findings? Research on pathophysiological mechanisms 
behind these correlations is mandatory as it will provide new targets for therapy. As 
MDS is a clonal disease that changes over time, a single drug approach seems not 
sufficient. Techniques that can monitor clonal evaluation might guide treatment 
discussions: if the clone starts to appear again, or starts changing a different 
therapeutic strategy is mandatory. Here FC has already proved its applicability 
in acute myeloid leukemia, but also other techniques such as next generation 
sequencing or mass cytometry are thinkable.12 However, these are complicated 
often expensive tools that are not yet ready for general application. SNP-array 
might be a good alternative as it becomes more widely available by commercial 
platforms.
Treatment options in MDS include growth factors (erythropoietin or G-CSF), 
hypomethylating agents (decitabine or azacitidine), or immune-modulating 
drugs (lenalidomide). The only potent curative option in MDS is an allogeneic 
hematopoietic stem cell transplantation (allo-SCT), upfront or after cytoreduction13. 
Although reduced intensity have decreased non-relapse mortality, overall survival 
remains around 30%. To improve allo-SCT outcome, more research needs to be 
performed in optimizing therapeutic strategies. As part of supportive care, most 
MDS patients receive multiple red blood cell transfusions (RBCT) during the course 
of their disease. Multiple transfusion can cause secondary hemochromatosis 
(reviewed in Chapter 7), a  deleterious effect of iron accumulation in heavily 
transfused MDS patients. In the following chapters we evaluate the influence of 
RBCT on outcome in allo-SCT.
In chapter 8 we moved scenery to prognosis in high risk myelodysplastic syndromes 
(MDS) and treatment with allo-SCT. Due to high treatment-related morbidity and 
mortality and high relapse risk the current long-term overall survival rate is around 
30%.14 Over the years reduced intensity regimens were introduced for the elderly 
and more frail patients to reduce non-relapse mortality. However, treatment 
selection and treatment timing remains challenging. Many retrospective analysis 
evaluated relevant prognostic parameters. In these studies MDS patients are 
often pre-treated, which leads to very heterogeneous patient cohorts in respect 
to patient and disease characteristics. To diminish these confounding factors 
the Chronic Malignancies Working Party of the EBMT analysed MDS patients 
treated by upfront allo-SCT, who were not extensively pre-treated. This part of 
the thesis aimed to identify prognostic parameters that aid treatment outcome 
prediction and assist patients selection for treatment with allo-SCT. The focus 
here, the influence of RBCT and its associated iron overload and iron toxicity. 
The retrospective analysis in chapter 9 formed the rational for the prospective 
non-interventional study in chapter 10. The prospective analysis concluded that 
transfusion burden influenced progression free survival, without a significant 
effect on survival. Treatment outcomes after 36 months in this not intensively pre-
treated patient cohort were 52% overall survival (95% CI: 45%-59%), 44% relapse-
free survival (95% CI: 37%-51%), 26% non-relapse mortality (95% CI: 19%-32%) 
and 31% relapse incidence (95% CI: 24%-37%). Expected parameters such as age, 
blasts percentage and comorbidity had a significant influence on outcome after 
ALLO-SCT.13 As also recently described in another large patient cohort, regimen 
intensity had no impact on overall survival in this study.15 Outcome might be 
predicted by serum ferritin levels, irrespective to CRP levels. Administration of 
iron reduction prior therapy prior to allo-SCT had no impact on primary outcome, 
but iron reduction therapy during the first year after allo-SCT increased overall 
survival. This thesis suggested the reduction of transfusion related iron overload 
in the allo-SCT setting. The easiest way to achieve this, is to reduce transfusions 
amount by shortening interval between diagnosis and curative therapy. The 
prediction of time of diagnosis until to leukemic evolution is difficult by current 
prognostic models. Development of better prognostic models, will lead to better 
treatment decisions (type of therapy and timing of starting therapy).
In summary, the thesis illustrates the efficacy of conventional and novel diagnostic 
tools in MDS. We provided suggestions for improvement of currently implied 
MDS-FC algorithms with the suggestion of a minimal panel and by reducing 
number of granulocytic markers and by the addition of the erythroid lineage. We 
illustrated the disease heterogeneity within MDS with the application of different 
diagnostic tools. And provide suggestions to improve disease analysis in the 
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future. The second part the thesis illustrated the deleterious effect of secondary 
hemochromatosis on long term survival in MDS patients treated with best 
supportive care and especially the negative impact in high risk MDS patients that 
undergo allogeneic ALLO-SCT. Here, a positive impact of iron reduction therapy 
was suggested.
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Nederlandse samenvatting voor niet medische ingewijden
Het myelodysplastiche syndroom (MDS) is een groep beenmergziekten met 
een variabel beloop, van een zeer langzame verslechtering tot zeer snelle 
progressie naar acute myeloïde leukemie. De verschillende typen MDS worden 
gekarakteriseerd door een gestoorde aanmaak en een gestoorde uitrijping van 
bloedcellen. Deze aanmaak en uitrijping van voorlopercellen tot bloedcellen vindt 
plaats in het beenmerg. MDS patiënten kampen dan ook met de gevolgen van 
een tekort aan bloedcellen: vermoeidheid (veroorzaakt door tekort aan rode 
bloedcellen), bloedingen (veroorzaakt door een tekort aan bloedplaatjes) of steeds 
terugkerende infecties (door een tekort aan witte bloedcellen). De geschatte 
incidentie van MDS is 5,4 nieuwe gevallen per 100.000 personen in de Nederlandse 
populatie. Deze incidentie neemt toe met de leeftijd, tot 84,4 per 100.0000 rond 
het 80ste levensjaar.
Diagnose
De diagnose wordt gesteld op basis van onderzoek van het beenmerg en het 
perifere bloed. Na kleuring van de cellen, wordt met een microscoop de cel-
uitrijping beoordeeld. De diagnose MDS kan worden gesteld wanneer er sprake is 
van meer dan 10% dysplastische (afwijkend uitrijpende) cellen in een of meerdere 
cellijnen, of wanneer er sprake is van ring sideroblasten (cellen met een afwijkende 
ijzerkleuring) in meer dan 15% van de rode bloedcel-voorloper cellen. Daarbinnen 
kan er sprake zijn van: MDS met uniliniaire dysplasie (afwijking in één cellijn), of MDS 
met multiliniaire dysplasie (afwijking in twee of meer cellijnen), al dan niet met ring 
sideroblasten. Aanvullend wordt chromosoomonderzoek verricht (cytogenetica). 
Bij ongeveer 50% van de MDS patiënten worden namelijk genetische afwijkingen 
gevonden die helpen bij het stellen van de diagnose, alsook iets zeggen over de 
prognose (ziektebeloop). In de laatste versie van de WHO-classificatie (World 
Health Organization: richtlijnen voor diagnostische classificatie) voor MDS wordt 
ook geadviseerd om specifiek te kijken naar een mutatie in het SF3B1-gen.
De diagnose MDS is niet altijd eenduidig te stellen. Zeker niet bij patiënten met 
cytopenie (cellen tekort) waar maar weinig dysplasie in het beenmerg gevonden 
wordt en er geen chromosomale afwijkingen zijn. In deze gevallen kan toevoeging 
van een andere laboratoriumtechniek, de zogenaamde flowcytometrie, uitkomst 
bieden. Zo laten we in hoofdstuk 2 van dit proefschrift zien dat flowcytometrie in 
deze gevallen MDS definitief kan uitsluiten.
Flow cytometrie
Flowcytometrie is een techniek die kan worden gebruikt voor het bestuderen van 
bepaalde celeigenschappen; met als doel cellen op basis van hun celkenmerken 
te sorteren. In MDS wordt flowcytometrie gebruikt om te kijken naar verdeling van 
de verschillende soorten bloedcellen, celgrootte (voorwaartse lichtverstrooiing) 
en aanwezigheid van korrels in de cel (granulatie; zijwaartse lichtverstrooiing). 
Bovendien kan de uitrijping van de witte en rode cellijnen worden bestudeerd. 
In hoofdstuk 3 van dit proefschrift evalueren we de analyse van de granulocyten 
(een vorm van witte bloedcellen), die zoals gezegd een belangrijke rol hebben 
binnen MDS diagnostiek. Dit komt doordat deze populatie relatief groot is en 
er veel flowcytometrie-merkers (CD-nummers) beschikbaar zijn om de cellen te 
onderscheiden. De meeste markers worden aangeduid met een CD-nummer, bijv. 
CD45 en CD34. CD45 herkent alle witte bloedcellen en CD34 alleen de hele vroege 
bloedvormende cellen. Een combinatie van flowcytometrie-merkers die getest 
wordt heet een flowctometrie-panel. Door een selectie te maken van de meest 
informatieve merkers, kunnen flowcytometrie-panels korter worden, dit betekent 
minder werk en goedkoper. Dit zonder dat het ten koste gaat van de specificiteit en 
sensitiviteit van flowcytometrie. De algemene specificiteit en sensitiviteit van MDS-
flowcytometrie is ongeveer 93% en 71%, d.w.z. in 93% gevallen zegt FC terecht dat 
de diagnose anders is dan MDS, in 71% van de gevallen klopt de diagnose MDS met 
de microscoopbeoordeling.
De meeste MDS patiënten zullen kampen met de gevolgen van bloedarmoede, een 
tekort aan rode bloedcellen. De huidige MDS-flowcytometrie modellen omvatten 
echter niet de analyse van voorloper rode bloedcellen. In dit proefschrift voegen we 
de analyse van de rode cellijn toe aan de gebruikte modellen, waarop de sensitiviteit 
van MDS-flowcytometrie toeneemt tot 80%. De specificiteit blijft hiermee gelijk aan 
die van de bestaande MDS-flowcytometrie modellen (~95%) (Hoofdstuk 4-5).
Zoals gezegd is MDS een gevarieerd ziektebeeld, waarbij het moeilijk blijft te 
voorspellen of en wanneer een patiënt een leukemie zal ontwikkelen. Om meer 
inzicht te krijgen in dit ziektebeeld en de ontwikkeling, analyseren we in hoofdstuk 
6 een groot patiëntencohort met laag risico MDS waarbij we verschillende 
diagnostische technieken gebruiken. Naast de morfologie, cytogenetica en 
flowcytometrie, gebruiken we hier ook SNP-array (een manier om naar DNA 
foutjes te kijken) en next generation sequencing (een techniek om grote stukken 
DNA te analyseren). Hier tonen we een divers landschap met velerlei aberranties 
(o.a. op basis van flowcytometrie) en mutaties, die niet correleren met de huidige 
diagnostische indeling van de WHO. Waarbij we dus kunnen stellen dat de door ons 
onderzochte technieken aanvullende waarde kunnen hebben in de diagnostiek 
van MDS. Mogelijk kan ons onderzoek ook aanvullend zijn aan de WHO-classificatie 





Om een keuze te maken voor een type behandeling moet er eerst een inschatting 
gemaakt worden van het ziektebeloop. Patiënten waarvan namelijk verwacht 
wordt dat zij snel progressie naar acute myeloïde leukemie zullen vertonen, zullen 
eerder en intensiever moeten worden behandeld. Een model dat hiervoor is 
ontwikkeld, is het International Prognostic Scoring System (IPSS), die in 2012 werd 
gereviseerd (IPSS-R). De IPSS-R bestaat uit: het percentage aan jonge voorloper 
cellen (blasten) in het beenmerg, chromosomale afwijkingen, het aantal en de 
diepte van de celtekorten. Afhankelijk van de prognostische waarden, worden 
punten toegekend. Deze score verdeelt patiënten in 5 subgroepen: ‘heel laag’, 
‘laag’, ‘gemiddeld’, ‘hoog’ en ‘heel hoog’. Deze subgroepen correleren met een 
algemene overleving van 8,8 jaar tot 0,8 maanden en de tijd tot leukemische 
ontaarding van nooit tot 0,7 maanden.
Eerdere studies hebben laten zien dat flowcytometrie in staat is om prognostische 
subgroepen aan te tonen binnen de vijf IPSS-R subgroepen. Betere prognostificatie 
kan leiden tot betere therapiekeuze. Een patiënt waarvan verwacht wordt dat 
hij niet gaat transformeren naar een acute myeloide leukemie kan zo therapie 
bespaard blijven. Bovendien kan een patiënt met een heel hoog risico op 
leukemische transformatie veel sneller in aanmerking komen voor een allogene 
stamceltransplantatie. Het diagnostische model dat in hoofdstuk 6 beschreven 
wordt, zou kunnen dienen als basis voor een prognostisch model.
Behandeling
De enige genezende behandeling voor MDS patiënten is het ondergaan van een 
allogene stamceltransplantatie, waarbij de patiënt beenmergcellen van een donor 
krijgt. Deze donor beenmergcellen vervangen het beenmerg van de patiënt, nadat 
deze uitgeschakeld is door chemotherapie. Een allogene stamcel transplantatie 
is een zware behandeling, waarbij patiënten soms zelfs kunnen overlijden aan 
de gevolgen van de therapie in plaats van aan de ziekte. Oudere patiënten, of 
patiënten met andere onderliggende ziektes (zoals long- of hartproblemen), 
komen daarom niet in aanmerking voor deze behandeling. Deze patiënten worden 
in studieverband behandeld met verschillende vormen van chemotherapie, of 
krijgen alleen ondersteunende therapieën zoals bloedtransfusies en antibiotica 
bij infecties.
In de inleiding van het tweede deel van dit proefschrift (hoofdstuk 6) wordt het 
schadelijke effect van bloedtransfusies beschreven. Transfusieafhankelijkheid 
kan worden gezien als een maat voor agressiviteit van de ziekte, maar mogelijk 
ook als maat voor toxiciteit van de transfusies zelf. Iedere eenheid bloed bevat 
ongeveer 200 mg ijzer - 100 keer de normale dagelijks benodigde hoeveelheid. 
Omdat het lichaam geen fysiologische mechanismen heeft om dit overtollige 
ijzer te verwijderen, ontstaat als gevolg van veelvuldige transfusies ijzerstapeling 
(secundaire hemochromatose). Op korte termijn leidt dit tot orgaanschade en 
op lange termijn zou dit invloed kunnen hebben op de (leukemievrije) overleving. 
We hebben in dit proefschrift met name gekeken naar het overlevingsnadeel 
van transfusieafhankelijke patiënten die een allogene stamceltransplantatie 
ondergaan. Zo kijken we in hoofdstuk 8 en 9 naar factoren die de uitkomst van 
een stamceltransplantatie kunnen voorspellen. Dit zijn bijvoorbeeld de genoemde 
diagnostische WHO-classificaties, bepaalde chromosomale afwijkingen, het 
al hebben van andere ziektes (co-morbiditeit), maar dus ook het ondergaan 
van bloedtransfusies. We laten zien dat het toepassen van ijzer-reductie-
maatregelen (met medicatie dan wel met aderlatingen) na de transplantatie een 
overlevingsvoordeel geven. Dit zal echter nog bevestigd moeten worden in een 
gerandomiseerde studie.
Conclusie
MDS is een complex ziektebeeld waarbij het stellen van de diagnose een continue 
uitdaging blijft. Dit proefschrift draagt op verschillende vlakken bij aan het oplossen 
van het diagnostische probleem. Het eerste deel van dit proefschrift dient als basis 
voor verdere verbetering van MDS-FC modellen. Modellen die zowel sensitief als 
specifiek zijn en bovenal kort en makkelijk te implementeren. Verder kunnen 
de artikelen dienen als hulpmiddel om MDS-FC te gaan gebruiken in andere 
laboratoria. We bieden in dit proefschrift handvatten om betere diagnostische 
categorieën te definiëren. Deze nieuwe classificatie zou dan weer kunnen dienen 
om de therapie beter af te stemmen en de keuze voor een bepaald geneesmiddel 
makkelijker te maken.
Het tweede deel van het proefschrift onderstreept de negatieve invloed van 
bloedtransfusies op de overleving na allogene stamceltransplantatie. De beste 
manier om tranfusieschade te verminderen is het verkorten van de periode tussen 
diagnose en curatieve (genezende) therapie. Betere prognostische modellen 
kunnen hierbij helpen doordat de therapie dan beter kan worden afgestemd op 
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ingezet voor mijn wetenschappelijke ontwikkeling en ook voor mijn persoonlijke 
groei. Beste Joop, door de samenwerking die al bestond binnen de HOVON89 
raakte je betrokken bij mijn proefschrift. Dank voor de fijne samenwerking en voor 
de tijd die je nam om mij de technische kant van de moleculaire technieken uit te 
leggen.
Graag wil ik de leden van de leescommissie: prof. dr. Ossenkoppele, prof. dr. 
Kern, dr. Poddighe, prof. dr. Huls, prof. dr. Vellenga, prof. dr. Raaijmakers, prof. dr. 
Swinkels en dr. Schols bedanken voor het lezen en beoordelen van dit proefschrift. 
Mijn paranimfen Claudia en Clea, dank dat jullie naast mij willen staan op deze 
bijzondere dag.
De leden van de EBMT-CMWP, allemaal hard werkende, gedreven mensen. In het 
bijzonder wil ik Anja, Liesbeth, Dimitris, Dirk-Jan, Linda, Erica en Marijke bedanken 
voor alle tijd en moeite die jullie gestoken hebben in twee hoofdstukken van dit 
proefschrift.
Beste prof. dr. Zweegman en prof. dr. Huijgens, beste Sonja en Peter, het begon 
allemaal in 2010 op de rieten stoel bij jullie samen op de koffie. Het moest de 
Hematologie worden. Dank voor jullie vertrouwen, motivatie, sturing en steun. 
Beste prof. dr. Ossenkoppele, beste Gert, dank voor je interesse in mijn onderzoek, 
op de achtergrond maar altijd voelbaar aanwezig.
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De afdeling Hematologie van het VUmc wil ik bedanken voor de mooie en leerzame 
tijd die ik er als co-assistent en onderzoeker gehad heb.  Zowel op de afdeling, 
de polikliniek als in het CCA heb ik hard werkende mensen mogen ontmoeten 
met liefde voor de patiënten en hun vak. Dit leidt tot een geweldige werksfeer. 
Angelika, ondanks de druk van het runnen van de afdeling was er altijd interesse 
in het onderzoek en in de personen daarachter. Petra en Irma, altijd behulpzaam 
en geïnteresseerd. Petra, ik bewonder hoe je al je taken weet te combineren.
Het MDS-team. Beste Claudia, Adri, Yvonne, Elsbeth, en Kelly, jullie hebben mij 
de technische kneepjes binnen de MDS diagnostiek bijgebracht. Met veel geduld 
leerden jullie me hoe een pipet werkte, hoe je een verdunning uitrekent en hoe ik 
gemaakte fouten steeds wel weer kon herstellen. Claudia, dat ik je gevraagd heb 
om naast me te staan op de grote dag is een teken van waardering voor onze fijne 
samenwerking en je waardevolle bijdragen aan dit proefschrift. Adri, dank dat ik 
altijd bij je terecht kon, samen kwamen we er uit! Yvonne, dank voor de gezellige 
uren samen op het lab. De tijd waarin de Canto 15 miljard events moest inladen, 
vlogen om. Elsbeth, onze momenten samen achter de microscoop koester ik, vol 
trots had ik dezelfde telling als jij. Kelly, helaas heeft onze samenwerking niet zo 
lang mogen duren. Toch wil ik je op deze plaats graag bedanken voor je inbreng 
en de gezellige momenten op het lab.
Beste Canan, jouw sterke en warme persoonlijkheid maakte dat ik me meteen 
thuis voelde op ons project. Dankzij jou had ik een droomstart op dit project. Ik 
hoop nog veel met je samen te werken.
Gerrit Jan, Anton, Niels, Mariëlle, Jeroen, José, Otto, Martine, Ellen, Henk, Linda, 
Jacqueline, Richard, Tuna, Henk-Jan, Marion, dank voor jullie inbreng en kritische 
blik tijdens presentaties van mijn onderzoek. Angèle, Pauline, Fedor, Marjolein, 
Yvonne, Jan Willem, Floortje, Karlijn, Zinia, Bo, Maaike, Payam, Bianca, Arjo, 
Willemijn, Dennis, Maaike, Sander, Johan, met vragen kon ik altijd bij jullie terecht. 
Dank voor alles wat jullie me geleerd hebben, dank voor alle gezellige momenten 
tijdens Callantsoog, op het lab en in de wandelgangen. Sander, Maastricht ligt nog 
steeds NIET in  België (fijn om eindelijk eens het laatste woord te hebben).
Mijn mede AIOs: Rolf, Han, Anna, Carolien, Rocco, Esther, Nathalie, Wendelien en 
Denise. Samen konden we keihard werken en keihard ouwehoeren. Ik heb mooie 
herinneringen aan kamer 4.04. Jullie zijn allemaal toppers! We zullen elkaar nooit 
helemaal uit het oog verliezen. Rolf, dank dat je mij steeds weer die foute uitspraak 
wist te ontlokken. Han, ik denk dat het een western blot was, of toch niet? Anna, 
thanks for sharing THE dance moves and my humor (yes it was funny!). Carolien, 
altijd zorgzaam en betrokken. Sorry dat ik je cactus vermoord heb. Rocco, thank 
you for being your authentic self. Fireballlll! Esther, je viel er tussen en hoorde erbij. 
Je positieve instelling brengt je overal!  Wendelien, je gedrevenheid is inspirerend, 
wij dokters hielden ons toch maar mooi staande tussen die lab-nerds. Denise, de 
bikkel die haar promotie in 4 jaar af had. En altijd tijd had om samen te borrelen, 
rennen, fietsen en congressen te bezoeken. Nathalie, MDS-collega, dokter turns 
lab-nerd turns dokter en altijd de volle 100%. Nathalie, Wendelien en Denise, ik 
hoop dat we nog vele jaren samen met onze mannen menig weekend met elkaar 
mogen doorbrengen. Waar ook ter wereld.
Beste Louise, mijn Radboud-buddy, ik zie ons nog zitten daar in het kamertje in die 
lange gang. De life-events die we samen doormaakten maakten dat we veel steun 
hadden aan elkaar. Samen lachen, schelden, het hoorde er allemaal bij.
De AIOS van het eerste uur: Canan, Dave, Jurjen, Costa, Monique, Willemijn, 
jullie waren de smaakmakers. Wij hoefden alleen maar te volgen wat jullie 
begonnen waren. Ik wens alle inmiddels al lang niet meer nieuwe AIOs: Margot, 
Lisa, Diana, Carolien en alle anderen heel veel succes, kennis, creativiteit en 
doorzettingsvermogen om ook hun project tot een goed einde te brengen. 
Carolien heel veel succes als opvolger op dit project, ik weet zeker dat je het 
geweldig gaat doen!
Mijn promotie werd zeker mede mogelijk gemaakt door mijn liefste vriendinnen. 
Het was altijd weer even hartluchten en dan snel over op de belangrijke zaken. 
Dank jullie wel voor de gezelligheid, steun, interesse en het ‘samen groot worden’. 
Met sommige al jaren, met andere pas net. Maar allemaal even dierbaar. Verder 
wil ik mijn lieve collega’s van het Zuyderland MC bedanken die er iedere dag weer 
voor zorgen dat werk en privé vloeiend in elkaar overlopen.
Hanna ik ben heel dankbaar dat na al die jaren als onze oppas, je nog steeds een 
vaste plaats in mijn leven inneemt.  Joop, Nini en Jules, vanaf dag een voelde ik me 
welkom in jullie gezin. Dank voor jullie liefde, interesse en gezelligheid tot in de 
kleine uurtjes.
Mijn lieve zus, Clea, je sterke karakter en doorzettingsvermogen maken je niet 
alleen een geweldige zus, maar ook een geweldige moeder. Lieve Clea en Geert 




Lieve papa en mama, dank voor jullie onvoorwaardelijke liefde en steun. Nooit 
beperkend, steeds motiverend. Papa, ik ben heel erg trots op je. Je houdt je 
toch maar mooi staande naast je altijd-beter-wetende dochters. Helemaal zelf 
wist jij je ontwrichte leven op de rit te krijgen en ons ‘thuis’ te behouden. Mama, 
onrechtvaardig plots moest je ons verlaten, ik mis je nog iedere dag. Ik hoop dat 
je erbij mag zijn op deze dag.
Lieve Marenz, samen vormen we een ijzersterk team: een stabiele basis met 
vrijheid voor ontwikkeling, berustend op onvoorwaardelijke liefde. Samen weten 
we de logistiek altijd weer rond te krijgen. Samen is thuis, samen komt het altijd 
goed.
